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of their specificity is difficult in vivo. Alterations in the profile of choline metabolites are detectable by
magnetic resonance spectroscopy (MRS), but because of competing catabolic contributions from the
phospholipases, the relative role of ChoKa is not absolutely discernable in a clinical setting. The goal of this
work was to develop ChoKa-specific imaging probes to assist in the development of ChoKa as a diagnostic
biomarker and therapeutic target. A series of compounds were synthesized for this purpose, and JAS239 was
identified as the most promising choline-mimetic with inherent near infrared fluorescence. Attenuation of
choline phosphorylation by JAS239 in human breast cancer cells was observed using 14C-choline
radiotracing and high-resolution 1H MRS. Microscopy was used to explore the interaction of JAS239 with the
ChoKa protein. These in vitro studies, using the established MN58b as a positive control, indicated that
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cancer xenografts were injected i.v. with trace doses of JAS239 for imaging studies. In vivo optical imaging of
JAS239 accumulation delineated breast tumor margins, and the signal intensity was capable of distinguishing
both genetic overexpression and pharmacologic inhibition of ChoKa in breast xenografts. At therapeutic
doses, JAS239 and MN58b reduced murine xenograft growth rates, and JAS239 was more effective than
MN58b at reducing tumor total choline levels. Histological assessment found both JAS239 and MN58b
reduced tumor cell density, decreased proliferation, and elicited an apoptotic response. In a parallel study,
ChoKa inhibition was shown for the first time to be an effective therapeutic strategy in glioma tumors,
however, JAS239 was not found to cross the blood-brain barrier. A library of derivatives were synthesized and
these are being investigated to improve the potency, biodistribution, and tumor specificity. These results
represent a new paradigm of multifunctional small molecules that can be used for ChoKa measurement, as
companion diagnostics to validate new ChoKa inhibitors, and as therapeutically-effective inhibitors of choline
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ABSTRACT 
 
NEAR INFRARED FLUORESCENT CHOLINE KINASE ALPHA INHIBITORS FOR 
CANCER IMAGING AND THERAPY 
 
Sean Philip Arlauckas 
E. James Delikatny, Ph.D.  
 
Choline kinase alpha (ChoKα) deregulation is associated with a more aggressive phenotype and 
greater malignancy in many human cancers. Inhibitors of ChoKα induce apoptosis in tumorigenic 
cells, but validation of their specificity is difficult in vivo. Alterations in the profile of choline 
metabolites are detectable by magnetic resonance spectroscopy (MRS), but because of competing 
catabolic contributions from the phospholipases, the relative role of ChoKα is not absolutely 
discernable in a clinical setting. The goal of this work was to develop ChoKα-specific imaging 
probes to assist in the development of ChoKα as a diagnostic biomarker and therapeutic target. A 
series of compounds were synthesized for this purpose, and JAS239 was identified as the most 
promising choline-mimetic with inherent near infrared fluorescence. Attenuation of choline 
phosphorylation by JAS239 in human breast cancer cells was observed using 14C-choline 
radiotracing and high-resolution 1H MRS. Microscopy was used to explore the interaction of 
JAS239 with the ChoKα protein. These in vitro studies, using the established MN58b as a 
positive control, indicated that JAS239 functions as a competitive inhibitor of ChoKα. Athymic 
nude mice inoculated with human breast cancer xenografts were injected i.v. with trace doses of 
JAS239 for imaging studies. In vivo optical imaging of JAS239 accumulation delineated breast 
tumor margins, and the signal intensity was capable of distinguishing both genetic overexpression 
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and pharmacologic inhibition of ChoKα in breast xenografts. At therapeutic doses, JAS239 and 
MN58b reduced murine xenograft growth rates, and JAS239 was more effective than MN58b at 
reducing tumor total choline levels. Histological assessment found both JAS239 and MN58b 
reduced tumor cell density, decreased proliferation, and elicited an apoptotic response. In a 
parallel study, ChoKα inhibition was shown for the first time to be an effective therapeutic 
strategy in glioma tumors, however, JAS239 was not found to cross the blood-brain barrier. A 
library of derivatives were synthesized and these are being investigated to improve the potency, 
biodistribution, and tumor specificity. These results represent a new paradigm of multifunctional 
small molecules that can be used for ChoKα measurement, as companion diagnostics to validate 
new ChoKα inhibitors, and as therapeutically-effective inhibitors of choline metabolism.  
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CHAPTER 1 
Introduction 
 1.1 Preamble  
The purpose of this thesis is to explore the mechanisms surrounding choline kinase 
alpha (ChoKα) and its involvement in cancer progression. Past studies have suggested 
that ChoKα expression and activity may serve as valuable biomarkers in cancer. The goal 
of this work is to explore the rationale behind targeting ChoKα to elicit a response in 
tumors. Molecular imaging applications as well as pharmacologic studies are included in 
the study of ChoKα’s clinical importance. 
 1.2  Hallmarks of cancer 
The idea of a “magic bullet” was proposed by Paul Ehrlich during his investigations 
of histological stains in human tissue (Ehrlich, 1911). His realization that dyes could 
interact with specific targets in cells led to the concept of chemotherapy, wherein 
molecules could be designed to bind and inactivate cellular targets at the pathological 
source of cancer (Strebhardt and Ullrich, 2008). The War on Cancer was declared in 1971 
when scientists and legislators promised a universal “cure” for the ailment we now know 
to be caused by hundreds of pathologically-unique diseases (Sporn, 1996). After several 
decades and billions of dollars’ worth of research funding, the scientific community has 
dramatically tempered its expectations for universal “magic bullets” as the complexities 
of these diseases have become realized. The treatment options for many cancers are so 
limited that life extensions of one or two months can be sufficient for FDA approval of 
new and often prohibitively expensive drugs. There have been success stories for specific 
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patient populations, notably paclitaxel in ovarian cancer, cisplatin in testicular cancer, 
imatinib mesylate treatment in chronic myeloid leukemia and gastrointestinal stromal 
tumors, and bevacizumab in VHL-mutated renal and colon cancers (Chabner and 
Roberts, 2005). These breakthroughs are becoming increasingly possible as we continue 
to classify cancers by their genetic and environmental driving factors, tissue of origin, 
and response to therapy, understanding the pathways of each cancer type so that potential 
susceptibilities can be explored for therapeutic intervention (Sawyers, 2004). Certain 
attributes have also been identified that are common to all cancers. These have been 
known since 2000 as the “Hallmarks of Cancer” and include: self-sustaining growth 
signaling, evading growth inhibitors, resisting apoptosis, acquiring replicative 
immortality, inducing angiogenesis, and promoting cell motility to surrounding tissues 
(Hanahan and Weinberg, 2000). These hallmarks were updated in 2011 to include four 
additional trends: genome instability, immune system evasion, tumor-promoting 
inflammation, and altered cellular energetics (Hanahan and Weinberg, 2011). 
As signal transduction-targeted drugs have begun to replace traditional chemotoxic 
agents, the need for novel therapeutic targets has left researchers scrambling to identify 
clinical markers of tumor malignancy that can be exploited for pharmaceutical 
intervention. The cancer hallmarks include a host of promising biomarkers for imaging 
and therapeutic intervention. Bevacizumab was developed as an anti-angiogenic agent 
when it was proposed that cancers grow and spread by highjacking the mechanism for 
blood vessel formation (Los et al., 2007). The epidermal growth factor receptor (EGFR) 
is commonly mutated and hyperactive in tumors, leading to the identification of EGFR 
inhibitors to treat lung, colon, and glioblastoma multiforme cancers in which these 
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mutations are common (Kris et al., 2003; Cunningham et al., 2004). Therapies like these 
have made remarkable strides toward prolonged patient survival, but new agents are 
needed to overcome the challenges of treatment resistance, cancer metastasis, and tumor 
recurrence. Promising therapeutic strategies based upon the new cancer hallmarks are 
emerging, for instance the CAR-T therapies designed to train the immune system to 
recognize and kill tumor cells (Maude et al., 2014). In many instances, methods of early 
detection would allow a therapeutic regimen to be started at an earlier pathological stage 
where there is a greater likelihood of tumor response (Etzioni et al., 2003). Recognizing 
that areas of chronic inflammation are more susceptible to malignant transformation has 
helped guide the location and frequency of screening procedures (Mantovani and Sica, 
2010). The drive to improve cancer detection led to a number of advances in our 
understanding of how cancers use nutrients and produce energy in ways that can provide 
distinction from normal tissue.  
The work of Otto Warburg was first to report that tumors exhibit aerobic glycolysis, 
although the advantage this provides to cancer cells has only recently begun to be 
elucidated (Warburg, 1956; Burk and Schade, 1956; Gatenby and Gillies, 2004). Besides 
the immune-protective effect of microenvironment acidosis, this metabolic 
transformation produces glycolytic intermediates that the tumor can use for biosynthetic 
precursors to support the growing biomass (Kroemer and Pouyssegur, 2008). A number 
of the most common oncogenic mutations upregulate hypoxia inducible factor-alpha 
(HIFα), a transcription factor that causes global changes in gene expression and result, 
among other cancer-associated outcomes, in promotion of the glycolytic pathway 
(Semenza, 2003). It is seemingly counter-productive for cancers to switch from the more 
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energy-efficient aerobic ATP production in the mitochondria even in situations where 
oxygen levels are not low. This glycolytic shift, however, permits the shunting of carbon 
atoms to other important factors required for growth, including nucleosides and amino 
acids (Vander Heiden et al., 2009). Upregulation of the glycolytic pathway enhances 
uptake of 18F-fluoro-D-glucose (FDG), which has been useful for identification of tumors 
using positron emission tomography (PET) imaging (Mankoff et al., 2007). The clinical 
success of FDG has sparked efforts to develop radiotracers derivative of many naturally 
occurring metabolites relevant to tumorigenesis. These metabolites include estrogens 
(Katzenellenbogen et al., 1997), thymidine (Shields et al., 1998), folate (Muller, 2013), 
pyruvate (Toyoda et al., 1989), glutamine (Lieberman et al., 2011), and, notably, choline 
(Hara et al., 1997). 
 1.3 Choline metabolism 
Magnetic resonance spectroscopy (MRS) provides a profile of endogenous 
metabolites within an MRI-selected voxel, and is complementary to PET studies of 
exogenous metabolite distribution. MRS is capable of detecting the density of any non-
zero spin nuclei such as 1H, 31P, and 13C (Glunde et al., 2010). By studying cancer cell 
and tumor extracts, a number of biomarkers unique to malignant tissue have been 
reported (Daly and Cohen, 1989; Gillies and Morse, 2005). One such phenomenon that 
has been described in a range of cancers, including breast, ovarian, prostate, lung, bone, 
colon, brain, hepatic, and lymphocytic, is the concomitant increases in 
phosphomonoesters (PME) observed in 31P spectra and total choline-containing 
metabolites (tCho) observed in 1H spectra (de Certaines et al., 1993; Glunde and Serkova, 
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2006; Podo et al., 2011). PME and tCho accumulation is one way that cancer cells are 
able to provide the metabolic precursors necessary for proliferation, and has been linked 
to overall poorer prognosis in numerous cancers (Negendank, 1992). Similarly, early 
drops in PMEs and tCho are predictive of responsiveness to both chemo- and 
radiotherapies (Shukla-Dave et al., 2002; Podo et al., 2011). The nine chemically 
equivalent protons in the methyl groups adjacent to the quaternary nitrogen of choline 
yield a strong singlet resonance at 3.2 ppm that is detectable by 1H MRS (Fig. 1.1). This 
technique can be adapted to study whole animals, perfused cell models, biopsy tissue, and 
cell extracts, with the capacity to resolve individual contributors to the PME and tCho 
peaks improving in that order (Ackerstaff et al., 2003).  
 
Figure 1.1. MRS detection of elevated tumor choline levels. (A) Glioblastoma multiforme 
tumor visible in a gadolinium-enhanced T1-weighted MRI image is demarcated by the right voxel. 
(B) Using chemical shift imaging at 3.2 ppm, a map of choline distribution (Cho) demonstrates 
elevated tCho in the tumor region. (C) MR spectra acquired for the tumor (right voxel) or the 
contralateral normal tissue (left voxel) confirm elevated tCho in cancer and diminished N-
acetylaspartate (NAA) in the cancer tissue. Figure adapted with permission from Horská and 
Barker, 2010. 
A B 
C 
 
6"
"
The tCho peak is a composite resonance in in vivo 1H MRS spectra consisting of the 
sum of the choline-containing metabolites: free choline (3.20 ppm), phosphocholine (PC, 
3.22 ppm), and glycerophosphocholine (GPC, 3.23 ppm). Tumor tissue extracts studied 
using high resolution MRS have revealed that the major contributor to the tCho signal is 
PC (Daly and Cohen, 1989). PC is an important precursor to phosphatidylcholine 
(PtdCho), the predominant phospholipid in mammalian cell membranes. In fibroblasts, 
generation of PC is required for the induction of DNA synthesis by a number of growth 
factors including PDGF, FGF, EGF and phorbol esters (Cuadrado et al., 1993). Inhibiting 
PC production prior to PDGF or FGF addition eliminates activation of the Raf-1 and 
MAP kinase signaling cascades responsible for relaying the mitogenic growth signal 
(Jiménez et al., 1995). Microinjection of PC itself is sufficient to induce a mitogenic 
response (Cuadrado et al., 1993), although a different paper demonstrated that PC added 
to cellular media was not taken up by cells but still exhibited a pro-mitogenic response (T 
Chung et al., 1997). Results from this paper suggest that extracellular ATP detection by 
the purinergic P2 receptors induces release of mitogenically active levels of PC from 
fibroblasts. PC acts synergistically with ATP, insulin, and/or sphingosine-1-phosphate to 
stimulate phosphatidylinositol-3’-kinase (PI3K) and pp70s6k, which regulate progression 
from the G1 to the S phase of the cell cycle (T Chung et al., 1997). PC levels have been 
found using MRS to increase substantially following oncogene transfection, loss of tumor 
suppressor function, and immortalization (Aboagye and Bhujwalla, 1999; Mori et al., 
2004). Comparison of spectra from tumor-derived cells versus their normal counterparts 
has revealed elevated PC levels in breast (Aboagye and Bhujwalla, 1999; Eliyahu et al., 
2007), glioma (Gillies et al., 1994), ovarian (Iorio et al., 2005), and prostate (Ackerstaff 
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et al., 2001) cells. Because it only measures the total steady-state pool of PC, MRS is 
unable to detect the relative contribution of the anabolic and catabolic pathways by which 
PC is generated. 
Free choline can be transported across the cell membrane by a number of transporters 
(ChoT), which can be classified into four major groups: high-affinity choline transporters 
(CHTs), choline transporter-like proteins (CTLs), organic cation transporters (OCTs), and 
organic cation/carnitine transporters (OCTNs). Each transporter group is composed of 
multiple genes and splice variants (Michel et al., 2006). Members of each class have been 
found at elevated levels in tumors, although the expression of each transporter seems to 
differ between cancers (Glunde et al., 2011). CTL1 for example has been reported in 
colon cancer (Kouji et al., 2009), lung cancer (Wang et al., 2007), and leukemia 
(Fullerton et al., 2006). In a study of breast cancer cells, CHT1 and OCT2 were found to 
be the primary choline transporters (Eliyahu et al., 2007). The role of each choline 
transporter in each tumor type is still poorly understood, due to the complexity of the 
isoforms present in each transporter class. 
Upon entering the cell, choline can be incorporated into a variety of important cellular 
components, including acetylcholine, betaine, sphingomyelin, or PtdCho (Fig. 1.2). In 
healthy individuals, the CHT family is primarily expressed in neurons, which take up 
choline and synthesize the neurotransmitter acetylcholine in a one-step pathway catalyzed 
by choline acetyltransferase (D Wu and Hersh, 1994). Choline can also be oxidized in the 
mitochondria at the hydroxyl position to form the common osmolyte betaine. 
Betaine:homocysteine S-methyltransferase transfers a methyl group from betaine to 
homocysteine, replenishing the methionine pool needed for the synthesis of the crucial 
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methyl donor S-adenosylmethionine (SAM) (Gonzalez et al., 2004). Among other 
functions, SAM can be used by phosphatidylethanolamine N-methyltransferase (PEMT) 
to methylate phosphatidylethanolamine (PtdEtn) for PtdCho synthesis during choline 
deficiency (Cui and Vance, 1996). In humans PEMT is almost exclusively expressed in 
the liver (Vance, 2013). The majority of cells in the human body use choline as a head 
group for cell membrane lipids. The Kennedy pathway leads to formation of the 
diacylglycerophospholipid, PtdCho. PtdCho can then be converted to the sphingolipid 
sphingomyelin (SM) via transfer of PC to a ceramide by the enzyme sphingomyelin 
synthase (Ullman and Radin, 1974).  
Anabolic production of PC occurs during the Kennedy pathway (Fig. 1.2) for PtdCho 
biosynthesis (Weiss et al., 1956). Free choline in the cytosolic space is rapidly 
phosphorylated to PC by the enzyme choline kinase (ChoK) (Wittenberg and Kornberg, 
1953). PC conversion to CDP-choline is the rate-limiting step catalyzed by the enzyme 
choline phosphate cytidylyltransferase (CCT) (Kennedy and Weiss, 1956). CCT is 
inactive in soluble form but recruited to the nuclear membrane in a highly regulated 
fashion (Glunde et al., 2011). Cytidine monophosphate is then replaced with 1,2-sn-
diacylglycerol (DAG) by the enzyme phosphocholine diacylglycerol transferase (PCT) in 
the final step of PtdCho synthesis (Kennedy, 1957). 
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Figure 1.2. Phosphatidylcholine catabolic and choline anabolic routes. PtdCho is 
synthesized in most cells via the Kennedy Pathway, where choline (bottom center) is 
phosphorylated by ChoK, then DAG is added via a CDP-mediated two-step mechanism. PtdCho 
can be metabolized at a variety of cleavage sites by the phospholipase enzymes. The byproducts 
of both the PtdCho catabolic and anabolic steps have important signaling functions, which can go 
awry in diseased tissue. Reproduced from Baykal et. al., 2008, with permission. 
 
PC formation can also occur by a number of catabolic paths, which are mediated by a 
class of enzymes known as the phospholipases (Fig. 1.2). PC can be cleaved directly 
from PtdCho by PtdCho-specific phospholipase C (PC-PLC), releasing a DAG second 
messenger that can go on to activate protein kinase C. While the activation of PC-PLC at 
the plasma membrane and the inhibition of its activity by the compound D609 have been 
studied, the gene(s) encoding its protein(s) have yet to be identified (Ramoni et al., 
2004). PC can also be derived by phospholipases using indirect methods. These methods 
include conversion of PtdCho to free choline and phosphatidic acid (PA) by 
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phospholipase D (PLD), and the coordinated activity of phospholipase A2 (PLA2), 
lysophospholipase (LPL) and glycerophospholipase:phosphodiesterase (GPC:PDE) to 
render free choline. In both cases, the enzyme ChoK is again responsible for conversion 
of free choline to PC. These enzymes have been found to be differentially expressed in 
some but not all cancers, and much work is still required to fully elucidate their 
involvement in PC production (Podo et al., 2011). A number of mitogenic second 
messengers are released as byproducts of PtdCho cleavage, including DAG, 
lysophosphatidic acid, PA, arachidonic acid, and PC itself (Agwu et al., 1989; Nishizuka, 
1992; Moolenaar, 1999; Du et al., 2010). 
 1.4 Choline kinase 
The primary mediator of PC levels in cancer cells is believed to be the enzyme ChoK, 
which is responsible for phosphorylation of free choline upon cell entry or release by a 
catabolic process. Enhancement of intracellular PC by Ras transformation is a ChoK-
dependent process, as ChoK inhibitors have been demonstrated to halt these alterations 
(Ramírez de Molina et al., 2001). The growth factors that rely on PC production to exert 
their mitogenic effects also require ChoK; ChoK inhibition in primary human mammary 
epithelial cells blocks EGF, insulin, and hydrocortisone-induced DNA synthesis (Ramírez 
de Molina, Báñez-Coronel, et al., 2004). It can therefore be inferred that the production 
of PC as a mitogenic second messenger is regulated by ChoK and cannot be salvaged in 
most cases by a compensatory catabolic mechanism.  
There are three different isoforms of ChoK in mammals coded by two different genes. 
CHKA encodes the protein ChoKα, which exists in two splicing variants. ChoKα variant 
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2 includes an 18 amino acid insertion between Met150 and Gly151 (Aoyama et al., 2004). 
While the importance of this splicing difference is not certain, some evidence indicates it 
may impact subcellular distribution (Miyake and Parsons, 2012). The CHKB gene 
encodes the protein ChoKβ, which has approximately 60% sequence homology to the 
ChoKα isoforms (Aoyama et al., 1998). ChoK is only functional in homodimer or 
heterodimer form, and the distribution of each isoform varies widely between tissues. 
While the testis and liver exhibit relatively high ChoKα expression, the heart and liver 
have the highest ChoKβ protein (Aoyama et al., 2002). Each isozyme is capable of 
phosphorylating choline, as well as the structurally similar ethanolamine. Only ChoKα 
has been found to have a link to tumor transformation (Gallego-Ortega et al., 2009), but 
defects in ChoKβ can lead to muscular dystrophy (Sher et al., 2006). While the ChoKα 
protein is more selective for the choline substrate, ChoKβ has higher affinity for 
ethanolamine (Gallego-Ortega et al., 2009). CHKA but not CHKB deletion is 
embryonically lethal (G Wu et al., 2008), further implicating the ChoKα variants as the 
crucial contributors to PtdCho biosynthesis. ChoK α/α complexes have the highest ChoK 
activity (higher Vmax and lower Km), β/β complexes have low activity, and α/β dimer 
complexes have intermediate catalytic activity (Aoyama et al., 2004; Gallego-Ortega et 
al., 2009). 
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Figure 1.3. ChoKα phosphorylates choline via an unusual ping-pong mechanism. 
Unprotonated Asp306 at the active site of human ChoKα can accept a phosphate group by a Mg2+-
coordinated reaction resulting in protonation of the amino acid and subsequent ejection of ADP. 
The phosphate-primed enzyme can accept choline, which induces a conformational shift in the 
enzyme resulting in PC exit. The deprotonated ChoKα enzyme reverts to its original conformation 
and is again ready for ATP binding. Adapted with permission from Hudson et. al., 2013. 
 
ChoK is similar to other kinases in that its N- and C-terminal lobes come together to 
form the ATP-binding site, but it is classified as an “atypical kinase” because there is a 
flexible ATP-binding loop in place of the glycine-rich P-loop found in typical eukaryotic 
kinases (Peisach et al., 2003; Scheeff and Bourne, 2005). It has been known since its 
discovery that the conversion of the phosphate group from ATP to choline requires 
magnesium ions for reaction coordination (Wittenberg and Kornberg, 1953). It was only 
recently reported by Hudson et. al. that ChoK works by an iso double-displacement 
mechanism, meaning that no ternary choline-ATP-ChoK complex is formed during 
catalysis (Fig. 1.3). Instead, ATP transfers a phosphate group directly to the enzyme at 
residue Asp306, which upon protonation causes ADP to leave (Hudson et al., 2013). The 
protonated, phosphate-bound Asp306 favors the binding of choline, which causes a 
conformational shift in ChoK that deprotonates Asp306 and releases PC in a process that 
then makes the original ChoK conformation more favorable. This ping-pong mechanism 
was supported by the surprising finding that ChoK has ATPase activity even in the 
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absence of choline (Hudson et al., 2013). The active site of ChoK is unlike the cleft-like 
structure of most protein kinases; the choline binding site exists in a tunnel-like pocket of 
hydrophobic residues with a rim of negatively-charged amino acids (Malito et al., 2006). 
Reports generally agree on Km values for choline between 100-180 µM, Km values for 
ATP between 410-760 µM, and kcat values for the enzyme of 69-83 s-1 (Malito et al., 
2006; Hong et al., 2010; Hudson et al., 2013). 
Heightened ChoK activity was first reported in rat hepatocytes following treatment of 
carcinogenic polyaromatic hydrocarbons; reversal of this phenomenon by addition of 
transcription inhibitors (cyclohexamide or actinomycin D) suggests the increase in 
activity was due to an increase in ChoK protein expression (Ishidate et al., 1980). 
ChoKα, but not ChoKβ, expression can also be induced in liver cells by carbon 
tetrachloride (CCl4) (Aoyama et al., 2002). This hepatotoxin was later found to cause 
upregulation of the oncogenic transcription factor c-jun that binds to an activator protein 
1 (AP1) element site in the promoter region of CHKA (Aoyama et al., 2007). Hypoxia 
response elements (HREs) in the CHKA promoter region have linked HIF1α activity to 
ChoKα expression (Glunde et al., 2008; Bansal et al., 2011). Inhibitors of the 
mitochondrial electron transport chain in neuroblastoma cells can increase ChoKα 
expression and phospholipase activity, leading to elevated choline metabolites (Baykal et 
al., 2008). Additional reports have shown that the oncogene c-Myc can increase ChoKα 
expression ultimately leading to higher levels of PC detected using 1H-MRS (Morrish et 
al., 2008; 2009). ChoKα activation can be mediated by the oncogenic small GTPase 
RhoA and its effectors (Ramírez de Molina et al., 2005). Ras mutation in NIH3T3 
fibroblasts was shown to increase ChoK activity via Ral-GDS and PI3K downstream 
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pathways (Ramírez de Molina, Penalva, et al., 2002). Treatment of human prostate and 
colon carcinoma cells with the PI3K inhibitor PI-103 reduced ChoKα and PC levels, 
indicating PI3K is regulative of PtdCho biosynthesis by promoting CHKA expression 
(Al-Saffar et al., 2010). In yeast, direct phosphorylation at Ser30 and Ser85 of choline 
kinase (CKI) by protein kinase A (PKA) increases PC production (Yu et al., 2002), 
although only rudimentary evidence in humans exists to suggest similar regulation of 
ChoK by PKA (Wieprecht et al., 1994). Phosphorylation of ChoKα at the Tyr197 and 
Tyr333 residues has been reported in human breast cancer cells, and these alterations 
increase the activity of ChoKα when in a complex with epidermal growth factor receptor 
(EGFR) and c-Src (Miyake and Parsons, 2012). In human breast cancer cells, 
extracellular calcium has been used to stimulate ChoK activity and PC formation by a 
Rho-dependent pathway (Huang et al., 2009). This is of interest because calcium, along 
with other growth factors, is released in large quantities at sites of metastases to bone 
(Silver et al., 1988; Hoey et al., 2003).  
The diversity of cancer-associated factors that can stimulate ChoK activity establishes 
the critical role this oncoprotein plays in tumorigenesis. Overexpression of ChoKα, but 
not ChoKβ, is sufficient to drive tumor transformation (Gallego-Ortega et al., 2009). 
Amplified ChoKα expression was first reported in breast carcinomas, and these studies 
found elevated ChoK activity in 39% of patient-derived tumor specimens (Ramírez de 
Molina, Gutierrez, et al., 2002). ChoKα deregulation has since been found in 47% of 
colon cancer, 56% of lung cancer, and 48% of prostate cancer tissues (Ramírez de 
Molina, Rodríguez-González, et al., 2002). ChoKα over-activity has additionally been 
reported in ovary (Iorio et al., 2010), endometrial (Trousil et al., 2014), and pancreatic 
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cancers (Penet et al., 2015). A retrospective study of non-small-cell lung cancer patients 
who had received prior surgical tumor resection found that individuals with tumor 
ChoKα levels 1.91-times higher than healthy tissue had four-year survival rates of just 
49%, compared to a survival rate of 71% in patients with ChoKα expression below this 
threshold (Ramírez de Molina et al., 2007). ChoKα activity is clinically correlated with 
histological tumor grade in breast cancer, and is inversely proportional to estrogen 
receptor positivity in patients (Ramírez de Molina, Gutierrez, et al., 2002). This is 
significant in that it implicates breast cancer patients resistant to the anti-estrogen 
tamoxifen may have pro-survival pathways mediated by ChoK. In murine models of 
bladder cancer, ChoKα overexpression is associated with larger, more metastatic tumors 
and contributes to a more aggressive carcinoma (Hernando et al., 2009). HDAC 
inhibitors Vorinostat, LAQ-824, and belinostat provide the only example running 
contrary to this conventional wisdom, in that they induce differentiation and apoptosis in 
cancer cells but cause a rise in PC and ChoK levels (Sankaranarayanapillai et al., 2006; Y 
Chung et al., 2008; Beloueche-Babari et al., 2010; Ward et al., 2013). ChoKα expression 
and activity are otherwise described consistently as robust biomarkers for tumor 
aggressiveness in a growing number of cancers, with few exceptions. 
1.5  Choline kinase inhibition 
ChoKα suppression. There is growing clinical interest in the suppression of ChoKα 
activity to ameliorate the pro-growth, drug resistant, and invasive phenotype this enzyme 
seems to impart on cancers originating from a wide range of tissues. An siRNA screen of 
human kinases and phosphatases which are critical for cell survival found ChoKα knock-
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down to cause a two-fold increase in apoptosis (MacKeigan et al., 2005). The first study 
to explore RNAi knockdown of ChoKα in-depth found reduced proliferative markers and 
signs of differentiation in the highly-metastatic triple-negative MDA-MB-231 human 
breast cancer cell line (Glunde et al., 2005). Chua et. al. performed an siRNA screen of 
more than 90 kinases to identify regulators of Akt, a critical molecular mediator in 
metabolism and cell survival pathways. In MDA-MB-468 breast cancer cells, both 
ChoKα and ChoKβ activities were found to promote phosphorylation of Akt at Ser473, 
activating Akt in a PI3K-dependent manner (Chua et al., 2009). While ChoKα RNAi 
silencing prevents mitotic entry and induces apoptosis in HeLa cells, knockdown of 
ChoKβ in addition to ChoKα rescues this lethality implying that the ChoKα to ChoKβ 
ratio is key to regulating release from G0/G1 arrest (Gruber et al., 2012). The Lacal group 
used stable ChoKα knockdown by shRNA and found enhanced PARP cleavage in 
cervical, lung, and bladder cancer cells. This study also found ChoKα shRNA induces 
apoptosis in MDA-MB-231 cells and tumor xenografts, but is tolerated in untransformed 
human mammary epithelial cells (Báñez-Coronel et al., 2008). Suppression of ChoKα 
expression also appears to sensitize cancer cells to chemotherapeutics (Mori et al., 2007; 
Granata et al., 2014). In 2009, a lentiviral approach to deliver ChoKα shRNA to MDA-
MB-231 xenografts achieved 80% reduction in ChoKα protein and attenuated PME levels 
were detected noninvasively using in vivo 31P MRS (Krishnamachary et al., 2009). An 
early study that sought to explain the observation that myo-inositol and choline addition 
to growth media reduces de novo PtdCho synthesis found this effect is due to down-
regulation of ChoKα expression, rather than direct chemical inhibition of the protein 
(Hosaka et al., 1990). 
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Early inhibitors. In studying the interaction between ChoK and its natural substrates, 
early propanol, butanol, and methyl-substituted derivatives of choline were described as 
ChoK inhibitors (Shelley and Hodgson, 1970). Wittenburg and Kornberg reported that 
ChoK activity could be stimulated by cysteine (Wittenberg and Kornberg, 1953). This 
early observation led Brostrom and Browning to study choline phosphorylation in the 
presence of the thiol group inhibitors and found ChoK inhibition by both N-
ethylmaleimide and Ellman’s reagent (Brostrom and Browning, 1973). A preliminary 
study as far back as 1974 linked inhibition of ChoK to membrane morphological changes 
in cancer cells, and demonstrated anti-tumor activity using purinyl-6-histamine to inhibit 
choline phosphorylation (Mayer and Werner, 1974). A comprehensive review of agents 
known to inhibit ChoK activity in any way includes a wide variety of Kennedy pathway 
intermediates (e.g. ethanolamine, PC, CDP-choline) and choline derivatives (e.g. ethyl 
choline mustard, acetylcholine, betaine) (Lacal, 2001). A variety of muscarinic receptor 
antagonists (e.g. quinacrine), ATP analogs (5’-AMP, AMP-PNP), and ions capable of 
displacing Mg2+ have also been reported, although for many of these agents it is likely 
that this effect is non-specific and due to action on the choline transporters, widespread 
interaction with ATP-binding sites in kinases, or other metal-dependent enzymes 
(Ishidate, 1989). Finally, ChoK is most catalytically efficient at alkaline pH ranges (8.0-
9.5) and can be effectually inactivated in acidic environments (Wittenberg and Kornberg, 
1953).  
Hemicholinium-3. Since its discovery as a ChoK inhibitor (Ansell and Spanner, 
1974), the symmetric dicationic choline-mimetic hemicholinium-3 (HC-3, Fig. 1.4) has 
been a prototype for ChoK inhibitors (Hamza et al., 1983). Prior to its study as a ChoK 
18"
"
inhibitor, HC-3 was used as a research tool for its ability to inhibit acetylcholine 
synthesis in the nervous system (Gomez et al., 1970). First discovered in 1954 (Long and 
Schueler, 1954), HC-3 was shown to disrupt ChoK activity in the brain by blocking 
sodium-dependent high-affinity choline uptake (Yamamura and Snyder, 1973; Guyenet et 
al., 1973) and diminishing acetylcholine synthesis (Macintosh, 1961; Gardiner, 1961). 
While HC-3 is capable of reducing PC levels and inhibiting growth factor-induced DNA 
synthesis in vitro (Jiménez et al., 1995), administering HC-3 at doses necessary for in 
vivo ChoK inhibition causes substantial off-target action on the neuronal high affinity 
choline transporters as well as acetylcholinesterase (Cannon, 1994). HC-3 toxicity results 
in a “curare-like” death due to its disruption of cholinergic neurotransmission (Boobis et 
al., 1975). The first exploration of HC-3 derivatives took place in the late-1980s and 
found that hydrophobic spacer length was critical in establishing the distance between 
quaternary ammonium groups (Tedford et al., 1986; Bhattacharyya et al., 1987; Cannon 
et al., 1988; Sheff et al., 1988). A fourteen-atom spacing between the cationic head-
groups yielded the most potent modulators of acetylcholine content in the caudate 
nucleus, one of the structures that makes up the basal ganglia and controls motor function 
(Bhattacharyya et al., 1987). Most tertiary ammonium derivatives are inactive, however 
the choline-like oxazinium group can be replaced with 4-methylpiperadine, suggesting 
that a hydroxyl group is not essential for choline uptake inhibition (Tedford et al., 1986; 
Sheff et al., 1988).  
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Figure 1.4. Structures of symmetric ChoKα inhibitors. The oxazinium rings of HC-3 can exist 
in open or ring structures, but crystallization studies indicate the closed ring is more favorable in 
vitro. Two classes of HC-3 analogs mimic the heterocyclic head-groups with either pyridinium or 
quinolinium moieties on each end of a hydrophobic spacer. Electron-donating substituents at the 
R-group improve potency against ChoKα. MN58b is a representative of the bis-pyridinium class. 
TCD-717 is a bis-quinolinium ChoKα inhibitor currently in clinical trials. 
 
Bis-pyridiniums. The IC50 of HC-3 against purified ChoK is 500 µM, so as new links 
between cancer and choline phosphorylation were discovered in the 1990s, it became 
clear that more selective and potent ChoK inhibitors were needed. Based upon prior HC-
3 derivatives, new ChoK inhibitors were soon developed in the lab of Juan Carlos Lacal. 
This initial class of bis-pyridinium compounds improved the potency against pure ChoK 
and the growth inhibitory concentration in cancer cells by several orders of magnitude 
(Hernández-Alcoceba et al., 1997). Quantitative structure-activity relationships (QSAR) 
demonstrated that electron-donating groups substituted at the C4-position of the 
pyridinium head-groups (Fig. 1.4) give the strongest ex vivo ChoK inhibition, the –NMe2 
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moiety is one of the most electron-donating substituents known (Campos et al., 2001). 
The most promising of these compounds, MN58b (Fig. 1.4), is effective against a variety 
of cancer cell lines, significantly retards xenograft growth, and, most importantly, is more 
specific for ChoKα than HC-3 (Hernández-Alcoceba et al., 1999). Improved activity was 
found when the 4,4’-biphenyl linker of HC-3 was replaced by a 1,2-ethylene(bisbenzyl) 
fragment (Campos et al., 2003). Although tri-pyridinium structures exhibit superior 
potency against purified ChoKα, the additional charge on these molecules makes them 
impenetrable to the cell membrane and relatively weak anti-proliferative agents (Conejo-
García, 2003). Likewise, attempts to make these structures more rigid to reduce rotational 
bonds and conform to “drug-likeness” principles ultimately led to IC50s as low as 30 nM 
in purified recombinant ChoKα, but these bis-pyridinium cyclophane compounds are 
ineffective at inhibiting growth of HT29 colorectal adenocarcinoma cells (Conejo-García 
et al., 2003). A rigid bi-phenyl linker did yield the most potent compounds, and when 
paired with a 4-chloro-N-methylanilino substituent on the pyridinium moiety, gave rise to 
a number of promising agents (Conejo-García et al., 2004). Extensive molecular 
modeling of these compounds with the crystal structures of ChoKα have helped to 
highlight the importance of the linker moiety, distance between quaternary ammoniums, 
delocalization of positive charge by electron-donating groups, and steric hindrance 
(Janardhan and Srivani, 2006). 
Bis-quinoliniums. The first attempt to make HC-3 analogous ChoKα inhibitors found 
pyridine derivatives to be the most potent, however insights gleaned from the QSAR 
studies of these bis-pyridiniums suggest lipophilicity could be a major factor 
disconnecting ex vivo ChoK inhibition from in vitro antiproliferative efficacy (Lacal, 
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2001). Additionally, with a better understanding of steric and electrostatic interactions at 
the active site, it became attractive to substitute the pyridine moiety with a variety of 
substituted quinolinium or isoquinolinium fractions to improve the cell permeability 
(Sánchez-Martín et al., 2005). The bis-quinoliniums (Fig. 1.4) have been demonstrated to 
have improved antiproliferative properties compared to the bis-pyridinium structures. 
This is due to overall greater hydrophobicity, although in both classes the same 3,3′-
biphenyl linker and electron-donating substitutions have yielded the most potent ChoKα 
inhibitors (Sánchez-Martín et al., 2005). These studies found that linker length has less of 
an effect on the antiproliferative properties than it does on ChoKα inhibition, and it was 
postulated that other mechanisms of cell death besides those induced by the interaction 
with ChoKα may exist for these compounds (Campos et al., 2006). Nonetheless, there 
have been excellent ChoKα inhibitor candidates derived from this class, which have sub-
micromolar IC50s and GI50s (Gómez Pérez et al., 2012). One clinical candidate, known as 
RSM-932A or TCD-717 (Fig. 1.4) has recently completed Phase I clinical trials for 
advanced solid tumor treatment (Lacal and Campos, 2015). 
Assymmetric inhibitors. The importance of symmetry was questioned even at the 
early stages of this field. However, when half-inhibitor fragments were found to be poor 
inhibitors and highly toxic, it was proposed that the dimeric form of ChoKα must allow 
each di-cationic inhibitor head-group to interact with a unique catalytic site (Lacal, 2001). 
With the crystal structures of inhibitors docked at the ChoKα active site having since 
been elucidated, the distance between catalytic units is now known to be too great for 
these inhibitors to span between bound ChoKα dimers, although the possibility that the 
unbound cationic head-group can bind to the choline-binding site of a free ChoKα 
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monomer or to the ATP-binding site on the same protein was never excluded (Hong et 
al., 2010). In fact, two separate efforts have been made to design asymmetric ChoKα 
inhibitors which link pyridinium head-groups with ATP-like structures (Trousil et al., 
2013; Schiaffino-Ortega et al., 2013). In each of these cases, there is little correlation 
between the potency of ChoKα inhibition and the antiproliferative effect, most likely due 
to toxicities linked to disruption of ATP binding to other critical targets. Use of the 
ChoKα structure for in silico screening led to the discovery of N-(3,5-dimethylphenyl)-2-
[[5-(4- ethylphenyl)-1H-1,2,4-triazol-3-yl]sulfanyl] acetamide (referred to as CK37) 
(Clem et al., 2011). Modeling of the active site for structure-directed discovery is now 
underway at Vertex Pharmaceuticals, and has already yielded incredibly potent and 
kinase-selective ChoKα inhibitors (Falcon et al., 2013; Hudson et al., 2013). These have 
proven to be useful tools for studying ChoKα mechanism and how it relates to 
tumorigenesis. 
Attenuation of enzymatic activity. There are several pharmacodynamic markers of 
ChoKα inhibition, which have been identified using a combination of RNAi and small 
molecule chemical inhibitors. The earliest studies with bis-pyridinium ChoKα inhibitors 
found they are tolerated by untransformed NIH3T3 cells and only cytotoxic following 
oncogenic (Ras, Raf, Src, or Mos) overexpression (Hernández-Alcoceba et al., 1997). It 
was presumed at this time that ChoKα’s involvement in cell cycle signaling is based 
solely on its ability to regulate production of the mitogenic second messenger, PC, and 
that the anticancer effect of ChoKα inhibition is primarily due to attenuation of this 
growth signal and depletion of substrates required for PtdCho biosynthesis (Lacal, 2001). 
Indeed, depletion of PC, tCho, and ChoK activity has been measured using both ChoKα-
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targeted RNAi and small molecule approaches in both in vitro and in vivo settings 
(Hernández-Alcoceba et al., 1999; Glunde et al., 2005; Al-Saffar et al., 2006). While this 
is a rational conclusion, it does not explain why normal cells are resistant to apoptosis 
under the same conditions.  
Cancer cell sensitivity. In 2004, it was discovered in primary lymphocytes that the 
ChoKα inhibitor MN58b causes dephosphorylation of the cell cycle checkpoint 
retinoblastoma protein (pRb), driving these cells into a reversible quiescent state until 
drug removal (Rodríguez-González et al., 2004). Due to defunct cell cycle regulation in 
lymphoma cells, the inability to dephosphorylate pRb causes Jurkat cells to continue 
proliferating. The cells compensate for inhibited de novo PC production by cleaving the 
PC head-group from the abundant membrane sphingolipid, sphingomyelin (Rodríguez-
González et al., 2004). The accumulation of ceramides as a byproduct leads to tumor-
specific apoptosis, as confirmed by cleavage of PARP due to caspase-9 activation 
(Rodríguez-González et al., 2004). Caspase-3 activation can be detected prior to a loss in 
mitochondrial potential and cytochrome-c release, suggesting apoptosis by a non-intrinsic 
pathway (Rodríguez-González et al., 2005). MN58b has no effect on other enzymes 
involved in the PtdCho anabolic/catabolic cycles, interference in the MAPK pathway, or 
DNA-intercalation (Rodríguez-González et al., 2003). Although MN58b has no 
measurable effect of MAPK signaling, an independent study found that siRNA 
knockdown of ChoKα does inhibit the MAPK cascade by reducing PA levels crucial for 
Ras anchorage and activation (Yalcin et al., 2010). To support this hypothesis, this group 
developed a ChoKα inhibitor known as CK37 and found disrupted actin cytoskeleton and 
membrane ruffling in addition to suppressed signaling pathways downstream of Ras 
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(Clem et al., 2011). The only known relationship between ChoKα and the plasma 
membrane is recruitment by EGFR in a c-Src dependent manner; whether this occurs 
specifically at focal adhesion sites has yet to be explored (Miyake and Parsons, 2012). 
This remains an important area of interest, as recent studies suggest that a scaffolding 
role, rather than or in addition to PC production, may be responsible for ChoKα’s role in 
cancer (Falcon et al., 2013).  
Anti-proliferative effect of ChoK inhibitors. The classic understanding of the effects 
of ChoKα inhibition began to unravel when a highly specific ChoKα inhibitor developed 
in Vertex labs was discovered to dramatically decrease PC pools, but cause a panel of 
cancer cell lines to enter a quiescent, rather than an apoptotic state (Falcon et al., 2013). 
This work found that reduction of ChoKα protein, not PC levels, is the crucial 
mechanism of cell death (Falcon et al., 2013), making it unclear why some but not all 
ChoKα inhibitors elicit an antitumor response. The discovery that MN58b and TCD-717, 
but not ChoKα siRNA, elicit an endoplasmic reticulum (ER) stress response finally 
provided a clue to explain this discrepancy (Sanchez-Lopez et al., 2013). MN58b and 
TCD-717 cause a distinct activation of the unfolded protein response in cancer cells by 
elevating protein chaperones and the pro-apoptotic transcription factor CHOP (Sanchez-
Lopez et al., 2013). Inhibitor-induced apoptosis in cancer cells can be marginally 
reversed by addition of ChoKα siRNA, suggesting the conformational changes in ChoKα 
elicited by these inhibitors cause the inhibited enzyme to be recognized as a misfolded 
protein. This is non-lethal in normal cells due to a more moderate ER-stress response 
triggered by the pro-survival transcription factor ATF4 and its downstream network of 
genes responsible for ER repair (Sanchez-Lopez et al., 2013). It appears that among the 
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molecules capable of blocking the choline-binding site, there is a smaller subset with 
antiproliferative activity. This therapeutic response is dependent on an inhibitor’s ability 
to trap ChoKα in an inactive position, prompting cancer cells toward apoptosis by 
provoking an overly sensitive unfolded protein response. The difference between 
cytotoxic (e.g. bis-pyridinium, bis-quinolinium) and cytostatic (e.g. Vertex’s V-11-0711) 
ChoKα inhibitors may be the length of the molecule and the ability to extend from the 
choline-binding site to one of the adjacent clefts formed by residues which open or close 
depending on enzyme conformation (Rubio-Ruiz and Figuerola-Conchas, 2014). The 
possibility of undetected off-target binding, however, remains a concern until these 
discrepancies are resolved. 
In vivo validation of ChoKα inhibition. The difficulty in confirming ChoKα 
specificity is due to the contributions from other phospholipid and choline-handling 
enzymes that can confound the interpretation of changes in PC levels. Most notably, 
drugs with known effects on phospholipase activity have been studied for oncological use 
(Ackerstaff et al., 2007). It is known that mitochondrial complex inhibitors are capable of 
enhancing activity through the Kennedy pathway (Baykal et al., 2008), a factor that is 
especially concerning considering that many ChoK inhibitors feature cationic ammonium 
species similar to mitochondrial-targeted agents such as metformin and carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP). A reliable panel of pharmacodynamic 
biomarkers of ChoKα inhibition has not been established, due to conflicting cellular 
responses to ChoKα targeted RNAi and small molecule inhibitors. It is yet unknown 
whether inactivated ChoKα protein is more crucial than PC depletion to these inhibitors’ 
antiproliferative activities, although there is increasing evidence which supports this 
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hypothesis (Falcon et al., 2013; Sanchez-Lopez et al., 2013). Concrete evidence relies on 
strategies to detect ChoKα in its native state in the absence and presence of inhibitors. 
Unfortunately, choline tracers are dependent on choline transporters and cannot 
distinguish choline transport inhibitors from choline phosphorylation inhibitors (Hara et 
al., 2006). MRS-based studies can detect steady-state metabolite levels, but enzymes 
from many pathways can affect these pools. The Phase-I clinical trial for TCD-717 in 
advanced solid tumors had an efficacy outcome measure based upon Response 
Evaluation Criteria in Solid Tumors (RECIST), but two years into the trial was amended 
to include in vivo MRS-based measurements of tCho to validate patient response 
(ClinicalTrials.gov Identifier: NCT01215864). It is unclear how necrosis due to poor 
blood supply or general chemotherapeutic effect could be deconvoluted from the ChoKα 
inhibitory response, except with advanced chemical shift imaging or follow-up 
histological assessment (Horská and Barker, 2010). One approach using systemically-
delivered 11C- or 18F-labeled HC-3 to compare choline distribution in 9L glioma rats 
found a tumor/muscle ratio as high as 5, however these were subcutaneous xenografts 
and poor tumor delivery was observed relative to the high renal and liver signals (Zheng 
et al., 2007). The authors developed this probe to image CHT1 transporters, but this work 
still represents the first effort to label a choline-like inhibitor for imaging purposes and 
represents an interesting strategy of ChoKα inhibitor validation if a ChoKα specific probe 
were identified.  
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1.6  Carbocyanine Dyes 
The cyanines represent a diverse class of fluorescent molecules that share a common 
structure composed of one tertiary nitrogen and one quaternary nitrogen connected by an 
odd number of methine groups (alternating single and double bonded carbons). The 
terminal nitrogen on each end of this resonant polymethine structure is typically part of a 
larger heterocyclic system. The first cyanine was described by Greville Williams in 1865 
who mixed quinolone (with an unforeseen lepidine impurity) with amyl iodide and 
obtained a brown oil that, when treated with ammonia, became a brilliant “corn flour 
blue” substance he termed “cyanine” (Williams, 1856). After investigation by many 
colleagues, it was realized the methyl impurity in lepidine provided the central methine 
carbon between the quinoline rings (Hoogerwerff and Van Dorp, 1883). As this reaction 
became better understood, new isoforms were described with 0 (apocyanines), 1 (true 
cyanines), 3 (carbocyanines), and 5 (tricarbocyanine) methine groups between the 
terminal rings. When non-similar head-groups flank the methine linker, these structures 
are known as isocyanines (Adams and Haller, 1920). These head-groups can be 
quinolinium, indolium, thio-indolium, oxa-indolium, pyridinium, imidazolium, and 
benzo-indolium rings with infinite substituent groups possible (Doja, 1932). The distance 
between the nitrogen atoms is the primary determinant of the wavelength of maximal 
light absorption, and it is possible to make general predictions of optimal fluorescence 
excitation wavelengths using particle-in-a-box theory (Autschbach, 2007). The 
carbocyanines are useful as a class of dyes because the optical properties can be tuned in 
a predictable manner and there are many potential sites for functional modifications. 
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While the original interest in cyanines was for textile coloring agents, it was quickly 
discovered that these compounds make excellent photo-sensitizers in silver halide plates, 
allowing photography to advance into an expanded range of wavelengths (Doja, 1932). 
Cyanines have since been implemented in a variety of industrial uses which include laser 
disk storage, solar energy, paints, and semiconductors (Mishra et al., 2000). The first 
widespread use of a cyanine in humans followed clinical approval of indocyanine green 
(ICG. Fig. 1.5A) for measurement of cardiac function (Fox et al., 1957). In 1966, the 
report of an interaction between a cyanine and DNA questioned the notion that cyanine 
derivatives were biologically inert (Kodama et al., 1966). Changes in red blood cell 
membrane potential in response to valinomycin can cause quenched aggregation or 
fluorescent dissociation of a panel of cationic cyanine dyes (Sims et al., 1974). It was 
even found that 3,3’-dipropyl- and 3,3’-diethyl-thiadicarbocyanine are capable of 
inhibiting K+ efflux through the Ca2+-dependent K+ transporters (Simons, 1976). 
Cyanines with longer lipophilic alkyl chains can incorporate into the plasma membrane 
and were used as a stable labeling system for tracking neuronal growth (Honig and 
Hume, 1986). When it was discovered that carcinoma cell mitochondria selectively 
accumulate cationic dyes such as rhodamine (Bernal et al., 1983), Oseroff et. al. were 
able to accomplish similar results using N,N'-bis(2-ethyl-1,3- dioxolane)kryptocyanine 
and found that effective photodynamic therapy could be achieved in bladder, colon, and 
squamous cancer cells with no light-induced death in normal keratinocytes or kidney 
epithelial cells (Oseroff et al., 1986). Since these reports of biological activity, however, 
the enthusiasm for cyanines as fluorescent tags attached to antibodies (Folli et al., 1994; 
Ballou et al., 1995; Vogel et al., 1996; Ballou et al., 1997), receptor ligands (Becker et 
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al., 2001; Tichauer, Samkoe, Klubben, et al., 2012), and natural products (Packard and 
Wolf, 1985; Becker et al., 2000; Licha et al., 2000) has far out-weighed the concern or 
interest in their pharmacodynamic effects.  
 
Figure 1.5. The use of ICG for NIRF-guided surgical resection. (A) ICG is a clinically 
approved cyanine with NIRF that binds to serum albumin and can be detected in blood vessels 
and lymph nodes. (B) Human tissue scatters and absorbs light in the visible range, but is 
relatively transparent to light in the NIR window. (C) To the naked eye, it can be difficult for 
surgeons to identify lymph nodes, (D) however, as a blood pooling agent ICG can be used to 
identify the sentinel lymph during tumor resection. (E) An overlay of the bright field and NIRF 
(green) channels offers a promising new intraoperative imaging tool. Panel (B) used with 
permission by Mahmood and Weissleder, 2003. Panels C-E adapted with permission from Crane 
et. al., 2011. 
 
More often, cyanines are being used as tools to measure physiological changes as a 
result of disease progression. One such application is the formation of hydrocyanine 
derivatives using sodium borohydride to reduce cyanines on the quaternary cationic 
ammonium group (Kundu et al., 2009). In this uncharged, non-fluorescent state, 
A 
ICG
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hydrocyanines are more cell-permeable and can be returned to their charged, fluorescent 
state by oxidizing agents. A number of commercially-available carbocyanines were 
modified to their hydrocyanine form and used to detect reactive oxygen species in 
lipopolysaccharide-induced inflammation (Kundu et al., 2009). A new class of cypate-
derived carbocyanines was recently discovered in the Achilefu lab to have dichromic 
fluorescence with emissions at 700 nm in the symmetric state and 800 nm when 
asymmetry is introduced by functional group addition. This is a particularly-promising 
discovery because cypate-derivatives with serine-mimicking alkyl groups were shown to 
undergo phosphorylation by Akt, rendering a measurable alteration in fluorescence which 
serves as a read-out of insulin-activated Akt activity (Shen et al., 2013). 
There are a number of optical, chemical, and biological properties that are desirable 
for a clinically suitable cyanine dye. The observed brightness of a fluorophore is the 
product of two factors. The first is the extinction coefficient (ε), which describes the 
number of photons a given concentration of dye (c) can absorb. The actual absorbance 
(A) of a particular wavelength of light is also dependent on the path length of the beam 
through the medium (ℓ), and is described by the Beer-Lambert law: A = εcℓ. The second 
factor is the fluorescence quantum yield (Φf), which relates to the efficiency with which 
absorbed photons are emitted at a longer wavelength (Rurack and Spieles, 2011). These 
factors can be influenced by the solvent system, as can the general solubility of the probe, 
thus testing needs to be performed in serum prior to animal studies (SL Gibbs, 2012). The 
wavelength of excitation and emission is of particular importance for in vivo fluorescence 
measurements, as human tissue has many components which can absorb, scatter, and 
fluoresce light, creating a broad range of wavelengths unsuitable for optical imaging 
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(Lewis et al., 2002; Mahmood and Weissleder, 2003). Endogenous molecules such as 
nucleic acids, fat, water, hemoglobin, and melanin limit light penetration in the UV and 
visible range, but within the spectral window known as the near infrared (NIR) 
wavelengths (Fig. 1.5B), human tissue is relatively transparent (Hale and Querry, 1973; 
Jobsis, 1977; van Veen et al., 2005). Near infrared fluorescence (NIRF) measurement is 
becoming a major tool for non-invasive disease measurement, however thus far only ICG 
and methylene blue are approved for clinical use. Due to strong binding to serum 
albumin, ICG is confined to the vasculature and has been used for retinal angiography, 
measuring cardiac output, evaluating hepatic clearance, defining lymphatic architecture, 
and delineating tumor margin (Marshall et al., 2010). While ICG’s excitation (760-785 
nm) and emission (820-840 nm) are within the therapeutic window, dye aggregation and 
photo-instability lead to relatively poor optical properties (Landsman et al., 1976). The 
mechanism of accumulation within cancer tissue is non-specific and based upon 
enhanced permeability and retention (EPR) within the disorganized vasculature and 
insufficient lymphatic system of the tumor (Marshall et al., 2010). Methylene blue is also 
a blood pooling agent but exhibits low tumor contrast due to its non-ideal optical 
properties (Ex. 668 nm, Em. 688 nm) (Matsui et al., 2010). Methylene blue has been 
useful in lymph node mapping (Tuttle, 2004), but ICG remains the best clinical option for 
NIRF-guided tumor margin identification (Frangioni, 2008). 
1.7  Near infrared fluorescence guided surgery 
Surgery remains a crucial part of oncological treatment and cures an estimated 50% 
of cancers, despite the fact that the vast majority of tumor resection relies on visual 
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recognition and palpation to discern cancerous from normal tissue (De Grand and 
Frangioni, 2003). Without the aid of tissue contrast guidance, resection of tumor 
boundary tissue and evaluation by histopathology remains the gold standard for 
confirming cancer-free margins (SL Gibbs, 2012). This technique is labor-intensive and 
time consuming, but necessary to identify tumor outgrowths which can be too narrow for 
the naked eye to detect. The need for sentinel lymph node identification and resection for 
histological assessment could also be aided by a real-time contrast agent. NIRF-guided 
surgery is a promising new field that seeks to pair enhanced cancer-tissue contrast with 
the operational simplicity and safety of optical imaging (Frangioni, 2003). Currently the 
most advanced technology in this field is the Fluorescence-Assisted Resection and 
Exploration (FLARE) system, which consists of a dual bright field and NIRF light 
acquisition overlay on a hands-free monitor set up in the surgical suite (Nakayama et al., 
2002; Troyan et al., 2009). With virtually no background signal, intraoperative NIRF 
imaging has been used to successfully identify tumor margins (Madajewski et al., 2012) 
and sentinel-node positivity (Fig. 1.5C-E) (Kitai et al., 2005; Crane et al., 2011) using a 
variety of fluorophores and cancer models (Weissleder and Ntziachristos, 2003). 
Britton Chance introduced optical imaging of the breast, using endogenous contrast in 
the NIR range created by oxygen levels and blood volume (Nioka et al., 1994). It is now 
widely thought that exogenous contrast agents are required to achieve the sensitivity 
necessary to justify the use of imaging systems during surgery (Weissleder and 
Ntziachristos, 2003). The pharmacokinetics and optical properties of a probe are the two 
most important factors that contribute to successful tumor-specific NIRF. There are two 
approaches to achieving tumor specificity: target affinity and site-specific activation. 
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Fluorophore-conjugated ligands have been designed for a number of cancer-specific 
molecules, including somatostatin receptors (Achilefu et al., 2000), folate receptors 
(Tung et al., 2002), immunoglobulin proteins (Ballou et al., 1995), carcinoembryonic 
antigen (Folli et al., 1994), oncofetal fibronectin isoform (Neri et al., 1997), and EGFR 
(Ke et al., 2003). Weissleder expanded the field using fluorescence resonant energy 
transfer (FRET) to design quenched fluorophores that could be released upon cleavage by 
an enzyme or physiological activity of interest (Weissleder et al., 1999). A number of 
enzyme-cleaved probes have since been designed to provide functional measurements of 
lysosomal proteases (Weissleder et al., 1999), matrix metalloproteinases (Bremer et al., 
2001), cathepsins B and D (Tung et al., 2000; Marten et al., 2002), and phospholipases 
(Mawn et al., 2011). While there are a growing number of such probes under 
investigation, the field of intraoperative NIRF imaging is limited by the number of 
clinically available imaging agents. Among the obstacles for clinical approval is tumor 
selectivity, in vivo sensitivity, barriers to intratumoral probe delivery (pore size, 
interstitial pressure), immunogenicity, and efficient clearance (Becker et al., 2001; 
Torosean et al., 2013). For this reason, small molecule drugs and imaging agents are still 
largely preferred over macromolecules/nanoparticles due to their favorable 
pharmacokinetics. 
1.8  Scope of thesis 
The focus of this work deals with improvement of the available methods to validate 
ChoKα inhibitors in vivo. The observation of structural similarity between the 
antiproliferative ChoKα inhibitors and the carbocyanines sparked the initial search for a 
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fluorescent dye capable of attenuating flux through the Kennedy pathway. The 
development of JAS239 as such a candidate is then described, with the in vitro 
characterization of its inhibitory and cell tracking capabilities included. Insights gleaned 
from JAS239 administration as a diagnostic probe and anticancer drug were then used to 
study the specificity of an established inhibitor. The final portion of this thesis describes 
the design of a library of JAS239 derivatives with structural modifications made based 
upon its described characterization. 
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CHAPTER 2 
Materials and Methods 
2.1 Chemistry Materials 
Solvents were purchased from Fisher Scientific. 1,4-Diphenyl-butane was purchased 
from Pfaltz & Bauer, Inc. 3,3’-dimethyloxacarbocyanine iodide (DMOCI) and 
1,1’,3,3,3’,3’-hexamethylindotricarbocyanine iodide (HITC) were purchased from Acros 
Organics. N-(3-Triethylammoniumpropyl)-4-(6-(4-(diethylamino) phenyl) hexatrienyl) 
pyridinium dibromide (FM 4-64) was purchased from Life Technologies. 
Hemicholinium-3 (HC-3) and indocyanine green (ICG) were purchased from Sigma-
Aldrich. IRDye-800CW carboxylate was purchased from Li-Cor Biosciences. E,E-
conjMN58b, E,E,E-conjMN58b, TCD-717, cycloJAS239, cycloJAS239.5, cycloHITC, 
and cycloHITC.5 were purchased from Peptech Corporation, Bedford, MA. All other 
chemicals were purchased from Sigma-Aldrich and used as received. The compounds 
were named with ChemBioDraw Ultra (v. 13, CambridgeSoft).  
1H NMR spectra were recorded on a Bruker DMX360 or UNI500 spectrometer in 
CDCl3 or CD3OD using tetramethylsilane (TMS) as an internal standard. Chemical shifts 
are reported in ppm. Mass spectra were recorded on a Bruker Microflex MALDI-TOF 
spectrometer. HPLC analysis was performed by Dr. Popov as described elsewhere 
(Kachur et al., 2013). Absorbance and fluorescence spectra were acquired by diluting 
each fluorophore in methanol, addition of the solution to a 1 cm wide crystal cuvette, and 
measurement in a Molecular Devices Spectra Max M5 plate reader. 
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2.2 Cell Culture 
Breast Cancer cell lines. The triple-negative MDA-MB-231 human-derived breast 
cancer cell line was obtained from American Type Culture Collection (ATCC) in 
November of 2011. These cells were expanded and frozen within 3 passage numbers after 
receipt. Cells were used within 6 months of resuscitation, and authorized by the ATCC 
via the COI assay, STR analysis, and BacT/ALERT 3D. The MDA-MB-231-derived cell 
line 4175-Luc+ was isolated from a murine lung metastasis and was generously provided 
by Dr. Andy Minn in August of 2013 (Minn et al., 2005). Both cell lines were maintained 
in monolayer culture in DMEM (Mediatech, Flemington, NJ) supplemented with 10% 
FBS (HyClone Laboratories, Logan, UT), 1% penicillin/streptomycin (Mediatech), and 
1% L-glutamine (Mediatech) at 37°C in a humidified atmosphere (5% CO2). The 4175-
Luc+ cells were maintained in 5 µg/mL blasticidin (Invitrogen), which was removed 
during experiments. MCF7 breast cancer cells expressing a Chk-4 clone (MCF7-CK+) or 
the empty vector (MCF7-EV) were provided by Drs. Zaver Bhujwalla and Tariq Shah of 
Johns Hopkins University in March 2012 (Shah et al., 2010). These cells were cultured in 
MEM (Mediatech) supplemented with 10% FBS, 1% penicillin/streptomycin, 1% L-
glutamine, and 400 mg/mL G418 sulfate selection agent (Mediatech). G418 was not 
included in the culture medium during experiments. All cell lines used were tested upon 
receipt and bi-monthly for mycoplasma. Cells were frozen in liquid nitrogen and only 
used at low passage numbers. 
Glioma cell lines. To assess the toxicity and efficacy of MN58b on growth inhibition 
of gliomas, we chose three rat brain tumor cell lines F98, 9L and 9L over-expressing 
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EGFRviii (Kapoor et al., 2007). The F98, 9L and 9L-EGFRviii glioma cell lines were 
maintained as adherent monolayers cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Sigma-Aldrich, St Louis, MO) supplemented with 10% fetal bovine serum 
(HyClone, Mississauga, Canada), 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer (Invitrogen; Carlsbad, CA), 200 U/mL penicillin and 200 mg/mL 
streptomycin sulfate at 37°C in 5% CO2 in air. Cells were maintained in exponential 
growth phase by routine passage twice weekly at 3 x 105 cells per T-75 flask. 9L and F98 
cell cultures were tested upon receipt from the lab of Dr. J. Biaglow (Department of 
Radiation Oncology at the University of Pennsylvania) in 1999 using the Rat Antibody 
Production (RAP) Test performed by Charles River Laboratories (Wilmington, MA) and 
re-screened in 2005 using IMPACT III PCR profiling performed by RADIL (Columbia, 
MO). Cell lines were used within 6 months of resuscitation and tested bi-monthly for 
mycoplasma. The 9L-EGFRviii cell line was cloned from the 9L cells in the laboratory of 
Dr. Donald M O’Rourke, Department of Neurosurgery, University of Pennsylvania. We 
obtained the 9L-EGFRviii cell line from Dr. Donald M O’Rourke in 2010. No additional 
characterization has been performed on this cell line. 
2.3 Western Blotting 
MCF7-EV and CK+ cells were plated in 10-cm dishes (1.0 x 106 cells) and grown for 
24 hours. Proteins were extracted on ice using radioimmunoprecipitation lysis buffer 
(Abcam) fortified with a cOmplete Mini, EDTA-free protease inhibitor cocktail (Roche) 
and quantified using the BCA Protein Assay Kit (Pierce). Approximately 30 µg total 
protein was resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane, 
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blocked using nonfat milk, and blotted for ChoKα (Abcam) or GAPDH and imaged using 
Luminata Western Chemiluminescent HRP substrates (Millipore). Bands from each of 
three separate experiments were quantified using ImageJ software. Mansi Shinde of the 
Pharmacology Graduate Group, University of Pennsylvania provided technical support 
for electrophoresis, membrane transfer, immunoblotting, and film development.  
2.4 1H MRS studies of cellular extracts 
Breast cancer cells. MDA-MB-231, 4175-Luc+, MCF7-EV and MCF7-CK+ cells 
(~30 x 106) were harvested using trypsin and washed 2x with PBS. Dual-phase 
methanol/chloroform/water extraction was performed in a glass centrifuge tube as 
described elsewhere (Tyagi et al., 1996; Glunde et al., 2005). Cells were transferred to a 
glass centrifuge tube and 4 mL ice-cold methanol was added and cells were vortexed. 
After 10 minutes on ice, 4 mL of chloroform was added and the sample was again 
vortexed and allowed to settle on ice. After 10 minutes, 4 mL of water was added and the 
sample vortexed, and stored at 4°C overnight. Each glass centrifuge tube was then 
centrifuged at 20,000 x g at 4°C. The upper aqueous phase was separated, treated with 
Chelex beads to remove dicationic ions, roto-evaporated to remove methanol, and 
lyophilized to remove water. Samples were resuspended in D2O containing 0.7 µmol of 
trimethylsilyl propionate (TSP, Aldrich) as a chemical shift reference and concentration 
standard. Fully relaxed 1H NMR spectra were acquired with help from Weixia Liu and 
Stephen Pickup of the Small Animal Imaging Facility using an 11.7 T Varian INOVA 
high-resolution NMR spectrometer and a 90° pulse width (relaxation delay: 6 seconds; 
repetition time: 10.73 seconds; number of scans: 64; data size: 32 K; spectral width: 
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6,000 Hz; temp: 30°C; total acquisition time: 11 minutes 28 seconds).  
Brain cancer cells. For consistency between in vitro and ex vivo extract preparation, 
the F98 cells grown in culture were prepared for MRS evaluation using perchloric acid 
extraction. Cells were seeded (1x105/mL, 150 cm2 flasks) and incubated overnight, media 
was aspirated and replaced with fresh media containing 0, 10, and 20 µM MN58b. After 
24 hour MN58b treatment, cells were trypsinized, washed and an aliquot was removed 
for viability counts. The remaining cells were pelleted and homogenized in 3 volumes of 
6% PCA, transferred into an Eppendorf tube and centrifuged (13,000 rpm, 30 minutes, 
4°C), neutralized with 3 M potassium hydroxide (KOH, Sigma-Aldrich, St Louis, MO) 
and the neutralized samples were lyophilized for 24 hours. Members of the Poptani Lab 
in the Department of Radiology performed the PCA extraction and samples were scanned 
on a 500 MHz vertical bore NMR scanner (Bruker, Billerica, MA) with the same 
parameters used for breast cell extracts. 
Spectra were analyzed using Mnova Lite 5.2.5 software (Mestrelab Research, 
Santiago de Compostela, Spain) with 0.5 Hz apodization. Following Fourier transform, 
spectra were phase-corrected using the TSP peak, which was also used as a chemical shift 
reference at 0.0 ppm. Minor baseline correction was applied as needed. Metabolite peaks 
were identified on the basis of their chemical shifts (Evanochko et al., 1984). The 
following choline-containing metabolites were identified from their N-trimethyl 
(+N(CH3)3) resonances: Cho 3.20 ppm (singlet); PC, 3.22 ppm (singlet); and GPC, 3.23 
ppm (singlet). Metabolite concentrations were calculated using the signal area in the 
proton spectrum, which is proportional to the concentration and the number of protons 
contributing to the signal. The metabolite concentrations were calculated and corrected 
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for the number of cells in the NMR experiment using the following formula: [(metabolite 
peak height /number of protons) /(TSP peak height /number of TSP protons)] x (TSP 
concentration /number of cells). The resonances at 3.2 ppm from the choline-containing 
metabolites are all composed of 9 protons, as is the 0.0 ppm resonance of TSP. 
2.5 ChoK activity 1H MRS assay 
MDA-MB-231, MCF7-EV, and MCF7-CK+ cells (~20 x 106) were trypsinized, 
washed 2x in ice-cold PBS, and homogenized on ice in 4 volumes of 100 mmol/L Tris-
HCl (pH 8.0) containing 10 mmol/L DTT and 1 mmol/L EDTA in D2O as described 
previously (Iorio et al., 2005). Samples were ultrasonicated 2x for 30 seconds at 4°C, 
centrifuged for 30 minutes at 12,0000xg, and the supernatant transferred to an NMR tube. 
ATP (Sigma-Aldrich), choline chloride (Sigma-Aldrich), and MgCl2 (Sigma-Aldrich) in 
Tris-HCl/D2O buffer were added to the sample with final concentrations of 10, 2.5, and 
10 mmol/L, respectively. 1H MR spectra were recorded immediately at 10-minute 
intervals for 500 minutes (90° pulse length, relaxation delay: 6.6 seconds; repetition time 
10 seconds; number of scans: 60; data size: 16 K; spectral width: 6,000 Hz; temp: 30°C; 
total acquisition time 8 hours, 20 min). Choline and PC peaks were fit from Fourier 
transformed spectra and were processed in the same manner as the extract data using 
Mnova Lite 5.2.5. Data were fit to the linear equation, y = mx + b, where x is time, y is 
the area of the PC or Cho peak, and m, the slope, gives the rate of conversion. To reduce 
the amount of JAS239 required to treat 20 x 106 cells (grown in 4 x 150 cm2 flasks 
containing 25 mL media each), treatment occurred after cells were pooled and 
centrifuged, thus 53 nmol of JAS239 were present in the 530 µL NMR sample, 
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equivalent to a concentration of 530 nmol/L if treatment were applied to the cells before 
trypsinization. 
2.6 14C-choline ChoK activity assay 
Intact cells. Cells for breast cancer studies were plated at 1.5 x 106 cells/well in 6-
well dishes and allowed to grow for 48 hours. For glioma cell studies, 5×105 cells/well 
were seeded in a 6-well plate and incubated for 24 hours at 37°C. Media was aspirated 
and replaced with fresh media containing varying concentrations of ChoK inhibitor or 
vehicle control, followed 1 hour later by treatment with 0.5 µCi/mL of [methyl-14C]-
choline chloride (Perkin Elmer). At the indicated time-points, cells were rinsed with ice-
cold PBS (Mediatech) and fixed in 16% trichloroacetic acid. Samples were scraped, 
collected in centrifuge tubes, washed 3x in diethyl ether, lyophilized, and resuspended in 
water for TLC separation using a solvent system of 0.9% NaCl: methanol:ammonium 
hydroxide (50:70:5, v/v/v). Quantification of the water-soluble choline metabolites was 
performed using autoradiography with a FujiFilm FLA-7000 in accordance with 
previously established protocols (Hernández-Alcoceba et al., 1999). The Rf values for the 
choline metabolites were 14C- choline (0.07), 14C-PC (0.14), and 14C-GPC (0.39).  
Cytosolic preps. For 14C-choline tracing studies independent of the choline 
transporters, cytosolic preps were made using the same procedure described in the ChoK 
activity 1MRS assay, with diH2O used in place of D2O. Approximately 5 x 105 cells were 
used per sample. To each sample, drug was added directly at the required concentration. 
MgCl2 and ATP were then added with the same final concentrations as in the NMR 
assay, whereas choline chloride levels were reduced to 200 µM. Finally, 3 µCi/mL 14C-
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choline was mixed in the sample. Samples were incubated for 1 hour, then fixed 
lyophilized, reconstituted, separated by TLC, and analyzed by autoradiography following 
the same procedure used for intact cells. Due to the higher salt content of these samples, 
the Rf values for PC (0.08) and Choline (0.28) changed and were determined using 
labeled standards. 
2.7 Cell viability studies 
Trypan exclusion assay. MCF-7 EV and MCF7-CK+ cells were plated at 1.0 x 106 
cells/well in 6-well plates. After 2 days, media was replaced with fresh media containing 
MN58b or JAS239 at concentrations ranging from 0-20 µM. At 17 hours, cells were 
gently rinsed with ice-cold PBS, trypsinized at 37oC, and a 200 µL aliquot was 
neutralized with fresh media containing Trypan Blue, and counted using a Neubauer 
hemocytometer. Counts were reported relative to untreated EV cells. In all viability and 
therapeutic studies of cells treated with JAS239, great attention was paid to protecting the 
samples from light, both to minimize probe degradation and the potential of a 
photodynamic therapy response. 
MTT assay. The MDA-MB-231 and 4175-Luc+ cell lines were plated in triplicate in 
96-well plates at 7.5x104 cells/well and incubated overnight. The culture medium was 
replaced with media containing varying concentrations of JAS239 or MN58b. After 
overnight incubation, 20 µL of 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; thiazolyl blue (MTT, Sigma-Aldrich, St Louis, MO) in 
sterile PBS was added and the cells were again incubated for 2 h. The media/MTT 
mixture was removed and replaced with 150 µL dimethyl sulfoxide (DMSO, Fisher 
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Scientific, Fair Lawn, NJ), shaken, and the absorbance read at 550 nm using a Spectra 
Max M5 plate reader (Molecular Devices, Sunnyvale, CA). Background signal was read 
as absorbance at 690 nm and subtracted from each sample reading. For the glioma cell 
lines, the same procedure was followed. The MTT assays on the glioma cell lines were 
run by Sona Saksena, Ph.D. (Department of Radiology, University of Pennsylvania) 
under my guidance, and the raw data from each of the three trials was analyzed by me.  
2.8 Epidermal growth factor stimulation 
ChoK activity assay. The 9L and 9L-EGFRviii gliosarcoma lines were plated at a 
density of 1 x 105 cells/well in 6-well plates. After 24 hours, media was replaced with 
DMEM + 0.1% bovine serum albumin (BSA, Sigma-Aldrich). After overnight serum 
starvation, the 6-well plates were aspirated and DMEM + 0.1% BSA with and without 20 
µM MN58b was added. Epidermal growth factor (EGF, UPenn Cell Center) was 
immediately added to half the treatment groups at a final concentration of 200 ng/mL. 
The other half in each treatment group received the same volume of PBS. After 1 hour of 
incubation, [methyl-14C]-choline chloride was added to each well at a final activity of 0.5 
µCi/mL. After a final hour of incubation, media was aspirated, cells were washed in PBS, 
and 16% TCA was added to fix each well. PC production was quantified using the 
TLC/autoradiography method described above. 
MTT assay. The 9L and 9L-EGFRviii cell lines were distributed at 7.5 x 103 
cells/well in 96-well plates. After 24 hours, media was replaced with DMEM + 0.1% 
BSA. Cells were incubated in serum-starved conditions for 2 days, at which time the 
media was replaced with fresh serum-free media containing either 20 µM MN58b or 
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saline control, with half of each treatment group receiving 200 ng/mL EGF and the other 
half receiving PBS. After 24 hours, 20 µL of 5 mg/mL MTT was added to each well, 
incubated 2 hours, and plates were analyzed using the MTT assay procedure described 
above. 
2.9 Fluorimetry analysis 
Uptake competition assay. MDA-MB-231, MCF7-EV, MCF7-CK+ cells were grown 
for 48 hours in 6-well plates (1.5 x 105 cells/well). Each well was aspirated and replaced 
with fresh media containing JAS239 with or without choline and incubated for 2 hours. 
Samples were washed in PBS, lysed in DMSO, and the fluorescence was measured using 
a Molecular Devices Spectra Max M5 plate reader with an excitation (Ex.) of 640 nm and 
emission (Em.) of 770 nm. 
Cell retention assay. MCF7-EV and MCF-CK+ cells were plated in 6-well plates (1.0 
x 105 cells/well). After 48 hours incubation, cells were treated with varying 
concentrations of JAS239 for 2 hours. Each well was aspirated and rinsed once with PBS. 
DMSO (500 µL) was added per well, plates were covered with tin foil to protect from 
light and shaken for 30 minutes prior to transfer of 200 µL of sample to a black-walled 
clear bottom 96-well plate for measurement of fluorescence in the Spectra Max M5 plate 
reader (Ex. 640 nm; Em. 770 nm). To study ChoKα dependent retention, the same cell 
conditions were set up and cells were treated with 10 µM JAS239 for 1 hour, rinsed with 
PBS, and incubated 15 minutes with fresh media over two separate cycles. After 3 rinses 
with PBS, DMSO was added and the same procedure as above was followed to measure 
JAS239 accumulation. 
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2.10 Confocal microscopy 
Live cell analysis. MDA-MB-231 cells were plated at 1.5 105 cells/dish in 35-mm 
glass-bottom dishes coated with poly-D-lysine (MatTek Corp.). After 2 days of 
incubation, cells were treated with fresh DMEM containing no phenol red and 2 µmol/L 
JAS239 and/or 5 µmol/L of the nuclear targeting dye SYTO9 dye (Life Technologies). 
The cells were subsequently imaged with assistance from James Hayden of the Wistar 
Imaging Facility using a Zeiss LSM 510 META confocal microscope with Ex. 633 nm 
and Em. filter 650 to 790 nm. 
Immunohistochemistry. MDA-MB-231 cells were plated on sterile 10 mm glass 
coverslips placed in 24-well plates and incubated 24 hours. The media was gently 
aspirated, the wells were washed with PBS and immersed in 4% paraformaldehyde for 15 
minutes. Cells were washed 2x with PBS and incubated 15 minutes on ice in 0.2% Triton 
X-100 diluted in PBS. Cells were washed with cold PBS and blocked in 1% BSA diluted 
in PBS for 30 minutes. Coverslips were transferred to racks and 200 µM JAS239 was 
added evenly along the surface of three coverslips. After 30 minutes, these slides were 
washed 2x with PBS, 30 µL of rabbit anti-human ChoKα antibody (ab38290; Abcam) at 
1:1000 dilution was added to the top of the slide, and the slides were incubated at room 
temperature for 1 hour. A separate batch of three coverslips were first incubated in anti-
ChoKα antibody, rinsed 2x with PBS, then treated with 200 µM JAS239. A control group 
receiving anti-ChoKα antibody only were included to ensure that Texas Red fluorescence 
emission did not overlap with the JAS239 filter setting. Coverslips from each group were 
transferred to wells in a fresh 24-well plate, washed 2x with PBS, and incubated for 40 
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minutes in 200 µL of dilute (1:500) goat anti-rabbit secondary antibody conjugated to 
Texas Red (Vector Laboratories; TI-1000). Each well was washed 3x with PBS then 
dehydrated using 50%, 70%, and 100% ethanol in successive 10-minute increments. Each 
coverslip was air-dried in the dark, mounted with VectaShield (Vector Laboratories) on 
slides, and kept at 4°C overnight. Alex Glavis-Bloom of the Yang Lab in the Department 
of Cancer Biology assisted with the development of this protocol. Confocal micrographs 
were acquired on a Zeiss LSM 510META NLC using Ex. 543 nm and Em. 565-615 nm 
for Texas Red and Ex. 633 nm and Em. >650 nm for JAS239. Images were acquired with 
help from Andrea Stout and Jasmin Zhao of the Cell and Developmental Microscopy 
Core. Background was subtracted from the images in each channel using the Fiji version 
of ImageJ. The Coloc 2 plug-in was used to assess colocalization (Dunn et al., 2011) of 
the anti-ChoK-α antibody and JAS239 by calculating Pearson’s Correlation Coefficients 
and Manders’ Colocalization Coefficients for at least three separate ROIs.  
2.11 Animal model and tumor cell implantation 
Murine breast xenografts. All animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of Pennsylvania. Six week old 
syngeneic female athymic nude Foxn1nu/nu mice were acquired from the National Cancer 
Institute and housed in a temperature-controlled environment with 12 hour light/dark 
cycle. General anesthesia was induced using 2% isoflurane in oxygen for inoculations, 
injections, and imaging experiments. All cell lines were trypsinized, counted, washed 2x 
with cold PBS, and resuspended in ice-cold Matrigel (BD Biosciences, Bethesda, MD). 
For MCF7 inoculations, athymic nude mice were supplemented with 60-day release 0.36 
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mg 17β-estradiol tablets (Innovative Research of America, Sarasota, FL) using a trochar 
in the nape of the neck. After 1 week of recovery time, 4x106 MCF7-CK+ cells were 
inoculated into the left mammary fat pad (which appears on the right when the animal is 
in the ventral position) and 4x106 MCF7-EV cells on the contralateral fat pad. MDA-MB-
231 and 4175-Luc+ tumors were inoculated orthotopically unless specifically noted. 
These tumors were grown on the shoulder as subcutaneous xenografts, to allow for the 
kidneys to be cloaked during parallel optical imaging studies. Tumor growth was 
determined via caliper measurement of the longest (length) and two orthogonal 
dimensions (width and height) and tumor volume calculated as length * width * height * 
π/6.  
Rat glioma model. Manoj Kumar and Ranjit Ittyerah of the Poptani lab were 
responsible for rat tumor inoculation, treatment, and tumor resection. These methods are 
described in detail elsewhere (Kumar et al., 2015). Six week old syngeneic female Fisher 
F344/NCr (120-150 gm weight) rats (n = 13) were purchased from the National Cancer 
Institute and housed in a temperature controlled animal facility with a 12 h light-dark 
cycle. General anesthesia was induced by intraperitoneal injection of ketamine/xylazine 
(80/8.0 mg/kg). The animal was placed on a stereotactic frame. A small burr hole was 
made 3-mm lateral and 3-mm posterior to the bregma and 2-mm deep into the right 
cerebral hemisphere using a drill bit. F98 tumor cells (5x104) in a 10-µl suspension in 
PBS were inoculated over a 5-min period with a Hamilton syringe and a 30-gauge needle 
using a stereotactic apparatus. After injection of the cell suspension, the needle was 
withdrawn slowly and the wound was closed by suturing the skin. Animals were 
monitored periodically for 2 weeks during recovery. 
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2.12 In vivo optical imaging 
JAS239 biodistribution in 4175-Luc+ bearing mice. One week prior to imaging, 
athymic nude mice bearing orthotopic 4175-Luc+ tumors were placed on a low-
fluorescence alfalfa-free diet (5V02; LabDiet, St Louis, MO). Mice were anesthetized 
with 2% isoflurane and a pre-scan bioluminescence and NIRF (Ex. 745 nm; Em. 800 nm) 
image was acquired in an IVIS Spectrum with settings set to Automatic mode (Perkin 
Elmer, Hopkinton, MA) to be used as a reference for eliminating auto-fluorescence in 
later acquisitions. NIRF is measured in Average Radiant Efficiency, which is a measure 
of photons per second (p/sec) corrected for the area (cm2) of the region of interest (ROI) 
and the efficiency of the lamp at the sample distance and filter settings used (µWatts 
*cm−2 / steradian-1). Bioluminescence is measured in Radiance, which has the units of 
p/sec/cm2/sr. Each mouse was injected i.p. with 150 mg/kg of firefly D-luciferin sodium 
salt monohydrate (Biosynth, Switzerland) in saline and a time-course imaging sequence 
was used to establish that maximal luminescence was reached 15 minutes post-injection. 
No luminescence was detected in the NIR range. After 24 hours, a pre-scan 
bioluminescence and NIRF image was again acquired to ensure that no residual 
luminescence was remaining. Mice were injected via tail vein with either control vehicle 
or 20 nmol JAS239 in 100 µL of 0.1% Tween-80 in 50 mM Tris-HCl buffer. Mice were 
imaged for NIRF over a time-course of 20 minute increments. After initial hepatic 
clearance diminished (approximately 75 minutes), mice were again injected i.p. with D-
luciferin and imaged for bioluminescence and NIRF 15 minutes later. ROIs with a 20% 
threshold were automatically drawn around the tumor using the bioluminescence image 
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in the LivingImage software (PerkinElmer) program, and this region was used to analyze 
intratumoral JAS239 accumulation in the NIRF images. Technical assistance was 
provided by Julie Czupryna of the Small Animal Imaging Facility. 
A different formulation of JAS239 was tested in a separate cohort of mice bearing 
orthotopic 4175-Luc+ tumors. Approximately 4 weeks after tumor inoculation, each 
animal was injected i.v. with 20 nmol JAS239 dissolved in ethanol and diluted 1:100 in 
0.9% saline. The tumor contrast with this 1% ethanol/saline formulation was compared to 
the contrast in response to 20 nmol indocyanine green (ICG) injected one week after the 
JAS239 was no longer detectable. A new cohort of mice was then inoculated on the back 
right shoulder with 4175-Luc+ subcutaneous xenografts. The location of these tumors 
allowed us to cloak the lower extremities of the mice and minimize background signal 
related to excretion. These mice were each injected with 20 nmol JAS239 in the 
ethanol/saline formulation after 4 weeks of tumor growth. Whole-body NIRF imaging of 
each mouse was used to determine the time of maximum intratumoral accumulation. 
Delivery of JAS239 in hydrocyanine form (hydro-JAS239) was first performed by i.v. 
injection in a new cohort of five athymic nude mice with subcutaneous 4175-Luc+ 
xenografts. Time-course images were acquired using the excitation and emission 
parameters for JAS239. After fluorescence in these animals diminished to undetectable 
levels, 20 nmol of either JAS239 or hydro-JAS239 was administered by gavage and 
NIRF images in the IVIS Spectrum were acquired over a span of 24 hours. 
JAS239 in the ethanol/saline formulation was injected into three mice at time points 
1, 4, and 24 hours prior to euthanasia by CO2 asphyxiation. Tumor resection from these 
mice was then recorded in the integrated imaging device built in the laboratory of Sunil 
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Singhal of the Department of Surgery at the University of Pennsylvania. This device 
features a screen displaying the overlay brightfield image from a standard webcam with 
the NIRF signal detected by a charged coupled device (CCD) camera. Time-stamped 
images were recorded as separate files and overlay of the bright light (grey-scale) and 
NIRF (green) channels was performed in ImageJ with assistance from Ryan Judy of the 
Singhal lab. 
As a preliminary experiment, a single athymic nude mouse bearing a 9L glioma 
xenograft on the right shoulder was injected with 20 nmol JAS239 in 1% ethanol and 
imaged for NIRF (Ex. 710 nm; Em. 800 nm) in a LiCor Pearl by Sona Saksena in the 
Delikatny Lab.  
2.13 Ex vivo optical imaging 
Biodistribution. Once the maximal intratumoral levels of JAS239 were determined 
by whole-body NIRF imaging for each vehicle formulation, animals were re-injected 
with the same formulation approximately 1 week later (allowing the first dose to clear 
entirely). Animals were euthanized 90 minutes after injection with JAS239 in Tween-
80/Tris buffer or 24 hours after injection with JAS239 in ethanol/saline, as these were the 
times of maximal tumor/background fluorescence determined by whole-body NIRF 
imaging for each formulation. Tumors as well as relevant organs were resected, placed in 
a 24-well plate, and imaged for NIRF in an IVIS Spectrum. ROIs were drawn around 
each well and quantified using the LivingImage software. Tumor-to-muscle NIRF ratios 
were reported relative to a section of excised quadriceps muscle.  
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Diagnostic studies. Twenty mice bearing both MCF7-EV and MCF7-CK+ tumors 
were monitored until tumors reached approximately 200 µL. Ten days prior to optical 
imaging, mice were switched to low-fluorescence chow. Two mice became moribund 
before imaging and three additional mice were excluded from these studies because their 
tumor inoculations missed the mammary fat pad. The remaining cohort was separated 
with eight mice receiving 20 nmol JAS239 in Tween-80/Tris buffer and seven receiving 
20 nmol JAS239 in ethanol/saline. The cohort receiving JAS239 in Tween-80/Tris buffer 
was euthanized after 90 minutes, and the tumor-bearing flanks were surgically exposed. 
Using an IVIS Spectrum, NIRF from the tumor-bearing fat pads was subtracted from 
background muscle signal and the Average Radiant Efficiency reported. The same 
procedure in the remaining cohort was performed 24 hours following injection of JAS239 
in ethanol/saline. 
2.14 In vivo MRI 
Animal preparation for MRI scan. Mice were prepared individually for MRI exams 
by induction of general anesthesia with 3% isoflurane in oxygen delivered in an induction 
chamber. The anesthetized animal was secured to a custom-built restraining device to 
minimize motion-induced artifacts. The head was positioned within a nose cone 
delivering 2% isoflurane in oxygen. Each limb was secured to a custom in-house 
restraining device to minimize motion artifacts. A respiration pillow was placed on the 
dorsal side of the body to monitor respiration rate, while a thermister was inserted into 
the rectum to measure body temperature. Both sensors were connected to a small animal 
monitoring device (SA Instruments Inc, NY, USA) that reported vital signs during 
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scanning. A slotted-tube resonator (inner diameter = 11 mm, depth = 9 mm) built in-
house and tuned to 400 MHz was used for 1H spectroscopy and imaging (Poptani et al., 
2003). The tumor of each animal was placed in the coil and the probe was then centered 
in the magnet. Body temperature was regulated at 37 ± 1°C by blowing warm air into the 
magnet bore through a hose connected to a thermostatically controlled device (SA 
Instruments, NY, USA). Animal preparation and MRI/MRS acquisitions were performed 
by Manoj Kumar of the Poptani Lab, with my assistance and processing of the data. 
In vivo single voxel spectroscopy. Athymic nude mice bearing subcutaneous tumors 
(approximately 300 µL in volume) underwent pre-treatment MRS scans in a 9.4 T 
horizontal bore magnet equipped with 40 G/cm gradients interfaced to an Agilent Direct-
Drive console (Agilent, Palo Alto, CA, USA) operating vnmrj 2.3.C software. Multi-slice 
gradient and spin echo images were used for tumor localization. T2-weighted spin echo 
anatomical images acquired using a spin echo multi-slice (SEMS) pulse sequence 
(TR=1000 ms, TE=10.0 ms, number of slices=20, field of view=20x20 mm2, slice 
thickness=1 mm, NT=1, matrix size=256x128) were used for voxel selection. A spectrum 
was acquired in a 3x3x3 mm3 voxel using a PRESS sequence (TR=3000 ms, TE1=12.68 
ms and TE2=10.01 ms, number of averages=128, complex points=4096, and spectral 
width=4000 Hz with an acquisition time of 6 min 24 sec). Water suppression was 
achieved using variable power and optimized relaxation delays (VAPOR) (Tkac et al., 
1999). An unsuppressed water spectrum was subsequently acquired with 8 averages to be 
used as a chemical shift and concentration reference. One week following initiation of 
treatment, a post-therapy in vivo single voxel 1H MR spectrum was acquired for each 
animal. Pre and post-treatment spectra were processed and analyzed using Mnova Lite 
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5.2.5 software (Mestrelab Research, Santiago de Compostela, Spain). The water 
suppressed and unsuppressed free induction decays were processed by apodization of 10 
Hz followed by Fourier transformation. The spectra were phased and chemical shift and 
baseline correction were performed prior to integration of the water (4.7 ppm), tCho (3.2 
ppm), PUFA (2.8 ppm), and lipid (1.3 ppm) resonances. The metabolite/water ratio was 
determined for both pre- and post-treatment spectra. The percent change in metabolite 
concentration was then estimated by the formula: [post-treatment concentration – pre-
treatment concentration] *100% / pre-treatment concentration.  
2.15 Animal treatments 
Companion diagnostic evaluation in breast model. MRS was used to establish 
baseline tCho levels in a cohort of ten athymic nude mice bearing 4175-Luc+ tumors. 
Mice were injected i.p. for 5 consecutive days with either 100 µL saline or MN58b. 
Previous studies have reported that a 5 day treatment regimen of 4 mg/kg of MN58b was 
sufficient to lower tCho levels in mice (Al-Saffar et al., 2006). However, in our 
experience this dose was found to be toxic, thus the MN58b dose was reduced to 2 
mg/kg. A follow-up scan was then acquired 1 week after the pre-treatment scan. After 
post-treatment scanning, each animal was then injected i.v. with a trace dose (20 nmol) of 
JAS239 in ethanol/saline vehicle. After 24 hours, the mice were euthanized and each 
tumor was analyzed for NIRF as described above.  
Breast tumor growth inhibition. A cohort of fifteen athymic nude mice were 
inoculated with 4175-Luc+ tumors and split evenly into three treatment groups. A 2% 
DMSO in 0.9% saline vehicle was used to solubilize JAS239 at concentrations required 
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for therapeutic injection. Beginning 3 days post-inoculation, animals received a 100-µL 
i.p. injection of either control DMSO/saline vehicle, 2 mg/kg MN58b in DMSO/saline 
vehicle, or 4 mg/kg JAS239 in DMSO/saline vehicle daily for 5 consecutive days. Tumor 
volumes were assessed by caliper measurement for 30 days. 
Pharmacodynamic indicators of ChoKα inhibition in breast cancer. A second 
cohort of fifteen athymic nude mice was inoculated with MDA-MB-231 cells, which had 
previously been used in the literature for MRS assessment of our positive control ChoKα 
inhibitor, MN58b (Al-Saffar et al., 2006). When a volume of approximately 300 µL was 
reached, tumors were scanned for baseline metabolite levels. Tumor volume estimates 
were made based upon the T2-weighted images. The animals were separated randomly 
into treatment groups, and for 5 consecutive days each group was injected i.p. with 100 
µL of control DMSO/saline vehicle (n = 5), 2 mg/kg MN58b in DMSO/saline vehicle (n 
= 4), or 4 mg/kg JAS239 in DMSO/saline vehicle (n = 3). Differences in cohort size are 
due to variability in tumor growth rate and the inability to place voxels within post-
treatment tumors that were too small, resulting in the animal being removed from further 
study. Follow-up MRI/MRS scanning was used to assess tumor growth inhibition and 
changes in metabolite levels between treatment groups. Blood was collected from each 
animal by cardiac puncture and stored in heparin-coated tubes. Each resected tumor was 
embedded in Optimum Cryo-Temperature (Sakura Finetek, Torrance, CA), flash-frozen 
in liquid nitrogen, and stored at -80°C for histological assessment. Blood samples were 
submitted to the Diagnostic labs of the Ryan Veterinary Clinic for liver profiling and 
toxicological assessment. 
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ChoK inhibition in glioma tumors. The Poptani group treated ten tumor-bearing 
animals with MN58b at 2 mg/kg/day i.p. for 5 days (Kumar et al., 2015). This dose was 
calculated using the FDA guidelines for cross-species equivalence, which suggests a 2 
mg/kg rat dose is roughly equivalent to a 4 mg/kg mouse dose. A separate cohort of 
tumor bearing animals (n = 3) were treated with an i.p. injection of 1 mL saline daily for 
5 days. Two animals died during the MN58b treatment resulting in post-MN58b data 
from only 8 animals. The death of these animals was most likely due to the tumor burden, 
as no overt indications of toxicity were noted as a result of MN58b toxicity: loss of 
weight, change in grooming or social habits, fur ruffling, or change in eye color. 
The tumor bearing animals were anesthetized with an overdose of ketamine/xylazine. 
Following lack of deep tendon responses, the head was decapitated and the brain was 
removed from the skull. Tumor tissue and contralateral normal brain tissue were 
harvested from each animal under aseptic conditions in a laminar flow hood. PCA 
extractions and high-resolution 1H NMR studies were performed on tissue samples from 
contralateral normal brain, saline, and MN58b-treated tumor tissue on a 500 MHz vertical 
bore NMR scanner (Bruker, Billerica, MA) using the same experimental protocol as 
described for cell extracts. 
2.16 Histopathology 
Tumors were kept frozen (-80°C) in Optimum Cryo-Temperature blocks for 1 week. 
For hematoxylin and eosin (H&E) staining, slides were first post-fixed in methanol at -
20°C before staining using a Shandon Gemini automated stainer (ThermoFisher). Briefly 
slides were rehydrated by immersion in a series of descending ethanol dilutions (100%-
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70%) then rinsed in water. Slides were stained in hematoxylin (Azer Scientific) for 1 min 
followed by a water rinse and dip in acid alcohol (0.1% HCl, 50% EtOH). Slides were 
then rinsed in tap water for 15 minutes followed by 1 minute in eosin (Azer Scientific). 
Slides were dehydrated in a series of ascending ethanol dilutions (70%-100%) followed 
by xylene before cover-slipping with Cytoseal (Fisher Scientific).  
For immunohistochemistry of tissue slices, slides prepared from each fresh frozen 
tumor were placed directly in pre-cooled (-20°C) methanol and dried for 10 minutes at 
room temperature and 5 minutes at 55°C. Slides were then placed in 10% neutral 
buffered saline for 20 minutes, rinsed in ddH2O, and rinsed for 5 minutes at room 
temperature in 0.1 M Tris Buffer. Caspase-3 (R&D Systems AF835) and Ki67 (Abcam 
ab16667) antibody staining was performed on a Bond Max automated staining system 
(Leica Microsystems) using the Bond Intense R staining kit (Leica Microsystems 
DS9263). The standard kit protocol was followed with the exception that the primary 
antibody incubation period was extended to 1 hour at room temperature. Avidin-Biotin 
Blocking was added to reduce non-specific binding (Vector Labs SP-2001), and a Peptide 
Blocking step was added (DAKO X0909). The Caspase-3 antibody was used at a dilution 
of 1:1000 and Ki67 was used at 1:100. Antigen retrieval was performed using E2 (Leica 
Microsystems) retrieval solution for 20 minutes. Biotinylated Anti-Rabbit Secondary 
(Vector BA-1000) was used at a 1:200 dilution. After staining, slides were rinsed, 
dehydrated in a series of ascending concentrations of ethanol and xylene, then cover-
slipped. Cryo-sectioning and slide-staining was performed by Socrates Agrio-O'Reilly 
and Carly David of the CHOP Pathology Core Laboratories.  
57"
"
Each slide was scanned at 20X magnification using the Aperio Scan Scope OS 
(Aperio Technology, Vista, CA). The Image Scope viewing software and nuclear staining 
algorithm V.9 (version 9; Aperio Technologies, Inc.) were used to quantify Ki67 and 
Caspase-3 positive nuclei in representative regions of each slice. Intensity thresholds and 
cell segmentation parameters were optimized by Daniel Martinez of the CHOP Pathology 
Core Facility to ensure unbiased manual scoring. The percentage of nuclei with strong-
positive staining were reported for each region of interest and averaged among treatment 
cohorts. 
2.17 Statistical analysis 
Data are reported as the mean + standard deviation (SD) of three separate 
experiments (n = 3), unless noted otherwise. Probability (P) values were calculated in 
Microsoft Excel 2010 (Version 14.0.7128.5000 32-bit) using a 2-tailed Student’s t-test, 
except in specified cases. P-values < 0.05 were considered statistically significant. 
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CHAPTER 3 
Chemical Synthesis 
3.1 Introduction  
There are a number of limitations to the current approach to identify and validate 
ChoKα inhibitors in vivo. Small molecules offer a pharmacokinetic advantage over 
macromolecules, but the choline-mimetic 11C and 18F-labeled tracers cannot distinguish 
choline transporter inhibition from choline phosphorylation inhibition (Zheng et al., 
2007). This is a limitation because choline transport inhibition can often lead to severe 
toxicities (Boobis et al., 1975). Non-invasive MRS evaluation can measure choline 
metabolite pools in the steady state, but cannot distinguish ChoKα activity from the 
diverse anabolic and catabolic pathways that use choline as a building block. Several bis-
pyridinium and bis-quinolinium small molecules that have been demonstrated to bind to 
and inhibit ChoKα in a specific manner (Campos et al., 2006). These ChoKα inhibitors 
share many structural features (symmetric terminal heterocyclic groups containing 
quaternary ammonium groups connected by a lipophilic linker moiety) with a class of 
fluorescent small molecules known as the carbocyanines. In this work, a number of 
choline mimetic molecules were prepared, and their optical properties were characterized 
to identify possible inhibitors with fluorescence in the NIR range (Fig. 3.1). Three 
synthetic approaches were employed: 1) addition of a NIR fluorophore to choline, 2) 
modification of the known ChoKα inhibitor called MN58b, and 3) incorporation of 
choline-like moieties to a carbocyanine structure. 
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Figure 3.1. Class of compounds synthesized as potential ChoKα inhibitors. Each of the 
above compounds were synthesized in the Delikatny Lab under guidance of Dr. Anatoliy Popov. 
These structures represent derivatives of choline, bis-pyridiniums, and carbocyanines. 
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3.2 Pyro-Choline 
A pyropheophorbide conjugated to a methyl group of choline via a 
polyethyleneglycol (PEG) spacer was generously provided by Dr. Anatoliy Popov of the 
Department of Radiology at the University of Pennsylvania. This product, named 
PyroCho, exists as a dark green solid. Susceptible to photodegradation, PyroCho was 
stored at -20oC and reconstituted in stock solutions by measuring the absorbance in a 
cuvette and calculating concentration using the Beer-Lambert law and the extinction 
coefficient value (at 665 nm) of 50,000 L mol-1 cm-1. There are two absorbance peaks 
occurring at 418 nm and 665 nm.  Excitation at either absorbance peak results in 
fluorescence with maximal emission at 670 nm. Excitation at 660 nm also produces a 
second fluorescence at 725 nm that can be used for NIRF optical imaging. Above 10 µM, 
the fluorescence is no longer linearly-proportional to concentration due to stacking and 
self-quenching of the pheophorbide rings. The calculated partition coefficient (cLogP) of 
PyroCho is 6.24 (Table 1). 
3.3 MN58b 
1,4-Bis(4-bromomethylphenyl)butane. 1,4-Diphenylbutane (2 g, 9.51 mmol) was 
added to a mixture of 48% aqueous HBr (4.15 mL, 39.9 mmol) and glacial AcOH (50 
mL), followed by 1,3,5-trioxane (0.57 g, 6.34 mmol) and hexadecyltrimethylammonium 
bromide (52 mg, 0.143 mmol). The mixture was stirred such that only a single layer 
could be seen then heated to a gentle reflux for 8 hours. The volatiles were removed 
under reduced pressure. The product was isolated by column chromatography (silica gel, 
hexane/benzene 1/1, v/v). The isolated 1,4-bis(4-bromomethylphenyl)-butane (1.959 g, 
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yield 52%) was a white solid, mp 119 to 121oC (from acetone). 1H NMR (500 MHz, 
CDCl3, δ ppm) 7.04 ppm (AB, A = 7.18, B = 6.89, JAB = 9 Hz, 8H), 4.53 (s, 4H), 2.66 (m, 
4H), 1.62 (m, 4H).  
1,10 -((Butane-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4-
(dimethylamino)pyridin-1-ium) bromide (MN58b). The mixture of 4-
dimethylaminopyridine (238.0 mg, 1.948 mmol) and 1,4-bis(4-
bromomethylphenyl)butane (385.9 mg, 0.974 mmol) in dry ethanol (30 mL) was heated 
and stirred at 160oC in a 45 mL Parr autoclave equipped with a magnetic stirring bar for 3 
hours. The white solid product was precipitated twice from ethanol into diethyl ether, 
dissolved in deionized water and lyophilized. Yield: 96%, melting point (mp) 103 to 
106oC (from water). 1H NMR (360 MHz, CD3OD, δ ppm): 8.21 (dt, J = 7.6 Hz, J = 2.9 
Hz, 4H, H-2pyr), 7.29 (dm, J = 7.9 Hz, 4H, Ph), 7.23 (dm, J = 7.9 Hz, 4H, Ph), 7.00 (dm, 
J = 7.6 Hz, 4H, H-3pyr), 5.33 (s, 4H, CH2N+), 3.25 (s, 12H, N(CH3)2), 2.64 (m, 4H, 
CH2-C6H4), and 1.62 (m, 4H, C–CH2–C).  
3.4 WM-11 
To explore the effect of introducing a conjugated double bond network between the 
quaternary ammonium groups of MN58b, we replaced the 1,4-diphenylbutane linker with 
1,4-diphenylbutadiene and proceeded with the same bromination step used in MN58b 
synthesis. After 1 hour of heating at 105oC, however, the mixture turned into a black tar. 
Several strategies were employed to isolate crystals from the mixture by Dr. Anatoliy 
Popov and a student, William Marrero-Ortiz , but these were unsuccessful and it was 
determined that the desired product was not present in the mixture. A more stable 
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resonant linker using 4-(4-(4-(hydroxymethyl)phenyl)phenyl)phenyl)methanol in place of 
1,4-diphenylbutadiene has recently been proposed by Dr. Popov. The 1,4-bis(4-
(bromomethyl)phenyl)benzene intermediate has been successfully purified, and will soon 
be dissolved in ethanol and condensed with 4-dimethylaminopyridine in an autoclave 
reaction to produce the MN58b derivative WM-11. 
!
 
Figure 3.2. Colorimetric monitoring during JAS239 synthesis. (A) Cyanine dyes were purified 
by silica gel column chromatography and (B) fractions were separated by color. (C) A sample 
from each fraction was placed in a cuvette and analyzed for absorbance and fluorescence in a 
spectrophotometer. 
"  
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3.5 JAS239 
1-(2-Hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride. A mixture of 2,3,3-
trimethyl-3H-indole (1,592.3 mg, 10 mmol) and 2-chloroethan-1-ol (1,610.2 mg, 20 
mmol) in dry ethanol (15 mL) was heated and stirred at 160oC in a 45 mL Parr autoclave 
equipped with a magnetic stirring bar for 4 hours. The purple solid product was 
precipitated twice from ethanol with diethyl ether. Yield 86%. 1H NMR (360 MHz, 
CD3OD, δ ppm): 7.88 ppm (m, 1H), 7.77 (m, 1H), 7.65 (m, 2H), 4.68 (m, 2H), 4.06 (m, 
2H), 1.63 (s, 6H), labile OH and N = C–CH3 protons are in exchange with CD3OD. 
MALDI-TOF, m/z: (M-Cl)+ 204.35, calculated for C13H18NO 204.14. 
1-(2-Hydroxyethyl)-2-((1E,3E,5E)-7-((Z/E)-1-(2-hydroxyethyl)-3,3-
dimethylindolin-2-ylidene)hepta-1,3,5-trien1-yl)-3,3-dimethyl-3H-indol-1-ium chloride 
(JAS239). A solution of acetic anhydride (112.3 mg, 1.1 mmol) in CH2Cl2 (2 mL) was 
added to a cooled (-20oC), stirred suspension of N-((1E,3E,5Z)-5-(phenylimino)penta-
1,3-dien-1-yl) benzenaminium chloride (142.4 mg, 0.5 mmol) and triethylamine (222.6 
mg, 2.2 mmol) in CH2Cl2 (10 mL). The resulting clear solution was stirred for another 3 
hours at room temperature (RT) and concentrated under high vacuum. The residue 
containing N-phenyl-N-((1E,3E,5Z)-5-(phenylimino)penta-1,3-dien-1-yl)acetamide was 
dissolved in ethanol (5.0 mL) and added drop-wise to a refluxing solution of 1-(2-
hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride (360.0 mg, 1.5 mmol) and 
anhydrous sodium acetate (200 mg, 2.5 mmol) in ethanol (100 mL). The mixture was 
refluxed for 5 hours and concentrated. The product JAS239 was isolated by column 
chromatography [silica gel, ethyl acetate–methanol (0–100%)] (Fig. 3.2A). Fractions 
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isolated from the column (Fig. 3.2B) were concentrated under high pressure and the 
fraction containing pure product (JAS239) was identified by spectrophotometric analysis 
(Fig. 3.2C). Yield 19.9%. 1H NMR (360 MHz, CD3OD, δ ppm): 7.93 [t (dd), J = 13.1 Hz, 
2H]; 7.58 [t (dd), J = 12.8 Hz, 1H]; 7.46 (d, J = 7.2 Hz, 2H); 7.38 (td, J = 7.4 Hz, J = 1.1 
Hz, 2H); 7.29 (d, J = 7.9 Hz, 2H); 7.23 (td, J = 7.2 Hz, J = 0.7 Hz, 2H); 6.53[t(dd), J = 
12.6 Hz, 2H]; 6.35 (d, J = 13.7 Hz, 2H); 4.21 (t, J = 5.8 Hz, 4H); 4.92 (t, J = 5.8 Hz, 4H); 
1.70 (s, 12H). MALDI-TOF, m/z: (M–Cl)+ 469.56, calculated for C31H37N2O2 469.28. 
HPLC: one peak, retention time = 15.22 minutes."
3.6 hydro-JAS239  
The hydrocyanine form of JAS239 was prepared using a procedure outlined by 
Kundu et. al.  Briefly, 1.32 mg JAS239 was dissolved in methanol and a NaBH4 solution 
(3 mg dissolved in 0.5 mL methanol) was added drop-wise while stirring. The solution 
turned from dark green to yellow in an incremental fashion. After approximately 0.25 mL 
NaBH4 was added, the solution became colorless. The methanol was evaporated and 10 
mL of dichloromethane and 20 mL distilled water was added to the flask. The mixture 
was transferred to a separatory funnel and shaken vigorously. Pressure within the reaction 
vessel was relieved carefully. The bottom (organic) layer was added to a fresh flask and 
product was extracted from the aqueous phase with two additional dichloromethane 
separations. The organic phase was dried over anhydrous sodium sulfate and the 
dichloromethane was removed under reduced pressure. The resulting product, hydro-
JAS239, was used without further purification.  
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3.7 JAS239.5 
Addition of a benzo-moiety to the indolium group is common for in vivo fluorophore 
design because this induces a bathochromic shift of approximately 30 nm, which can help 
reduce background autofluorescence. This modification also has the potential to increase 
the lipophilicity of the compound, which may make it more cell permeable. We prepared 
a JAS239 derivative using 1,1,2-trimethyl-1H-benz[e]indole as a starting indolium for the 
head groups. The same synthetic procedure for JAS239 was followed for the synthesis of 
JAS239.5. Yield 17.3%. 1H NMR (360 MHz, CD3OD, δ ppm): 8.23 (d, J = 8.3 Hz, 2H); 8.04 (t, 
J = 13.3 Hz, 1H); 7.98 (d, J = 8.6 Hz, 4H); 7.68-7.56 (m, 6H); 7.47 (td, J = 7.4 Hz, J = 1.1 Hz, 
2H); 6.57 (t, J = 12.6 Hz, 2H); 6.38 (d, J = 14.0 Hz, 2H); 4.33 (t, J = 5.8 Hz, 4H); 3.99 (t, J = 5.4 
Hz, 4H), 1.90 (s, 12H). 
3.8 JAS259 
To improve the water solubility of JAS239, replacement of the dimethyl-substituted 
carbon at the C3 position of the starting indolium salt with sulfur was proposed. The 
same procedure described for JAS239 was followed using 2-methylbenzothiazole in 
place of the trimethyl-indolium group. Following successful alkylation with 2-
chloroethanol, the benzothiazole head group was dissolved in ethanol and heated under 
reflux conditions in the presence of sodium acetate and the precursor linker group (N-
phenyl-N-((1E,3E,5Z)-5-(phenylimino)penta-1,3-dien-1-yl)acetamide) using the same 
procedure described for JAS239 synthesis. The sulfur group was found to be thermolabile 
at high temperatures and the desired product was not detected by spectrophotometric 
analysis. A previous report in the literature (Okoh et al., 2014) described a similar 
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benzathiazole-based cyanine synthesis and found that the condensation reaction of the 
head group and acetylated linker could be achieved at room temperature without 
degradation. After this adjustment was made to the second synthetic step, 2-(2-
((1E,3E,5E)-7-(3-(2-hydroxyethyl)-1,3-benzothiazol-2-ylidene)hepta-1,3,5-trienyl)-1,3-
benzothiazol-3-ium-3-yl)ethanol chloride (JAS259) could be purified by column 
chromatography. Yield 15.7%. 1H NMR (360 MHz, CD3OD, δ ppm): 8.33-8.23 (m, 6H), 8.02 
(t, J = 13.1 Hz, 1H); 7.94-7.80 (m, 4H); 6.57 (t, J = 12.6 Hz, 2H); 6.37 (d, J = 13.7 Hz, 2H); 4.93 
(t, J = 5.4 Hz, 4H); 4.07 (t, J = 5.4 Hz, 4H).  
With the knowledge gained from synthesis of JAS259, a derivative using oxygen in 
the place of sulfur was designed (JAS275). In place of the indole starting group in 
JAS239, a 2-methylnaphth(2,1-d)oxazole was used. Alkylation with 2-chloroethanol was 
carried out following a similar scheme to that reported for JAS239 synthesis. Similar to 
the JAS259 precursor, the reduced steric hindrance in this sulfur derivative (relative to 
the dimethyl-substituted carbon group in JAS239) allowed for the alkylation reaction to 
be run at room temperature, rather than in an autoclave. The oxygen within this 
heterocyclic system proved to be too reactive under these conditions, and the reaction 
failed to produce the desired hydroxyethylated ring structure.  
3.9 JAS273 and JAS274 
To explore the importance of the hydroxylated alkyl chain, two JAS239 derivatives 
were prepared with either hydroxypropyl (JAS273) or hydroxybutyl (JAS274) alkyl 
substitutions. For JAS273, preparation of the 1-(3-hydroxypropyl)-2,3,3-trimethyl-3H-
indolium iodide precursor was performed in accordance with methods described 
previously (Darwish et al., 2010). Alkylation of 2,3,3-trimethylindolenine with 3-iodo-1-
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propanol in toluene was heated at reflux (130°C) for 2 hours. The color was observed to 
change from yellow to dark rose. The intermediate product was precipitated by addition 
of excess hexane. The acetylated linker group prepared for JAS239 synthesis was used 
for linkage of the hydroxypropyl-trimethyl-indolium head groups. The acetylated linker 
group, two times excess of the indolium group, and excess sodium acetate were heated in 
ethanol under reflux conditions (100oC) overnight while protected from light. A similar 
synthetic procedure was followed for preparation of JAS274 with 4-iodo-1-butanol as a 
precursor.  
3.10 PepTech compounds  
After the initial synthetic strategies for MN58b and JAS239 derivatives were 
designed with guidance from Dr. Popov and shown feasible, we turned to the PepTech 
Corporation (Bedford, MA) to synthesize a small library of analogs. These compounds, 
outlined in Figure 3.3, represent two major strategies. A variety of linker groups were 
used to make resonant MN58b analogs. In these compounds, cis (Z) and trans (E) 
conformations were explored. Movement of the quaternary ammonium groups from the 
outer ring moieties to the inner rings gave a stronger likelihood of fluorescence, as these 
compounds have a linker group whose structure was derived from the fluorophore 
viologen. As an additional positive control to be used in conjunction with MN58b, TCD-
717 was synthesized. The second modification strategy involved cyclization within the 
linker group of JAS239. Similar “cyclo” derivatives have been described in the literature 
with improved fluorescence quantum yield compared to the non-cyclized counterpart 
(Yang et al., 2010). To test the importance of the choline mimetic alkyl groups, the 
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hydroxyethyl moieties were replaced with methyl groups and represent the cyclized 
version of 1,1’,3,3,3’,3’-hexamethylindotricarbocyanine iodide (HITC). 
 
 
 
Figure 3.3. Second generation JAS239 analogs contracted to PepTech Corporation. The 
structures above were designed as next generation fluorescent ChoKα inhibitors. TCD-717 was 
also synthesized as an additional positive control. Due to unstable intermediate groups, the 
synthesis of Z-conformation (Z,Z and Z,E) and viologen MN58b derivatives was not feasible. 
"  
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3.11 Results 
The structural similarities between the bis-pyridinium/quinolinium ChoK inhibitors 
and the carbocyanine dyes led us to hypothesize that similar pharmacologic activity could 
exist between the 2 classes of compounds. To test our hypothesis, we designed a 
carbocyanine dye substituted with choline-like N+-CH2-CH2-OH moieties at the nitrogen 
atom of the indolium ring. The synthesis of the carbocyanine precursor, 1-(2-
hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride, was performed in ethanol within 
an autoclave at high temperature to shorten the reaction time considerably from previous 
reports in the literature (Ye et al., 2003). Stable 2-chloroethan-1-ol was used as the 
alkylating agent, rather than the unstable and more expensive bromo or iodo derivatives, 
to increase the yield and stability of the intermediates. In the final step, we modified a 
previously reported procedure for the synthesis of C7-carbocyanine (Ye et al., 2003) to 
run at a higher temperature by replacing methanol with ethanol as the solvent. This 
allowed a reduction in the condensation time from 16 to 5 hours. The reaction can be 
supervised by colorimetric monitoring as depicted in Figure 3.4A. The final compound, 
JAS239, demonstrated NIR fluorescence, with an excitation maximum at 740 nm and 
emission at 770 nm (Fig. 3.5). As a measurement of water solubility, the cLogP was 
calculated in ChemBioDraw Ultra (Version 13.0.0.3015) to be 3.37 (Table 1). 
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Figure 3.4. Synthetic pathway for the preparation of prototype ChoKα inhibitors. (A) 
JAS239 synthesis: (a) 2-chloroethan-1-ol, autoclave 160oC, 4 hr; (b) Ac2O, Et3N, DCM, -20oC-RT, 
3 hr; (c) AcONa, EtOH, reflux, 5 hr. (B) MN58b synthesis: (d) HBr, cetyltrimethylammonium 
bromide [C16H33N(CH3)3Br], acetic acid, reflux, 8 hr; (e) N,N-dimethylpyridin-4-amine, EtOH, 
autoclave 160oC, 3 hr. Synthesis was designed and performed with guidance of Anatoliy Popov. 
 
 
 
 
 
Figure 3.5. Optical properties of JAS239. Dissolved in methanol, JAS239 has maximal 
absorption at 745 nm and maximal fluorescence emission at 775 nm. 
"  
JAS239 
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Table 1. Calculated Partition Coefficients for synthesized structures.  
 
 
To compare the 2 classes of compounds, we synthesized MN58b as a positive control. 
The synthesis of MN58b has been reported in 2 papers where it was referred to as 
Compound 41 (Campos et al., 2002; Conejo-García et al., 2011). In this Chapter, we 
include a detailed description of the synthesis of the intermediate 1,4-bis(4-
bromomethylphenyl)butane (Fig. 3.4B), which was not provided in the original papers 
(Goodson and Goodwin, 1948; Cram and Steinberg, 1951) or in either of the papers 
describing the synthesis of MN58b (Campos et al., 2002; Conejo-García et al., 2011). In 
addition, we have improved upon the synthesis of MN58b (Fig. 3.4B) by using an 
autoclave method following the phase transfer catalyzed bromomethylation (Mitchell and 
Iyer, 1989). This decreases the reaction time from 192 hours (Conejo-García et al., 2011) 
to 3 hours with 50% yield and cLogP of 1.24 (Table 1). The melting point of our MN58b 
product differs from that in (Conejo-García et al., 2011), where it is reported as 161oC to 
163oC, but is consistent with the values of 98oC to 100oC when the compound was 
Compound cLogP 
PyroCho 6.24 
JAS239 3.37 
MN58b 1.24 
hydro-JAS239 7.29 
JAS239.5 5.72 
JAS259 2.74 
E,E-conjMN58b 0.63 
E,E,E-conjMN58b 1.23 
TCD-717 7.47 
cycloJAS239 4.42 
cycloJAS239.5 6.77 
cycloHITC 6.81 
cycloHITC.5 9.16 
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crystallized from water (Campos et al., 2002). Our attempts to make MN58b derivatives 
with a resonant structure, such as WM-11, have thus far failed to yield a final product. 
Reduction of JAS239 by sodium borohydride eliminated the characteristic dark green 
color of the dye and this colorless hydro-JAS239 (Fig. 3.6) could be separated from its 
fluorescent parent compound by extraction in an organic solvent. The transition from a 
hydrophilic to a hydrophobic state was successfully predicted by its cLogP of 7.29 (Table 
1). Inclusion of an additional benzyl moiety to the JAS239 head group (JAS239.5) 
resulted in the expected 30 nm bathochromic shift in absorbance (Ex. 775 nm) and 
fluorescence (Em. 815 nm) maxima. The theoretical cLogP was calculated to be 5.72 
(Table 1), confirming increased hydrophobicity from the two ring additions. The 
indolium head group of JAS239 was replaced with a benzothioazole heterocycle, and the 
fluorescence spectrum of JAS259 showed maximal absorbance at 755 nm and emission at 
785 nm. The cLogP was determined computationally to be 2.47 (Table 1). When the 
indolium head group was replaced with a naphthoxazole, however, the starting 
heterocyclic ring was unstable during the alkylation step, resulting in a number of 
impurities. A comparison of the 1H NMR spectra from the final product mixture and the 
starting naphthoxazole compound revealed that this ring degradation lowered the reaction 
yield to less than 25% of the desired product. For JAS273 and JAS274, the absorbance 
and fluorescence properties of each set of reaction products were assessed by 
measurement in a cuvette. No bathochromic shift in absorbance was observed when 
product absorbance spectra were compared to the starting materials. No fluorescence was 
detected in the near infrared wave range for either compound.  
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Figure 3.6. Colorimetric comparison of JAS239 before and after reduction. JAS239 
dissolved in 1% ethanol is dark green (left). Following reduction with NaBH4, the resultant hydro-
JAS239 is colorless. 
 
 
 
 
Figure 3.7. UV fluorescence of MN58b and JAS239 derivatives. Frozen vials of (clockwise 
from top left) water, TCD-717, E,E-conjMN58b, E,E,E,-conjMN58b, cycloHITC.5, cycloHITC, 
cycloJAS239.5, and cycloJAS239 are pictured under (A) white light and (B) UV light. UV 
fluorescence is detected in the E,E-conjMN58b and E,E,E,-conjMN58b vials. Background 
fluorescence is also observed from the parafilm wrapping. 
"  
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Seven compounds in total were successfully synthesized by the PepTech Corporation, 
including 1,1’-(((1E,3E)-buta-1,3-diene-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4-
(dimethylamino)pyridin-1-ium) chloride (PTC1452-01); 1,1’-(((1E,3E,5E)-hexa-1,3,5-
triene-1,6-diylbis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridin-1-ium) 
chloride (PTC1452-02), 1,1’-((1,1’-biphenyl)-4,4’-diylbis(methylene))bis(4-((4-
chlorophenyl)(methyl)amino)quinolin-1-ium) bromide (PTC1452-07); 1-(2-
hydroxyethyl)-2((E)-2-((E)-3-((E)-2-(1-(2-hydroxyethyl)-3,3-dimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)3,3-dimethyl-3H-indol-1-ium iodide 
(PTC1452-08); 3-(2-hydroxyethyl)-2((E)-2-((E)-3-((E)-2-(3-(2-hydroxyethyl)-1,1-
dimethyl-1H-benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)1,1-
dimethyl-1H-benzo[e]indol-3-ium iodide (PTC1452-09); 1,3,3-trimethyl-2-((E)-2-((E)-3-
((E)-2-(1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)3H- indol-
1-ium iodide (PTC1452-10); 1,3,3-trimethyl-2-((E)-2-((E)-3-((E)-2-(1,3,3-trimethyl-1H-
benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)1H- benzo[e]indol-3-
ium iodide (PTC1452-11). These will be referred to as E,E-conjMN58b (non-fluorescent; 
cLogP = 0.63), E,E,E-conjMN58b (non-fluorescent; cLogP = 1.23), TCD-717 (non-
fluorescent; cLogP = 7.47), cycloJAS239 (Ex. 748 nm, Em. 787 nm; cLogP = 4.42), 
cycloJAS239.5 (Ex. 784 nm, Em. 843 nm; cLogP = 6.77), cycloHITC (Ex. 743 nm, Em. 
783 nm; cLogP = 6.81), and cycloHITC.5 (Ex. 779 nm, Em. 840 nm; cLogP = 9.16), 
respectively. The synthesis and analysis of these compounds can be found in Appendices 
1-7. E,E-conjMN58b and E,E,E-conjMN58b did not exhibit fluorescence within the NIR 
range, however, when frozen and imaged under a UV lamp, fluorescence could be 
detected (Fig. 3.7). Attempts to synthesize MN58b derivatives with the Z-conformation 
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proved untenable due to double bond isomerization during the palladium-catalyzed 
reduction of the alkyne groups in the precursor compound. The viologen-based MN58b 
derivatives failed at the final condensation step. 
3.12 Discussion 
The goal of this study was to develop an NIR fluorescent choline mimetic by 
exploiting the structural similarities between the existing bis-symmetric inhibitors and the 
carbocyanine dyes. Taking into consideration the structural properties established by the 
Lacal group for ChoK-specific inhibition (Sánchez-Martín et al., 2005), we developed an 
autoclave Menshutkin alkylation method for carbocyanine synthesis, which successfully 
reduced the time required to alkylate the ammonium group of the indolium moiety by 11 
hours (Arlauckas et al., 2014). Choline-mimetic hydroxyethyl alkyl groups were attached 
at the ammonium sites within the heterocyclic head groups on either side of a 7-carbon 
spacer. The 7-carbon spacing is important because it imparts fluorescence in the NIR 
range, outside the range of autofluorescence. We then adapted the autoclave method to 
establish a rapid and high-yield synthesis of MN58b, the most-effective ChoK inhibitor 
in the literature. 
A number of JAS239 derivatives were prepared in an effort to test the effect of 
hydrophilicity, absorbance wavelength, and alkyl chain length. The hydro-JAS239 
compound was hydrophobic and colorless, consistent with our expectations for 
hydrocyanine modification. These properties have the theoretical potential to improve the 
permeability to the cell membrane and to reduce background signal from dye that is not 
cell-associated. However, these dyes also rely on being oxidized in cells or tissues in 
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order to be observed with fluorescence imaging. Similar attempts at synthesizing an oxa 
derivative were unsuccessful due to degradation of the reaction intermediate. A modified 
version of this synthesis running at -20°C is currently being explored in our group, but 
the product has yet to be isolated due to the time required for reaction completion. 
Similarly for compounds JAS273 and JAS274, where the alkyl chain of the choline 
mimetic was extended to 3 and 4 carbons, it is thought that impurities caused by 
cyclization of the alkyl group prevented the condensation reaction from occurring. 
Cyclization within the linker group seems to have yielded stable and bright JAS239 
(cyclo) derivatives, and this minimization of rotational bonds may improve the 
pharmacokinetics of these probes (Lipinski, 2003).  
While the syntheses of many resonant MN58b derivatives were unsuccessful, the 
E,E-conjMN58b and E,E,E-conjMN58b compounds are promising ChoKα inhibitor 
candidates. Detection of fluorescence in the solid state opens the possibility that binding 
of these less rigid molecules to a stable active site may stabilize the structure and impart 
fluorescence, albeit not at ideal wavelengths for in vivo imaging purposes. 
The number and variety of previously reported ChoK inhibitors suggests that there 
exists a certain degree of flexibility in the functional groups and spacers, which can yield 
effective candidate therapeutics. The major concerns for analogs of HC-3 in vivo are that 
they (i) will nonspecifically target normal tissue; (ii) will disrupt choline uptake into 
normal cells, which can lead to neuronal toxicity; or (iii) will be prone to DNA 
intercalation, resulting in ChoK-independent cell death. The inherent fluorescence of a 
carbocyanine-based inhibitor greatly simplifies the process of excluding candidates that 
inhibit choline phosphorylation, but are not properly delivered to the intended tissue or 
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subcellular compartment. The ability to track the cellular uptake of these fluorophores 
using fluorimetry and confocal microscopy also permits the determination of potential 
interactions with choline transporters, which could affect the interpretation of the efficacy 
of ChoK inhibition in vitro. This is also important because compounds that inhibit 
choline transport have been shown to lead to respiratory paralysis in animals. The broad 
excitation range of JAS239 and its fluorescence in the NIR window wherein breast tissue 
is relatively transparent makes it possible to study (i) plasma half-life, biodistribution and 
tumor localization; (ii) cellular uptake pathways and kinetics; and (iii) subcellular 
localization by in vitro and ex vivo microscopy.  
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Chapter 4 
JAS239 characterization in breast cancer cells 
4.1 Introduction  
Upregulation of choline kinase alpha (ChoKα) has been correlated with histologic 
tumor grade and resistance to antiestrogen therapies in breast cancer, ultimately 
indicating a poorer prognosis (Ramírez de Molina, Gutierrez, et al., 2002). ChoKα 
catalyzes the conversion of choline to phosphocholine (PC), an important second 
messenger and the first step in the biosynthesis of the predominant membrane 
phospholipid, phosphatidylcholine (PtdCho). ChoKα activity can be enhanced by a 
number of clinically relevant oncogenes (Bhakoo et al., 1996; Ramírez de Molina, 
Penalva, et al., 2002; Ramírez de Molina et al., 2005), growth factors (Warden and 
Friedkin, 1984; Cuadrado et al., 1993; Jiménez et al., 1995), transcription factors 
(Aoyama et al., 2007; Glunde et al., 2008), and carcinogens (Ishidate et al., 1980). 
Furthermore, ChoKα overexpression alone is sufficient to induce malignant 
transformation (Ramírez de Molina et al., 2005). The 9 chemically equivalent protons in 
choline yield a strong singlet resonance detectable by proton magnetic resonance 
spectroscopy (1H MRS). MRS studies have found increasing PC and total choline (tCho) 
levels as breast cell lines progress from normal to immortalized, to oncogene 
transformed, to malignant (Aboagye and Bhujwalla, 1999). In vivo 1H MRS studies have 
identified choline accumulation in 83% of breast lesions (Katz-Brull et al., 2002). 
Furthermore, alterations in choline and lipid metabolism detected by MRS are predictive 
of tumor response to certain therapies (Negendank, 1992; Delikatny et al., 2011). 
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Figure 4.1. Cellular mechanisms affecting the intracellular pool of PC. Choline (Cho) uptake 
via Cho transporters (ChoT) and entry into the Kennedy pathway of PtdCho biosynthesis (black) 
by which Cho is phosphorylated by ChoK (EC 2.7.1.32), then converted to CDP-Cho and PtdCho 
by choline phosphate cytidylyltransferase (CCT; EC 2.7.7.15) and phosphocholine diacylglycerol 
transferase (PCT; EC 2.7.8.2), respectively. The four catabolic routes: (ii) membrane 
sphingomyelin (SM) hydrolyzed by sphingomyelinase (SMase; EC 3.1.4.12; green) to PC and 
ceramide; (iii) PtdCho deacylation to lyso-PtdCho (LPC), GPC, and Cho (yellow) by 
phospholipase A2 (PLA2; EC 3.1.1.4), and lysophospholipase (EC 3.1.1.5) or phospholipase A1 
(PLA1; EC 3.1.1.32), and GPC: phosphodiesterase (GPC:PDE; EC 3.1.4.2), respectively; (iv) 
PtdCho hydrolysis directly to Cho and phosphatidic acid by phospholipase D (PLD; EC 3.1.4.4; 
red); (v) PtdCho hydrolysis directly to PC and diacylglycerol via PtdCho-specific phospholipase C 
(PLC; EC 3.1.4.3; blue). 1H MR-visible Cho metabolites that contribute to the composite tCho 
peak are in boxes. 
 
In vivo 1H MRS is limited by spectral resolution, with the tCho peak representing a 
composite resonance consisting of free choline, PC, and glycerophosphocholine (GPC). 
Phosphorus (31P) MRS is capable of distinguishing the phosphomonoester PC from the 
phosphodiester GPC, but 31P-MRS is relatively insensitive requiring large voxels in vivo. 
In addition, direct PC measurements are not always accurate descriptors of ChoKα 
activity because of the catabolic formation of PC by the phospholipase and 
sphingomyelinase enzymes (Fig. 4.1). There have been efforts to hyperpolarize choline 
with the intention of monitoring ChoKα activity (Gabellieri et al., 2008; Sarkar et al., 
2009); however, this approach is limited by the polarization lifetime of 15N and has yet to 
be demonstrated feasible in intact cells or in vivo tumor models. Radiolabeled 11C-choline 
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(Contractor et al., 2011) and 18F-choline (Bansal et al., 2008) are proving to be useful for 
positron emission tomography (PET) imaging in tumors that are not FDG avid, such as 
the prostate. However, isotope-labeled choline analogs are also dependent on the 
complex families of proteins responsible for choline transport (ChoT: high-affinity 
choline transporters, choline transporter-like proteins, organic cation transporters, and 
organic cation/carnitine transporters). Upregulation of these proteins has been 
demonstrated in some cancers but their involvement remains, for the most part, poorly 
understood (Eliyahu et al., 2007; Glunde et al., 2011). An alternative method to 
noninvasively detect ChoKα status would be useful to aid in clinical tumor assessment. 
ChoKα has garnered clinical attention as a biomarker of tumor malignancy, leading to 
its study as a treatment target. Silencing ChoKα via RNAi has been shown to reduce cell 
proliferation (Glunde et al., 2005), enhance the sensitivity of aggressive cell lines to 5-
fluorouracil (Mori et al., 2007), and reduce tumor growth rates (Al-Saffar et al., 2006) in 
breast cancer models. The choline mimetic, hemicholinium-3 (HC-3), has long been 
known to inhibit ChoKα, but also interrupts neuronal choline transport and 
acetylcholinesterase activity (Ansell and Spanner, 1974). Its neurotoxicity at doses 
relevant for ChoKα inhibition (Cannon, 1994) led to the development of molecules 
capable of blocking choline phosphorylation without causing respiratory paralysis 
(Hernández-Alcoceba et al., 1997). The most potent and specific ChoKα inhibitors to 
date have been established by the Lacal lab and were identified from quantitative 
structure–activity relationship studies of bis-pyridinium (Campos et al., 2001) and bis-
quinolinium (Sánchez-Martín et al., 2005) HC-3 mimetics (Fig. 4.2). These studies found 
that lipophilicity enhances antiproliferative activity but must be optimized because of 
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trade-offs in solubility. The top candidates identified were symmetric and featured 2 
aromatic heterocyclic head groups, containing quaternary ammonium elements, attached 
by a linker of optimized length (Campos et al., 2006). Many of the bis-pyridinium and 
bis-quinolinium structures feature electron-donating functional groups, which stabilize 
the positive charge and increase activity (Campos et al., 2001). Effective inhibitors have 
been identified from compounds with aromatic or aliphatic linkers, which can be used to 
optimize the antiproliferative properties. 
 
 
Figure 4.2. Templates for ChoKα-specific inhibitors. The bis-pyridinium (top) and bis-
quinolinium (middle) structures with electron-donating functional groups (R) and aromatic or 
aliphatic linkers. A novel template for ChoK inhibitors is proposed based upon the carbocyanines 
(bottom), whose fluorescence properties are determined by linker length and are substitutable at 
the A and R positions. 
 
1,10-((Butane-1,4-diylbis(4,1-phenylene))bis(methylene)) bis(4-
(dimethylamino)pyridin-1-ium) bromide (MN58b) is the best-characterized bis-
pyridinium ChoKα inhibitor, having been demonstrated to be effective against breast, 
colon (Al-Saffar et al., 2006), bladder (Hernando et al., 2009), and cervical cancer, as 
well as squamous cell carcinoma, histiocytic lymphoma, and chronic myeloid leukemia 
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models (Hernández-Alcoceba et al., 1999). As part of their transformation, cancer cells 
are thought to acquire an addiction to PC, which sensitizes them to ChoKα-targeted 
inhibition. MN58b treatment causes a temporary cell-cycle arrest in normal cells because 
of dephosphorylation of the checkpoint protein pRb. Active (unphosphorylated) 
retinoblastoma protein (Rb) prevents G1 to S-phase transition. Tumor cells are often 
insensitive to this growth arrest and attempt to bypass ChoKα blockade by excising the 
PC group from sphingomyelin for further PtdCho production, releasing ceramides as a 
by-product (Rodríguez-González et al., 2004). The accumulation of ceramides, in 
addition to attenuation of the proliferative PC signal, leads to tumor-specific apoptosis 
(Kolesnick, 2002). TCD-717, developed by TCD Pharma, is the best candidate among the 
bis-quinolinium compounds and has completed a phase I dose escalation clinical trial for 
solid tumor treatment (Ramírez de Molina et al., 2011). 
We sought to test the hypothesis that carbocyanine-derived HC-3 mimetics could be 
adapted to the established criteria for effective ChoKα inhibition (Fig. 4.2). The 
carbocyanine dyes contain a number of structural similarities to existing ChoKα 
inhibitors, including symmetric heterocyclic head groups containing quaternary 
ammonium moieties connected by an aliphatic spacer. A preliminary experiment run by 
Daniel Leung in our lab used 31P MRS to demonstrate that the addition of either HC-3 or 
dimethyloxacarbocyanine iodide (DMOCI; also abbreviated as CyDy) was capable of 
attenuating the conversion of choline to PC in a perfused cell model of prostate cancer 
(Fig. 4.3). This provided early evidence that this strategy is feasible and led to a search 
for fluorophores with better optical properties that could inhibit PC production. 
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Figure 4.3. Time dependent increases in PC resonances measured in 31P NMR spectra. 
DU145 cells grown on Biosilon beads were perfused in the presence of 2 mM choline (open 
circles). Time-dependent changes in PC concentration relative to beta-nucleoside triphosphate 
(β-NTP) were measured in real time in live cells following addition of hemicholinium-3 (HC-3, 
black circles) or DMOCI (CyDy, grey squares) to the perfusion media. Both the prototypical 
choline mimetic, HC-3, and the carbocyanine, DMOCI, are capable of attenuating choline 
phosphorylation (n = 1). Experiments were carried out by Daniel Leung of the Delikatny Lab. 
 
 
 
 
 
 
Figure 4.4. Choline metabolite and ChoKα levels in cultured cell models. (A) Western blots 
(insert) and quantification confirm that higher levels of PC are accompanied by increased 
expression of ChoKα. (B) MR spectra and (C) quantification of aqueous extracts of the cell lines. 
MDA-MB-231 and 4175-Luc+ have higher levels of PC than MCF7-WT. Overexpression of 
ChoKα leads to an increase in PC levels. Assistance with Western blots provided by Mansi 
Shinde of the Klein Lab, and technical support for MRS experiments provided by Weixia Liu of the 
Small Animal Imaging Facility. Preparation and MRS of 4175-Luc+ extracts performed by Michael 
Chiorazzo of the Delikatny Lab. 
"  
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We report here the development of a new prototype ChoKα inhibitor, JAS239, with 
both potent antiproliferative activity as well as fluorescence in the near-infrared (NIR) 
range. The optical properties of NIR fluorophores are ideal for in vivo optical imaging, as 
human tissue (water, hemoglobin, fat) has minimal absorbance in this wavelength range 
(650–900 nm). Although fluorescent kinase inhibitors in the visible range have been 
reported (Kim et al., 2010; Yenugonda et al., 2011; Kim et al., 2011), our approach using 
NIR fluorophores potentially allows for the imaging of kinase expression and function in 
vivo. 
4.2 Results 
The levels of ChoKα expression and choline metabolite concentrations were 
determined in a panel of breast cancer cell lines. Western blots (Figure 4.4A) show that 
the estrogen-receptor positive MCF7-EV cell line has a lower expression of ChoKα than 
the triple-negative and metastatic MDA-MB-231 cell line. Figure 4.4B shows 1H MR 
spectra of the aqueous fraction of chloroform:methanol:water extracts prepared from the 
4 cell lines. As previously reported (Shah et al., 2010), the non-metastatic MCF7-EV 
cells show lower levels of PC, the enzymatic product of ChoKα, compared to the 
metastatic MDA-MB-231 cells.!The ChoKα overexpressing cell line, MCF7-CK+, shows 
a 2.3-fold increase in PC levels accompanied by high expression of ChoKα. The 4175-
Luc+ cell line has slightly lower PC levels than the parent MDA-MB-231 cells (Fig. 
4.4C), but comparable expression of ChoKα. ChoKα activity assays were performed 
using 14C-labeled choline added to intact cells followed by extraction, thin layer 
chromatography (TLC) and autoradiography (Figure 4.5A). These assays show that 
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choline is rapidly phosphorylated to PC upon cell entry as a trapping mechanism, and that 
catabolic breakdown of PtdCho to GPC becomes detectable after 16 hours. Figure. 4.5B 
shows that MCF7-EV cells have the lowest relative activity of the tested cell lines, and 
that ChoKα overexpression enhanced the production of 14C-PC. ChoKα activity was also 
determined using an NMR-based assay on cytosolic preparations. The NMR spectra of 
MCF7 cell cytosolic preparations (Fig. 4.6A) demonstrate the rise in the PC peak (3.22 
ppm) at the expense of the choline peak (3.20 ppm) after choline, ATP, and Mg2+ ions 
were added. The PC and choline peak integrals were plotted over time (Fig. 4.6B) and 
regressions were fit to the linear portion of the curve to estimate ChoKα activity (Fig. 
4.6C). Both the radiotracing and the NMR assays directly measure choline depletion and 
the simultaneous increase in PC. Both assays show that over-expression in MCF7-CK+ 
significantly increased ChoKα activity to levels similar to MDA-MB-231 cells. 
A screen of potential fluorescent inhibitor-like compounds was performed using 1H 
NMR. Here MCF7 cells were used as a source for cytosolic ChoKα, as they have low 
baseline levels of PC. 1H NMR was used to assess ChoKα activity in the presence and 
absence of inhibitor (Fig. 4.7). MN58b added to the NMR tube at a final concentration of 
10 µM was found to reduce ChoKα activity by 57%. FM 4-64 at 10 µM caused an 
unexpected 50% increase in ChoKα choline phosphorylation (not shown), and doubling 
the final concentration to 20 µM resulted in only a 3% reduction. For DMOCI (3,3’-
dimethyloxacarbocyanine iodide), addition of 100 µM caused a 50% increase in PC 
formation. The NIR fluorophore HITC caused a 9% increase in ChoKα activity in this 
cytosolic model. These values represent single trials, as this experiment is too time 
intensive and expensive to justify the pursuit of ineffective compounds. In the presence of 
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100 µM JAS239, a 26.2% reduction in ChoKα activity (P = 0.02) was observed in MCF7 
cells (Fig. 4.7). ChoKα overexpressing MCF7-CK+ cells demonstrated no significant 
change in ChoKα activity (P = 0.20) when exposed to the same concentration of JAS239 
(Fig. 4.7). Further studies were performed on JAS239 using MN58b as a positive control.  
 
 
Figure 4.5. 14C-choline radiotracing assay for ChoK activity. (A) Cells were pulsed with 1 µCi 
of 14C choline for the times indicated. Extracts were separated by TLC and analyzed by 
autoradiogram. (B) Quantification of autoradiograms shows increased ChoK activity in MCF7-
CK+ relative to MCF7-EV control. Mouse adaptation of the 4175-Luc+ cell line did not result in 
significant changes in ChoK activity when compared to the parent MDA-MB-231 cell line. Values 
represent + SEM for 3 separate experiments, P < 0.05. 
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Figure 4.6. 1H NMR ChoK assay. (A) Superimposed 1H spectra obtained over 500 min following 
addition of choline, Mg2+, and ATP to cytosolic extracts of MCF7 WT cells show increases in PC 
at the expense of choline. (B) The corresponding PC and Cho peak integrals were plotted over 
time and linear regression of the early portion of (B) yields an estimate of ChoK activity in the 
breast cancer cell panel. (C) Quantification shows that ChoKα overexpression increases activity 
in MCF7 cells to levels of MDA-MB-231 cells, whereas no effect was caused by expression of the 
empty vector (MCF7-EV). *P < 0.05 
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Figure 4.7. ChoK inhibition by fluorescent choline mimetics measured by NMR. PC 
production in cytosolic preparations from MCF7 cells was measured using 1H NMR. Drastic 
reduction of PC production is observed following MN58b addition. Neither FM 4-64, DMOCI, or 
HITC are capable of inhibiting ChoK activity (n = 1). JAS239 causes significant reduction in PC 
production (n = 3) in MCF7-EV cells. Overexpression of ChoKα variant 1 reverses the inhibition 
by JAS239. 
 
JAS239 was able to inhibit the phosphorylation of 14C-labeled choline in MDA-MB-
231 triple-negative breast cancer cells with an IC50 of 4.6 µM at 17 hours of treatment, 
comparable to the IC50 of 2.3 µM observed for MN58b (Fig. 4.8A). Treatment with 10 or 
20 µM JAS239 for 17 hours or longer resulted in a statistically significant reduction in 
MDA-MB-231 viability as measured by Trypan blue exclusion (Fig. 4.8B). The 
antiproliferative EC50 of JAS239 at 24 hours is 13.3 µM, as measured by the Trypan 
exclusion assay. Figure 4.8C shows that the reduction in choline phosphorylation 
occurred as early as 2 hours after treatment at 10 and 20 µM, before any significant loss 
in cell viability was observed. By 17 hours, significant losses in both ChoKα activity and 
cell viability were found (Fig. 4.8D). Addition of 2 mM exogenous non-labeled choline 
to MDA-MB-231 cells was able to rescue the inhibition of ChoKα by JAS239 (10 µM), 
whereas 0.2 mM had no effect (Fig. 4.8E). By 17 hours, exogenous choline at 0.2 and 2 
mM was unable to outcompete JAS239 (Fig. 4.8F). 
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Figure 4.8. JAS239 is a competitive inhibitor of ChoK in MDA-MB-231 cells. (A) Cell 
treatment for 17 hr with MN58b or JAS239 inhibits 14C-choline phosphorylation with an IC50 of 2.3 
and 4.6 µM, respectively. (B) Cell viability determined by Trypan blue exclusion in response to 
JAS239, where ‡ indicates cell reduction (P < 0.05) versus untreated control at 2 and 17 hr and # 
indicates cell reduction (P < 0.05) versus untreated control at 17 and 24 hr. (C) 2-hr exposure to 
JAS239 causes inhibition of 14C-choline phosphorylation with no effect on cell viability. (D) After 
17 hr exposure to JAS239, both inhibition of 14C-choline phosphorylation and reduction in viability 
is observed. (E) Exogenous choline addition at high concentrations rescues 14C-choline 
phosphorylation in cells treated with 10 µM of JAS239 for 2 hr. (F) By 17 hr, exogenous choline 
addition does not significantly change 14C-choline phosphorylation in cells treated with 10 µM of 
JAS239. Data plotted as % control + SD for three separate experiments. *P < 0.05. 
 
Direct comparison of JAS239 and MN58b in each of the 4 breast cancer cell lines 
was then performed. The potency of ChoKα inhibition in intact cells was assessed using 
14C-PC production in 1 hour. Trypan blue exclusion was used to measure cytotoxicity at 
17 hours. Accelerated flux through ChoKα was observed in MCF7-CK+ cells, and 
MN58b normalized this aberrant flux to levels comparable to that of the control MCF7-
EV cell line (Table 2, Fig. 4.9A). MN58b was more than twice as potent as JAS239 at 
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this early time point in both cell lines (Table 2, Fig. 4.9A,B). After overnight treatment, 
there was little difference in the EC50s as determined by Trypan exclusion between 
MN58b (Table 2, Fig. 4.10A) and JAS239 in the MCF-7 EV and CK+ cell lines (Table 2, 
Fig. 4.10B).  
 
 
Figure 4.9. Characterization of ChoKα in a panel of human breast cancer cell lines. (A-D) 
Dose-response curves comparing the effect of MN58b (A, C) or JAS239 (B, D) on 14C-choline 
phosphorylation in MCF7-EV and MCF7-CK+ cells (A, B) or MDA-MB-231 and 4175-Luc+ cells 
(C, D). Values are reported as a percentage of the untreated EV group (for MCF7 cells) or 
untreated MDA-MB-231 group (for MDA-MB-231 and 4175-Luc+), and represent + SEM for 3 
separate experiments. 
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Figure 4.10. Breast cancer cell viability in response to ChoK inhibitors. (A,B) Cell viability 
measurements via Trypan blue exclusion demonstrate comparable cytotoxicity in MCF7-EV and 
MCF7-CK+ cells (A, B) exposed overnight to either MN58b (A) or JAS239 (B). MTT assays were 
performed on MDA-MB-231 and 4175-Luc+ (C, D) cells exposed to MN58b (C) or JAS239 (D). 
Values are reported relative to untreated control groups and represent + SEM for 3 separate 
experiments. 
 
 
 
 
Table 2. Potency of MN58b and JAS239 in a panel of breast cancer cell lines. 
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  IC50 (µM) EC50 (µM) 
Cell Line MN58b JAS239 MN58b JAS239 
MCF7-EV 3.85 + 0.42  11.1 + 5.64  3.29 + 0.48 4.04 + 0.55 
MCF7-CK+ 2.36 + 0.28 10.3 + 2.48 6.86 + 0.43 5.33 + 0.84 
MDA-MB-231 4.36 + 1.37 9.92 + 0.22 14.26 + 4.6 27.2 + 7.9 
4175-Luc+ 4.59 + 0.55 9.89 + 0.24 20.7 + 6.4 35.0 + 21.6 
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Figure 4.11. 14C-choline radiotracing to distinguish choline transport from choline 
phosphorylation. (A) MCF7-CK+ (CK) cells have higher PC levels than MCF7-EV (EV) cells. (B) 
Despite higher flux through the Kennedy pathway, at 16 hr the CK cells have less GPC than EV 
cells indicating that GPC is rapidly converted back to PC when ChoKα is overexpressed. (C-F) 
MCF-7 CK or EV cells were given either MN58b (left) or JAS239 (right). 14C-choline was added 1 
hr after MN58b (C & E) or JAS239 (D & F) and the 14C-PC (C & D) and 14C-GPC (E & F) levels 
estimated after 16 hr. While little difference in PC depletion is observed between the two drugs, 
JAS239 does not deplete 14C-GPC pools in EV cells. Overexpression of ChoKα rescues this 
effect. Values are reported relative to untreated MCF7-EV and represent + SD for 3 separate 
experiments. 
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No significant difference in PC production (IC50) was found between the MDA-MB-
231 and the derivative 4175-Luc+ cell lines following 2 hours of MN58b treatment 
(Table 2, Fig. 4.9C). Similarly, the mouse adapted and metastasis derived 4175-Luc+ cell 
line did not show altered sensitivity to JAS239 when PC production was compared to 
MDA-MB-231 cells (Table 2, Fig. 4.9D). The first attempt to characterize EC50s in the 
4175-Luc+ cell lines indicated that these cells were more resistant and required higher 
dosage. At high doses, it became difficult to distinguish JAS239 staining from Trypan 
blue during counting. For this reason, we switched assays from Trypan exclusion to the 
more automated MTT assay after ensuring that there was no overlap in absorbance 
readings between the formazan product and JAS239. As was found in radiotracing 
assays, MN58b was a more potent inhibitor of cell growth than JAS239 (Table 2, Fig. 
4.10C). A similar, although more variable, trend existed in 4175-Luc+ cells (Table 2, Fig. 
4.10D). 
After 16 hours of 14C-choline treatment, PtdCho breakdown could be detected using 
the formation of 14C-GPC as an indicator of phospholipase activity (as shown in Fig. 4.5). 
In MCF7 cells, it became apparent that ChoKα overexpression rapidly recycled this 
product back to 14C-PC, which helped to maintain high levels of 14C-PC (Fig. 4.11A) and 
resulted in diminished pools of 14C-GPC (Fig. 4.11B). Addition of MN58b (Fig. 4.11C) 
or JAS239 (Fig. 4.11D) was capable of reducing 14C-PC pools after 16 hours of tracing. 
In MN58b-treated MCF7-EV or MCF7-CK+ cells, the 14C-GPC pools were diminished 
to a similar degree (Fig. 4.11E). Interestingly, in the MCF7-EV cell line, JAS239 did not 
affect 14C-GPC pools except at concentrations of 20 µM, at which point the cells were 
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presumed to undergo apoptosis. This result was reversed when ChoKα was over 
expressed (Fig. 4.11F). 
Fluorimetry was used to observe the uptake of JAS239 into MCF7 cells after 2 hours. 
The uptake of JAS239 was concentration-dependent, and no difference in uptake was 
observed when ChoKα was overexpressed (Fig 4.12A). To determine probe retention, a 
series of washout phases were included following JAS239 administration, however only 
moderate differences were found (Fig 4.12B).  
 
 
Figure 4.12. Effect of ChoKα expression on JAS239 uptake and retention. (A) JAS239 
uptake over 2 hr is linear for MCF7 cells, and no change in uptake is detected following ChoKα 
overexpression. (B) Only moderate increases in JAS239 retention are observed in MCF7-CK+ 
cells compared to the MCF-EV control. Cell uptake was measured in a fluorimeter using 
excitation 640 nm and emission 770 nm, and corrected for cell number. Studies were performed 
in triplicate; error bars represent + SEM. 
 
JAS239 uptake was also analyzed using MDA-MB-231 cells treated for 2 hours at 
varying concentrations. Fluorescence accumulation was linear within the entire 
therapeutically relevant dose range (Fig. 4.13A). Addition of exogenous choline did not 
obstruct the uptake of JAS239 into these cells (Fig. 4.13B). MDA-MB- 231 cells treated 
with JAS239 for 2 hours and stained for 30 minutes with the nuclear stain SYTO9 were 
analyzed using fluorescence confocal microscopy. A distinct separation of SYTO9 (Fig. 
4.13C) and JAS239 (Fig. 4.13D) fluorescence was observed, indicating that the 
A B 
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localization of the novel probe was confined to the cytosolic space, appearing diffusely in 
the cytoplasm, as well as in punctate perinuclear spots (Fig. 4.13E). 
Fixed MDA-MB-231 cells were treated with a rabbit anti-human ChoKα antibody 
followed by a goat anti-rabbit antibody conjugated to Texas-Red. Fluorescence confocal 
micrographs from the Texas-Red channel and the NIR channel were acquired and merged 
(Fig. 4.14, top row). An average Pearson’s Correlation Coefficient of -0.31 + 0.1 was 
found for three experiments and confirmed that no overlap between the Texas-Red and 
JAS239 channels occurred (Fig. 4.15A). Confocal micrographs (Fig. 4.14, middle row) of 
fixed JAS239-stained MDA-MB-231 cells probed with the ChoKα-specific antibody 
revealed strong colocalization (Pearson’s Correlation Coefficient = 0.88 + 0.02) between 
JAS239 and ChoKα (Fig. 4.15A). Of the ChoKα-positive pixels analyzed, 89 + 9% were 
located in pixels also positive for JAS239 (Fig. 4.15B). Likewise, 89 + 10% of JAS239-
positive pixels were also positive for ChoKα (Fig. 4.15C). When fixed cells were pre-
treated with ChoKα antibody, marked reduction in JAS239 retention was detected (Fig. 
4.14, bottom row). Reduced JAS239 signal relative to noise caused a lower Pearson’s 
Correlation Coefficient (0.49 + 0.04; Fig. 4.15A), although 84 + 4% of the regions which 
were ChoKα-positive were also JAS239-positive (Fig. 4.15B), and 87 + 2% of the 
JAS239-positive pixels were ChoKα-positive (Fig. 4.15C). This demonstrates that the 
JAS239 that was retained in these cells was still associated with ChoKα, although the 
intensities of the two channels followed a different distribution trend. These results are 
consistent with JAS239 being out-competed by the antibody for binding sites.  
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Figure 4.13. Uptake and subcellular localization of JAS239. (A) MDA-MB-231 cells treated 
with varying concentrations of JAS239 for 2 hr demonstrate linear increases in relative 
fluorescence intensity (RFI; excitation 640 nm, emission 770 nm). (B) A fluorimetry study 
demonstrating that addition of exogenous choline to MDA-MB-231 cells could not outcompete 
uptake of JAS239. Fluorescence confocal micrographs show MDA-MB-231 cells stained for 30 
min with (C) the nuclear stain Syto9, (D) 2 µM of JAS239, and (E) merged images. Error bars 
represent + SD for three separate experiments. Images were acquired in the Wistar microscopy 
core with assistance from James Hayden. 
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Figure 4.14. JAS239 colocalizes with ChoKα. Fixed and permeabilized MDA-MB-231 cells 
treated with a ChoKα-specific antibody followed by a Texas Red-conjugated secondary antibody 
(Ex. 543 nm; Em. 565-615) were assessed by confocal microscopy (top row). In cells stained with 
JAS239 followed by the ChoKα antibody (middle row), strong colocalization between the JAS239 
(Ex. 633 nm; Em. >650 nm) and ChoKα is observed. Cells incubated with antibody prior to 
JAS239 staining (bottom row) no longer retain the NIRF probe. Scale bars represent 35 µm. This 
protocol was developed with help from Alex Glavis-Bloom of the Yang Lab and images were 
acquired in the CDB microscopy core with assistance from Jasmin Zhao. 
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Figure 4.15. Correlation coefficients to quantify JAS239/ChoKα colocalization. (A) JAS239 
is strongly correlated with ChoKα, unless fixed cells are pre-incubated with ChoKα antibody. (B) 
Manders’ Colocalization Coefficients for the Texas-Red channel confirm the majority of ChoKα is 
bound by JAS239 when JAS239 is present. (C) Manders’ Colocalization Coefficients calculated 
for the JAS239 channel indicate that the majority of JAS239 present intracellularly is co-
distributed with ChoKα. Values represent + SEM for 3 fields of view.  
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4.3 Discussion 
To identify a candidate NIR fluorophore capable of disrupting PC production, a panel 
of breast cancer cells was first characterized for ChoKα expression, activity, and native 
choline levels. A 1H NMR activity assay was used to explore ChoKα kinetics in response 
to a pulse of choline in the presence of!excess ATP and Mg2+. Choline depletion in MCF7 
cells was precisely mirrored by PC formation, confirming the inactivation of competing 
enzymes by the reducing environment of the cell lysis buffer. The enzymatic rate of 
ChoKα determined by this assay (6.25 nmol PC produced / 106 cells / hour) was 
consistent with estimates for ChoK activity in ovarian cancer cells (Iorio et al., 2005) and 
the observation that 14C-choline phosphorylation is nearly instantaneous upon cell entry. 
This assay was used to identify potential ChoKα inhibitors, because in the absence of 
choline transporters, phospholipases, or other members of the Kennedy pathway (Iorio et 
al., 2005), this assay can provide a true measure of ChoKα catalytic rate. 
The potent inhibition of ChoKα by MN58b reported in the literature (Lacal, 2001) 
was confirmed in MCF7 cytosolic preparations. DMOCI, however, was incapable of 
inhibiting ChoKα activity, despite preliminary studies from our lab that found a possible 
effect in perfused cells. This suggests choline transport inhibition may have influenced 
the reduction in PC observed in that model system. Neither FM 4-64 nor HITC had an 
inhibitory effect in the ChoKα activity assay. On the other hand JAS239 caused a 
significant reduction in ChoKα enzymatic rate, albeit at a higher concentration. These 
530 µL samples were highly concentrated with cytosol from 20 x 106 cells. As a 
reference, the same molar quantity of JAS239 dispersed in the cellular media of 20 x 106 
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cells would be at a relatively dilute concentration of 0.53 µM. Moreover, the inhibitory 
effect of JAS239 in MCF7 EV cells could be rescued by ChoKα overexpression, thus 
confirming ChoKα to be the primary target of JAS239 that leads to the reduction in 
choline phosphorylation observed in this assay. 
Using 14C-choline as a radiotracer, JAS239 was found to inhibit ChoKα activity at 
concentrations higher than, but comparable to MN58b, as indicated by reduced 
production of 14C-PC. ChoKα inhibition occurred at 2 hours, before the onset of cell 
death, and was reversible by addition of unlabeled choline, indicating that JAS239 acts as 
a competitive inhibitor. After 17 hours, choline addition was unable to reverse the effects 
of JAS239 on choline metabolism, suggesting that irreversible alterations to the Kennedy 
pathway or downstream pathways had already occurred. Because MN58b and JAS239 
are charged small molecules that may be impermeable to the cell membrane, we 
performed the 14C-choline radiotracing studies in intact cells to ensure the ChoKα 
inhibition observed in cytosol could be replicated in vitro. The improvement in JAS239 
potency relative to MN58b in intact cells is presumably due to JAS239 being more cell 
permeable with one less cationic charge. 
We next verified the efficacy of JAS239 in a panel of human breast cancer cells 
representing different germ lines (epithelial and mesenchymal), tumor stages (estrogen-
positive and triple-negative), derivation (mouse-naïve and mouse-adapted), and ChoKα 
expression (low, medium, and high). ChoKα inhibition in intact cells was assessed at 2 
hours of treatment, as this is sufficient time for PC formation but too early for 
phospholipase involvement or observable cell death. Due to the number of samples this 
required, we lowered the cell media volume from 3 mL per well to 2 mL per well, thus 
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lowering the amount of radioactive waste produced per sample. In all cell lines, MN58b 
was at least twice as potent. This was mirrored in the MDA-MB-231 and 4175-Luc+ cell 
viability data after 17 hours of treatment, however the MCF7 cell lines were more 
sensitive to JAS239 than would be expected from the IC50s. The IC50 at 2 hours for the 
MDA-MB-231 cells doubled from 4.6 µM to 9.92 µM when the cell media was decreased 
from 3 mL to 2 mL, reflecting the reduction in total drug molecules interacting with the 
same number of cells per sample. 
Against pure yeast ChoKα, the average reported IC50s of the bis-pyridinium and bis-
quinolinium ChoKα inhibitors were 37.1 and 33.9 µM, respectively; the antiproliferative 
activities, EC50s, in HT-29 cells were 19.7 and 3.7 µM, respectively (Campos et al., 
2001; Sánchez-Martín et al., 2005). Although determined in different systems, the 
measured IC50 of 4.6 µM for JAS239 represents potency comparable or better than 85% 
of the reported bis-pyridinium–based ChoKα inhibitors, and 61% of the bis-quinolinium 
compounds. The EC50 values are also comparable, although determined using different 
assays in cell lines of different tissue origin. The action of JAS239 against MDA-MB-231 
cells suggests ChoKα inhibition may be an effective strategy in triple- negative breast 
cancers, which are often therapy resistant. Its potency suggests that further modifications 
based upon the carbocyanine template, and subsequent structure–activity 
characterization, may yield compounds highly specific to ChoKα. 
An interesting difference in how MCF7 cells respond to treatment with MN58b and 
JAS239 was observed after 16 hours of radiotracing. Based upon the evidence that 
ChoKα overexpression causes depletion of 14C-GPC by promoting its conversion back to 
14C-PC, we hypothesized that ChoKα inhibition would reduce PC levels and not deplete 
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14C-GPC. We found JAS239 did not deplete the 14C-GPC pool in MCF7-EV cells, 
whereas MN58b caused depletion of both the 14C-PC and the 14C-GPC pools. This 
suggests some of the inhibitory effect of MN58b on PC formation may be due to choline 
transport inhibition in these cells. Further radiotracing studies with inhibitors added 
following 14C-choline addition and measurement of choline efflux from the cells are 
needed to better understand this mechanism. 
The uptake of JAS239 into intact MDA-MB-231 cells was analyzed by fluorimetry 
and was found to be both rapid and linearly proportional to the concentration of probe 
added; no quenching of signal intensity was observed even when high therapeutic doses 
were used. Moreover, the uptake into MCF7 cells was linearly dependent on 
concentration and independent of ChoK overexpression. Furthermore JAS239 appears to 
enter cells independent of the choline transporters, as exogenous choline addition had no 
effect on probe uptake. The ability to separate ChoKα expression from choline uptake is 
an advantage to using fluorescent ChoKα inhibitors. Reported observations made using 
MRS and PET tracers measure the effects of both choline transport and phosphorylation 
together. Our approach may yield a companion diagnostic that would aid in identifying 
patients best suited for ChoKα inhibitor-based therapies. Overexpression of ChoKα 
resulted in only moderate enhancement of JAS239 retention. The MCF7-CK+ cells were 
previously reported by Shah et. al. to have elevated drug and dye (Rhodamine 123) efflux 
capabilities, which may be a confounding factor to consider when interpreting the results 
from this assay (Shah et al., 2010).  
The inherent optical properties of this small molecule inhibitor allow for study of 
subcellular localization by fluorescence confocal microscopy. JAS239 collects in the 
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cytosolic space where ChoKα is active (Hosaka et al., 1990) and is excluded from the 
nucleus where DNA intercalation, mutagenesis, and nonspecific cell death would 
otherwise be confounding factors. Using confocal microscopy of fixed MDA-MB-231 
cells, JAS239 staining was compared with immunohistochemical ChoKα assessment. 
Colocalization of the probe with ChoKα was observed, indicating a direct interaction that 
could be blocked when the N-terminal antibody was bound ahead of time. 
Our results have indicated that JAS239 enters breast cancer cells independent of the 
choline transporters and competes with choline at the active site of ChoKα. The 
development of a small molecule kinase inhibitor with NIR-fluorescence confers the 
ability to noninvasively track the biodistribution of this probe with NIR optical imaging 
(Yang et al., 2010), greatly reducing the number of animals required for detailed 
pharmacokinetics studies. ChoKα expression can be up to 15-fold higher in malignant 
compared with non-transformed breast cells (Glunde et al., 2005), thus imaging agents 
targeted to this biomarker may benefit from substantial signal-to-noise. 
We describe here a novel strategy for reporting ChoKα expression, which has been 
clinically correlated to histologic tumor grade and estrogen receptor status in breast 
cancer. As interest in ChoKα inhibition for cancer therapy expands, these compounds 
have the unique potential to serve as companion diagnostics to identify patients most 
likely to benefit from this therapy and to make ongoing minimally invasive evaluations of 
their response.  
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Chapter 5 
JAS239 characterization in breast tumor models 
5.1 Introduction  
Choline kinase alpha (ChoKα) has become the subject of intense interest for its utility 
as an oncogenic biomarker as well as an anticancer therapeutic target (Rodríguez-
González et al., 2003). During malignant transformation, cells sequester high levels of 
PC which become detectable using magnetic resonance spectroscopy due to the 9 
chemically-equivalent protons on the methyl groups adjacent to the quaternary nitrogen 
(Negendank, 1992; Aboagye and Bhujwalla, 1999). Heightened ChoKα activity has been 
identified in approximately 40% of human breast tumor specimens (Ramírez de Molina, 
Gutierrez, et al., 2002). 
Inhibitors of ChoKα have been developed as tools to study the involvement of this 
enzyme in malignant transformation. Shutting down de novo phospholipid biosynthesis 
leads to lower levels of pro-mitotic second messenger Kennedy pathway intermediates, 
increased ceramide levels, and a de-stabilized endoplasmic reticulum membrane. The 
most potent of these agents, TCD-717, is a promising anti-cancer drug (Sanchez-Lopez et 
al., 2013) being evaluated in clinical trials (Lacal and Campos, 2015). MN58b, a di-
cationic ChoKα inhibitor, has been demonstrated to be lethal to lymphoma cells, but to 
cause a reversible cell cycle arrest in normal cells (Rodríguez-González et al., 2004). 
Although the mechanism by which ChoKα inhibition ultimately leads to cell death may 
not fully be related to the enzymatic function (Falcon et al., 2013), measures of tCho 
levels are still the primary method of validating novel ChoKα inhibitors. A limitation of 
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this approach is that tumor necrosis can lead to deceptive decreases in tCho in MR 
spectra and measurement of secondary biomarkers is required (Horská and Barker, 2010). 
PET and hyperpolarized choline tracers may be useful to identify ChoKα inhibition, but 
choline tracer accumulation can be blocked by choline transport inhibitors (Gomez et al., 
1970) which have known toxicities (Boobis et al., 1975). Measuring ChoKα expression 
and inhibition remains a difficult task that is complicated further by the complex 
contributions of the phospholipases, organic cation transporters, and sphingomyelinases 
to choline metabolite levels. 
Our group synthesized a small molecule choline mimetic with inherent NIRF which 
effectively attenuates choline phosphorylation with no observable interaction with the 
choline transporters (Arlauckas et al., 2014). This concept originated when the 
observation was made of structural similarity between the carbocyanines and the 
symmetric, bis-heterocyclic ChoKα inhibitors. This carbocyanine derivative called 
JAS239 is the first described kinase inhibitor with fluorescence in the near infrared 
wavelength range, wherein human tissue is relatively transparent (Jobsis, 1977). For this 
reason, NIRF optical imaging probes can be detected through several millimeters, and 
under certain conditions, centimeters of tissue (van de Ven, 2008). There is a particular 
need for more specific agents to assist surgeons in distinguishing tumor from normal 
tissue (Mahmood and Weissleder, 2003), and intraoperative imaging is an expanding 
field for which NIRF offers a relatively cheap method of delineating tumor margin and 
assessing lymph node involvement (De Grand and Frangioni, 2003). In this Chapter we 
test JAS239 as a ChoKα targeted optical imaging probe in murine models of cancer in the 
breast, which in humans, is a relatively homogenous, NIRF-transparent, and compressible 
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tissue (Busch et al., 2013). Following in vivo characterization of the diagnostic potential 
of this probe, JAS239 was then employed at higher doses, in conjunction with MN58b, to 
study the therapeutic potential of ChoKα inhibition. 
5.2 Results 
Athymic nude mice were used for inoculation with human derived breast cancer cell 
lines, which were injected into the mammary fat pad and monitored via caliper 
measurement for orthotopic tumor formation. In 30 days, tumors derived from MCF7-
EV, MCF7-CK+, MDA-MB-231, and 4175-Luc+ cell lines reached volumes of 24 + 5, 
170 + 30, 7.9 + 3.1, and 700 + 150 µL, respectively (Fig. 5.1). Due to their rapid in vivo 
growth that could additionally be monitored with bioluminescence imaging, 4175-Luc+ 
tumors were the early focus of this work.  
 
 
Figure 5.1. Tumor growth patterns in human breast cancer derived cell lines. (A) ChoKα 
overexpression accelerates tumor growth in an MCF7-derived orthotopic xenograft model. (B) 
Orthotopically inoculated 4175-Luc+ derived tumors exhibit accelerated growth in volume 
compared to orthotopic MDA-MB-231 xenografts. Values represent + SEM for 5 animals per 
cohort. 
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Figure 5.2. Bioluminescence of 4175-Luc+ tumors delineates tumor margin for NIRF 
measurement. (A) Two representative 4175-Luc+ tumor-bearing mice imaged for bioluminescent 
Radiance [p/sec/cm2/sr] 15 min after injection of luciferin. (B) Bioluminescence was used to draw 
an ROI (blue line) around the tumor margin, and was confirmed to be undetectable in the NIR 
filter range. (C) Mice injected with either control vehicle (left) or JAS239 were administered 
luciferin after 75 min and imaged 15 min later for bioluminescence to define tumor ROIs. 
Heightened radiance was observed in JAS239 mice presumably due to absorption of photons by 
JAS239 and emission at a longer, more tissue transparent wavelength. (D) Tumor margin (blue) 
defined by bioluminescent imaging of 4175-Luc+ tumors shows no NIRF in the vehicle-injected 
mouse (left) but intratumoral NIRF in the right mouse injected with Tween-80/Tris Buffer. Renal 
excretion of JAS239 is also seen outside the tumor boundaries. (E) Average Radiant Efficiency 
[p/sec/cm2/sr]/[µW/cm2] was quantified in each ROI (4 animals in JAS239 cohort). (F) The tumor 
NIRF (right mouse) begins to diminish relative to the renal signal 95 min after JAS239 injection. 
"  
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Bioluminescence emitted by mice bearing 4175-Luc+ orthotopic tumors was 
measured 15 min following luciferin injection (Fig. 5.2A). This signal was used to 
delineate the tumor margins (in blue) using the Auto ROI tool in the LivingImage 
software and was used during NIRF imaging to ensure that the bioluminescent signal did 
not overlap with the NIR range (Fig. 5.2B). The next day, mice were treated with control 
vehicle (left mouse) or 20 nmol JAS239 in Tween-80/Tris buffer (right mouse). Luciferin 
injection and bioluminescence imaging was again used to delineate tumor margin (Fig. 
5.2C), and no NIRF signal was detected in the control-treated animals (Fig. 5.2D, left 
mouse; n = 5). In the JAS239-injected animals, NIRF was emitted both from the tumor 
and from the kidneys (Fig. 5.2D, right mouse; n = 4). NIRF emission at 800 nm was over 
an order of magnitude stronger (5.4 + 1.1 x106 vs. 4.8 + 0.9 x105 
[p/sec/cm2/sr]/[µW/cm2]) in JAS239-injected animals vs. control (P = 0.001, Fig. 5.2E). 
Maximum NIRF contrast between the tumor and background was achieved 90 minutes 
post-JAS239 injection, as the tumor vs. renal fluorescence diminished after this time due 
to probe excretion (Fig. 5.2F). 
Approximately one week later, mice from this cohort were again injected with the 
same JAS239 formulation, euthanized 90 minutes later, and the major organs were 
resected and imaged for NIRF (Fig. 5.3A). The biodistribution of JAS239 is consistent 
with the renal signal detected in whole animals, however the signal from other internal 
organs (liver in particular) was higher than would be expected from the whole-body 
images (Fig. 5.3B). The tumor contrast seen in whole-body NIRF images probably arises 
because of the relative depth of these organs, compared to the surface tumor.  
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Figure 5.3. NIRF imaging for biodistribution of JAS239 in Tween-80/Tris formulation. (A) 
Organs from 4175-Luc+ tumor bearing mice (n = 4) were resected 90 min following injection with 
JAS239 in Tween-80/Tris imaged for NIRF. (B) NIRF was measured for each organ and the 
Average Radiant Efficiency [p/sec/cm2/sr]/[µW/cm2] was quantified for comparison. 
 
 
 
A cohort of five athymic nude mice bearing orthotopic 4175-Luc+ tumors were 
injected with 20 nmol JAS239 dissolved in an ethanol/saline solution. NIRF imaging 
found that background signal from the liver and kidneys was too high to achieve optimal 
tumor contrast (Fig. 5.4A). After JAS239 had cleared, 20 nmol of ICG was dissolved in 
the same vehicle and imaged for NIRF after 15 minutes, 45 minutes, 4 hours, and 24 
hours (Figure 5.4B). While tumor fluorescence was detected, cloaking the internal organs 
was necessary to improve contrast (Fig. 5.4C).  
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Figure 5.4. Limitations of whole body optical imaging. (A) NIRF imaging was performed on 
athymic nude mice (n = 5) 24 hr after i.v. injection with JAS239 in an ethanol/saline formulation. 
Poor fluorescence contrast is observed in orthotopic 4175-Luc+ tumors, due to high liver and 
renal signal. (B) Biodistribution of clinically-approved ICG was then imaged to confirm high 
fluorescence background was due to limitations of the model. The tumor (white arrow) is barely 
distinguishable at 0.25, 0.75, 4, or 24 hr post-injection. (C) With orthotopic breast tumors, even 
ICG requires cloaking of the excretory organs (n = 3). 
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Figure 5.5. NIRF imaging for biodistribution of JAS239 in ethanol/saline formulation. (A) 
Delivered in an ethanol/saline formulation, maximal intratumoral JAS239 (white arrow) relative to 
background is achieved 24 h post-injection. (B) Tumors (white arrow) were implanted on the right 
shoulder to allow organs involved in JAS239 excretion to be cloaked. (C, D) Resected organs 24 
hr post-injection of JAS239 were imaged for NIRF (C) and the Average Radiant Efficiency 
[p/sec/cm2/sr]/[µW/cm2] was quantified (D). (E) Tumor-to-muscle ratio was measured using 
quantified NIRF. Cohort size was 5 animals and values represent + SEM. Total JAS239 delivered 
was 20 nmol/animal. 
 
We inoculated a third cohort of five athymic nude mice with subcutaneous 4175-
Luc+ tumors high on the right flank as distant from the kidneys as possible. This cohort 
was injected with JAS239 in ethanol/saline. Fluorescence from the kidneys was the 
dominant source of NIRF signal (Fig. 5.5A). Intentional placement of these tumors on the 
shoulders allowed us to cloak the lower extremities and isolate the tumor for NIRF 
imaging (Fig. 5.5B). The tumor signal relative to noise was highest at the 24-hour time 
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point and the organs in these animals were resected and imaged to estimate JAS239 
biodistribution (Fig. 5.5C). Compared to the Tris/Tween vehicle, the hepatic signal from 
this formulation dropped nearly one order of magnitude, from 4.8 + 1.5 x108 to 5.4 + 0.3 
x107 [p/sec/cm2/sr]/[µW/cm2], drastically reducing the background signal (Fig. 5.5D). At 
this time, a nearly two-fold tumor-to-muscle ratio was found (Fig. 5.5E). 
 
 
 
 
 
Figure 5.6. Biodistribution of hydro-JAS239 using NIRF imaging. (A) A cohort of athymic 
nude mice (n = 5) bearing 4175-Luc+ tumors on the right shoulder were imaged for NIRF (Ex. 
745 nm; Em. 800 nm) following i.v. injection of 20 nmol hydro-JAS239. (B) Using an excitation 
745 nm and emission 820 nm filter set, intratumoral hydro-JAS239 can be detected in the cloaked 
animals. 
"  
A 
0.5 1.0 1.5 2.0 
Radiant Efficiency x108 
B 
0.5 
1.0 
1.5 
2.0 
Radiant Efficiency x108 
0.25 h 1 h 24 h 24 h 24 h 
113"
"
 
 
Figure 5.7. Bioavailability study of hydro-JAS239 and JAS239. Athymic nude mice bearing 
4175-Luc+ tumors on the right shoulder were administered hydroJAS239 (left mouse) or JAS239 
in ethanol/saline (right mouse) by gavage. NIRF images were acquired (A, B) 10 min, (C, D) 30 
min, (E) 4 hr, or (F, G) 24 hr post-delivery from the (A, C, E, F) right orientation or (B, D, G) 
ventral orientation. (H) Animals were then euthanized and the intraperitoneal cavity was exposed 
to reveal that hydro-JAS239 is cleared after 24 hr, whereas JAS239 is retained in the stomach 
and intestines. 
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A modified hydrocyanine form of JAS239 (hydro-JAS239) was created in our lab. 
When the resonant cyanine structure is chemically reduced, the molecule is non-
fluorescent and non-polar until an oxidizing agent such as a free radical is introduced. We 
sought to test if this non-polar variation would alter the pharmacokinetics or improve the 
signal-to-noise ratio. Injected intravenously, hydro-JAS239 ultimately distributed in the 
body in a pattern similar to JAS239 with high liver and renal accumulation early with 
progressively more of the total probe being directed toward renal clearance after 1 hour 
(Fig. 5.6A). After 24 hours, the majority of the probe was cleared by the kidney (Fig. 
5.6A) and undetected in the tumor even when the animal was cloaked (Fig. 5.6B). 
Interestingly, when keeping the excitation wavelength constant, but increasing the 
emission wavelength from 800 nm to 820 nm, there was weak signal detected in the 
tumors (Fig. 5.6E). Administration of either hydro-JAS239 (n = 3) or JAS239 (n = 1) by 
gavage found neither probe to be orally available; the hydrocyanine modification did not 
enhance bioavailability but accelerated clearance from the body (Fig. 5.7).  
A small (n = 3) cohort of athymic nude mice bearing 4175-Luc+ orthotopic tumors 
was dissected under the custom-built intraoperative NIRF imaging equipment in the 
Singhal laboratory. The highest background fluorescence from internal organs was found 
1 hour following JAS239 injection (Fig. 5.8A). This signal, as well as reflectance from 
the bright-field camera, limited the distinction between and tumor and normal tissue 
during resection (Fig. 5.8B). The tumor was seen to have elevated JAS239 in comparison 
to muscle, once the two tissues were isolated (Fig. 5.8C). After 4 hours, signal from the 
liver diminished (Fig. 5.8D), but the tumor contrast was also reduced (Fig. 5.8E). By 24 
hours, residual JAS239 could still be detected in the intact mouse (Fig. 5.8F) and in an 
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isolated tumor sample (Fig. 5.8G). A visualization of the equipment used for this pilot 
study is provided in Figure 5.8H.  
 
Figure 5.8. NIRF-guided surgical resection of breast tumors. Athymic nude mice with 4175-
Luc+ tumors were injected with 20 nmol JAS239 (A-C) 1 hr, (D, E) 4 hr, or (F, G) 24 hr prior to 
euthanasia. (B) Resection of each tumor was recorded simultaneously with a brightfield camera 
and a NIR CCD camera. The overlay was merged with help from Ryan Judy and Jack Jiang in 
the Singhal Lab. The highest tumor (white arrow) to muscle (white circle) ratio is observed at (C) 
1 hr, whereas this software is not sensitive enough to detect significant NIRF signal in tumors 
from the (E) 4 hr and (G) 24 hr time points at this trace dose. (H) A depiction of the NIRF imaging 
technology designed in the laboratory of Dr. Sunil Singhal is provided.   
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Figure 5.9. NIRF imaging for JAS239 accumulation can detect genetic overexpression of 
ChoKα. (A) Athymic nude mice were inoculated with MCF7-EV (left mammary fat pad) and 
MCF7-CK+ (right mammary fat pad) cells. (B) Tumor-bearing fat pads were surgically exposed 
and imaged for NIRF 24 h following JAS239 injection in an ethanol formulation. (C) Quantified 
Average Radiant Efficiency [p/sec/cm2/sr]/[µW/cm2] of resected fat pads for each of 7 animals 
reveals enhanced JAS239 retention in ChoKα-overexpressing tumors. (D) Quantified Average 
Radiant Efficiency of fat pads bearing MCF7-EV or MCF7-CK+ tumors show increased 
fluorescence 90 min after injection of 20 nmol in a Tween-80/Tris buffer. Values represent + SEM 
for 8 animals. 
 
The effect of genetic overexpression of ChoKα on JAS239 retention was studied in a 
cohort of mice bearing orthotopic MCF7-EV and MCF7-CK+ tumors (Fig. 5.9A). 
Optical imaging of the surgically-exposed mammary fat pad revealed distinct JAS239-
associated NIRF within the confines of the orthotopic tumor, and the tumor margins 
could clearly be delineated (Fig. 5.9B). JAS239 accumulation 24 hours post-injection (in 
ethanol/saline) was elevated 38 + 17 % (Paired Student’s t-test: P = 0.044) in the MCF7-
CK+ tumors compared to the contralateral MCF7 EV tumors (Fig. 5.9C). JAS239 in 
Tween-80/Tris buffer imaged 90 minutes post-injection yielded a similar difference in 
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NIRF between exposed MCF7-EV and MCF7-CK+ fat pad tumors (Paired Student’s t-
test: P = 0.024), although only a 19 + 8% increase in radiance was observed at this 90-
minute time point (Fig. 5.9D).  
 
 
 
Figure 5.10. NIRF imaging for JAS239 accumulation can detect pharmacologic inhibition of 
ChoKα. (A) Representative T2-weighted MRI image of a 4175-Luc+ tumor used to plan 3x3x3 
mm3 voxel placement. (B) MRS spectra expanded for investigation of the choline-containing 
region to compare control (black) and MN58b-treated (red) tumors. (C) MN58b-treatment 
prevents the increase in intratumoral tCho (3.2 ppm) observed between scans in the control 
cohort. (D) NIRF of the exposed saline (left) or MN58b-treated (right) tumors (E) was quantified 
[p/sec/cm2/sr]/[µW/cm2] and prior ChoKα inhibition diminishes JAS239 retention significantly. For 
saline and MN58b groups, n = 5. Values are reported as + SEM. Acquisition and processing of 
MR data was done in collaboration with Manoj Kumar of the Poptani group. 
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MN58b treatment in 4175-Luc+ tumors was then used as a model for pharmacologic 
inhibition of ChoKα. In vivo MRS (Fig. 5.10A) was used to verify that MN58b caused a 
25 + 30 % reduction in tCho after a 5-day dose regimen at 2 mg/kg/day i.p. (Fig. 5.10B). 
The change in tCho in response to MN58b was significantly lower (P = 0.044) than that 
of the control-treated animals, which actually experienced an increase (48 + 18 %) in the 
tCho resonance (Fig. 5.10C). Animals in this MRS-validated cohort then underwent 
JAS239 injection and follow-up NIRF imaging (Fig. 5.10D) which revealed a reduced 
accumulation (P = 0.01) of the ChoKα-targeted optical imaging probe in tumors treated 
with the ChoKα inhibitor MN58b (Fig. 5.10E). 
JAS239 was tested for its ability to act as a therapeutic and inhibit tumor growth. 
Three days after orthotopic inoculation of athymic nude mice with 4175-Luc+ tumors, a 
5-day intraperitoneal (i.p.) dose treatment regimen was started. Tumor volume 
measurements began 12 days after inoculation. Both 2 mg/kg/day MN58b-treatment (P = 
0.008) and 4 mg/kg/day JAS239-treatment (P = 0.009) resulted in animals bearing 
significantly smaller tumors on average compared to control animals (Fig. 5.11) at this 
time. One week later the control cohort’s tumors averaged 298 + 40 µL, which were 
significantly larger than both MN58b-treated tumors (135 + 16 µL, P = 0.010) and 
JAS239-treated tumors (132 + 41 µL, P = 0.012). Even by day 26, both the MN58b (372 
+ 35 µL) and JAS239 (368 + 77 µL) cohorts had significantly smaller (P = 0.021 and 
0.022, respectively) tumors than the vehicle-treated group (677 + 96 µL).  
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Figure 5.11. MN58b and JAS239 slow breast tumor growth. Treatment for 5 consecutive days 
with 2 mg/kg of MN58b (n = 4) or 4 mg/kg of JAS239 (n = 5) significantly reduced the growth rate 
of orthotopically-implanted 4175-Luc+ tumors, compared to control animals (n = 4). 
 
To study the therapeutic effectiveness of JAS239 in later-stage tumors, tCho was 
measured as a pharmacodynamic marker of ChoKα inhibition. MDA-MB-231 xenografts 
were used because prior characterization of MN58b in this model (Al-Saffar et al., 2006) 
allowed for the confident use of this inhibitor as a positive control. T2-weighted images 
were acquired and used for MRS voxel placement (Fig. 5.12A-C) in each tumor. 
Following baseline scans, mice were divided into treatment cohorts and injected daily for 
5 days with either vehicle control (Fig. 5.12D), 2 mg/kg MN58b (Fig. 5.12E), or 4 mg/kg 
JAS239 (Fig. 5.12F). Post-treatment 1H MR spectra were acquired and tCho was 
measured in the control vehicle-treated group to increase by 63 + 27% during the 
treatment course (Fig. 5.12D&G). Significant reductions in tCho levels compared to 
control were measured in response to MN58b (-25 + 13 %, P = 0.006, Fig. 5.12E&G) and 
JAS239 (-64 + 25 %, P = 0.004, Fig. 5.12F&G).  
* 
* 
* 
* 
* * 
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Figure 5.12. Evaluation of MN58b and JAS239-treated tumors using MRS. (A-C) T2-weighted 
images of MDA-MB-231 tumors acquired for tumor volume measurement and placement of 3x3x3 
mm3 voxels. (D-F) MR spectra acquired within the selected voxels before and after treatment. (G) 
Change in tCho (3.2 ppm) within MDA-MB-231 tumors was measured to show progressive tCho 
increase in (A, D) saline-treated animals (n = 5). Reductions in tCho in response to 5 days of (B, 
E) 2 mg/kg MN58b (n = 4) or (C, F) 4 mg/kg JAS239 (n = 3) are observed. (H) PUFA resonances 
at 2.8 ppm are unchanged in the control cohort and increase in response to both MN58b and 
JAS239, but not significantly. (I) Lipid resonances at 1.3 ppm are unchanged. (J) Vehicle-treated 
tumors grew during the treatment regimen, whereas both MN58b and JAS239 treated cohorts 
were unchanged. Values reported as + SEM, * indicates P < 0.05 compared to control group. MR 
data was collected in collaboration with Manoj Kumar of the Poptani group. 
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A trend of an elevated polyunsaturated fatty acid (PUFA) resonance, a measure of 
tumor apoptosis, after MN58b (190 + 120 %, P = 0.12) and JAS239 (150 + 130 %, P = 
0.21) treatment was observed, although these values were not statistically significant 
compared to control (5.79 + 50 %) due to high intra-cohort variability (Fig. 5.12H). High 
variability was also observed in the lipid peak at 1.3 ppm but no significant increases in 
lipid were found (Fig. 5.12I).  MRI-based volume measurements indicated that vehicle-
treated tumors grew in volume by 27 + 16 % during the week between the pre-treatment 
and post-treatment MRS scans (Paired t-test: P = 0.009), whereas MN58b-treated and 
JAS239-treated tumors grew only 6.5 + 14% and 3.0 + 2.3 % during the same time span 
(Fig. 5.12J). These volume increases were not statistically significant in MN58b-treated 
(Paired t-test: P = 0.44) or JAS239-treated (Paired t-test: P = 0.36) tumors.  
Figure 5.13 depicts a summary of the toxicological assessment of the MDA-MB-231-
bearing mice from this experiment, revealing no significant effects except for an 
elevation of blood urea nitrogen in the MN58b-treated animals (29.5 + 0.5 mg/dL) 
compared to control animals (20.0 + 3.0 mg/dL) (P = 0.012). Tumors from these animals 
were harvested for histological assessment immediately after follow-up MRI/MRS 
scanning. Evaluation of H&E slides (Fig. 5.14, left column) prepared from tumor slices 
of the untreated cohort measured an average cell density of 8,800 + 200 cells/mm2. Both 
MN58b and JAS239 caused significant reduction in cell density compared to control, 
with values of 5900 + 800 cells/mm2 (P = 0.007) and 5600 + 800 cells/mm2 (P = 0.01), 
respectively (Fig. 5.15A). MN58b (55 + 5 %, P = 0.026) and JAS239 (46 + 11 %, P = 
0.034) treatment significantly reduced the percentage of Ki67-positive cells compared to 
the high percentage of proliferative cells (78 + 1 %) in the vehicle treated group (Fig. 
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5.14, middle column). Consistent with reduced cell number and proliferation, higher 
Caspase-3 levels (Fig. 5.15, right column) were detected in MN58b (72 + 6 %, P = 0.016) 
and JAS239 (76 + 6 %, P = 0.015) treated tumors than in control tumors (21 + 8 %). 
Ki67-positive nuclei (Fig. 5.15B) and Caspase-3-positive cells (Fig. 5.15C) were 
quantified in different regions of each tumor and averaged among treatment cohorts. 
 
 
 
Figure 5.13. Renal damage associated with MN58b is not seen in JAS239-treated mice. A 
profile of enzyme function and blood metabolite levels reveals MN58b animals had elevated 
blood urea nitrogen (BUN) relative to control animals. No signs of elevated albumin, alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (AlkPhos), gamma-
glutamyl transferase (GGT), bilirubin, or cholesterol changes were found in response to MN58b or 
JAS239 treatment. Three animals were included per cohort and values represent + SEM. * 
indicates P < 0.05. 
* 
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Figure 5.14. Histological assessment of tumors reveals reduced cell density, lower 
proliferation, and elevated apoptosis in response to ChoKα inhibitors. H&E staining (left 
column) of MDA-MB-231 tumor xenografts reveals lower cell density in MN58b (middle row) and 
JAS239 (bottom row) treated tumors compared to vehicle-treated tumors (top row). Reduced 
Ki67-positive nuclei (middle column) and heightened Caspase-3 positive cells (right column) are 
also found in MN58b and JAS239 treated tumors. Scale bars represent 200 µm. Preparation and 
digital scanning of the slides were performed by members of the CHOP Pathology Core facility 
under direction of Daniel Martinez. 
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Figure 5.15. Histological assessment of ChoKα-inhibited MDA-MB-231 tumor sections 
reveals apoptosis and overall reduction in viable cells. (A) Significant reduction in cell density 
is observed in both MN58b and JAS239 treated tumors relative to control. (B) Lower Ki67 
positivity is found in MN58b and JAS239 treated tumors, indicative of a reduction in proliferative 
cells. (C) Elevated Caspase-3 in MN58b and JAS239 treated tumors relative to control indicate 
apoptosis in response to ChoK inhibition. * indicates P < 0.05.  
* * 
* * 
* * 
A
B
C
125"
"
5.3 Discussion 
In Chapter 4, we reported the development of JAS239, a ChoKα inhibitor whose 
inherent NIRF makes it possible to detect its interaction with cancer cells. While in vitro 
data can often be promising, translation to in vivo models is crucial for a true assessment 
of the feasibility of this technology. In this Chapter, we investigate further the utility of 
JAS239 to detect ChoKα expression in murine models of breast cancer. JAS239 is a 
cationic small molecule and this resulted in an unsurprising accumulation and clearance 
through the kidneys. An initial flush was observed in the liver where ChoKα is naturally 
abundant (Brophy and Vance, 1976) but this is also the site of first-pass metabolism. 
While most metabolic modifications of the probe would be expected to alter the optical 
properties (Shen et al., 2013) and make JAS239 undetectable in the NIRF range, there is 
much work related to characterizing the metabolism and clearance of this probe that will 
be the focus of future studies.  
With the guidance of bioluminescence imaging in the 4175-Luc+ tumor xenografts, 
intratumoral JAS239 NIRF was detectable but eventually drowned out by renal excretion 
of the intact probe. Despite its clinical utilization as a NIRF contrast agent (Marshall et 
al., 2010), even ICG required cloaking of the internal organs to achieve optimal in vivo 
tumor contrast. By moving tumors to the shoulders away from the kidneys, intratumoral 
JAS239 accumulation could similarly be visualized by cloaking the internal organs. We 
prepared hydro-JAS239 as an activatable form of JAS239 in an effort to minimize the 
interference from non-specific signal, but chemical modification of JAS239 to its non-
polar hydrocyanine form did not improve its tumor specificity, biodistribution, or 
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bioavailability. A NIRF intraoperative imaging system was capable of discriminating 
tumor from normal tissue, but only when isolated from the intraperitoneal organs. These 
results do not disparage the translational utility of JAS239, as clinical optical imaging is 
not a whole-body but rather a tissue or region-specific measurement.  
While the biodistribution studies show JAS239 can be detected in other major organs, 
the tumor/muscle ratio suggests that measurements confined to the breast region are 
robust enough to distinguish malignant from normal tissue. This was verified when the 
tumor-bearing mammary fat pads of JAS239-injected mice were surgically exposed and 
imaged for NIRF. JAS239 accumulation was found to be a reliable identifier of ChoKα 
overexpressing tumors in matched MCF7-EV and CK+ tumors. As an analysis of this 
imaging strategy’s utility in validating a previously studied ChoKα inhibitor, we treated 
tumor-bearing mice with MN58b or saline control. MRS evaluation before and after 
therapy was used as a benchmark to verify MN58b’s efficacy in vivo. While MRS 
required 1 hour per mouse—including set-up, anesthesia, shimming, and scanning—
before and after therapy, the optical imaging technique could be performed on up to 5 
mice at a time and required a much less cumbersome procedure involving one i.v. 
injection and follow-up surgery 24 hours later. The parallel use of both techniques told a 
more complete story: that MN58b bound ChoKα (blocking JAS239 accumulation) and 
attenuated flux through the Kennedy pathway (lowering tCho signals). It is important to 
note that a greater difference in measured biomarker was observed between treated versus 
untreated tumors using MRS measurement, although lower variability in the optical 
imaging method resulted in stronger statistical confidence.  
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To explore JAS239’s therapeutic properties, its ability to inhibit tumor growth and 
attenuate tCho in murine breast xenografts was determined. In orthotopic MDA-MB-231 
breast tumors, JAS239 significantly reduced the tumor growth rate to the same degree as 
MN58b. When dosed at 4 mg/kg, MN58b showed some toxicity despite a previous report 
(Al-Saffar et al., 2006) that this dose was used to lower PC levels in nude mice. No 
observable or measurable toxicity was found using 4 mg/kg JAS239, and 2 mg/kg 
MN58b appeared tolerable but post-mortem toxicological studies revealed evidence of 
elevated blood urea nitrogen indicative of impaired renal excretion in these mice. Both of 
these drugs were capable of reducing intratumoral tCho and increasing apoptosis-
associated PUFAs (Hakumäki et al., 1999). In control tumors, rising tCho was an 
indicator of progression during the week between pre and post-therapy scanning. Tumor 
status was also evaluated by histological methods that identified high cell number and 
proliferative index. Both ChoK inhibitors effectively reduced the cell number by reducing 
proliferation and inducing widespread apoptosis. 
Expanding interest in ChoKα inhibitors for cancer therapy has raised the need for 
rapid and reliable methods to validate these therapies in vivo. There have been concerns 
expressed with the reliability of RECIST measurement alone as a marker of treatment 
responsiveness (Jaffe, 2006). An addendum to the first clinical trial of TCD-717 in clinic 
was made to include MRS evaluation of tCho levels as a supplemental response indicator 
(Clinical Trials identifier: NCT01215864). MRS is the current gold standard for choline 
measurement in vivo due to its specificity, non-invasive acquisition, and feasible 
inclusion following MRI for RECIST measurements. To understand the degree to which 
choline metabolites represent a real biomarker of tumor progression and response to 
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therapy, it would be beneficial to design secondary methods of identifying the oncogenes 
that contribute to heightened choline in cancerous tissue. ChoKα has been reported 
throughout the literature as a key contributor to aberrant choline metabolism (Hernández-
Alcoceba et al., 1997). Its regulative role in cell growth and division directly links the 
Kennedy pathway to cancer malignancy (Ramírez de Molina, Báñez-Coronel, et al., 
2004). To measure ChoKα in whole tumors would provide an estimate of histological 
tumor grade, an indicator of tumor vs. normal tissue, and a secondary validation method 
for evaluating ChoKα inhibitors in the clinic.  
129"
"
Chapter 6 
Choline Kinase Inhibition as a Glioma Treatment Strategy 
6.1 Introduction  
Glioblastoma (GBM), the most common primary brain malignancy in adults, is an 
aggressive and locally invasive tumor. Despite advances in surgery, radiation, and 
chemotherapy, overall survival of patients affected by GBM has only marginally 
increased in recent decades from 6 to14 months post-diagnosis (Candolfi et al., 2007). 
This is partly due to a lack of effective therapeutic options and limited availability of 
robust and sensitive methods to assess therapeutic response. As survival with GBM is 
limited, it is critical to determine the efficacy of therapy early in treatment. An increased 
understanding of the molecular mechanisms underlying oncogenesis has led 
contemporary drug discovery programs to be aimed predominantly at signal transduction 
pathways and molecules that drive cancer initiation and progression (JB Gibbs, 2000). 
Elevated ChoKα activity has been associated with enhanced synthesis of PC in many 
cancer cell types and has been proposed as a potential target for anticancer therapy 
(Glunde et al., 2011). ChoKα catalyzes the phosphorylation of choline, consuming ATP 
in the presence of Mg2+, yielding PC in a process mostly independent of the rate of net 
PtdCho biosynthesis (Kennedy, 1957; Aoyama et al., 2004). Several agents such as 
growth factors, chemical carcinogens and oncogenes can induce ChoKα activation in 
malignant cells, leading to an accumulation of PC (Jiménez et al., 1995; Ramírez de 
Molina, Penalva, et al., 2002; Aoyama et al., 2007). 
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A novel molecular therapeutic strategy focused on ChoKα inhibition has recently 
been developed, resulting in the characterization of a group of compounds with inhibitory 
activity against ChoKα (Hernández-Alcoceba et al., 1997; Lacal, 2001; Ramírez de 
Molina, Rodríguez-González, et al., 2004). The inhibition of ChoKα using small 
molecule inhibitors such as MN58b is a promising new treatment strategy against solid 
tumors (Hernández-Alcoceba et al., 1999). MN58b is an anticancer drug previously 
reported to inhibit ChoKα activity resulting in attenuated PC levels, reduced proliferation 
of cancer cells in vitro, and growth delay of human tumor xenografts (Rodríguez-
González et al., 2003; Ramírez de Molina, Báñez-Coronel, et al., 2004). ChoKα has 
recently been discovered to be activated at the plasma membrane by EGFR in breast 
cancer cells (Miyake and Parsons, 2012). Although the existence of a similar mechanism 
in brain cells is unknown, EGFR mutations are common oncogenic drivers in GBM; one 
of the most common mutations, EGFRviii, is constitutively active and unresponsive to 
ligands (Gan et al., 2013). There is a strong need to obtain precise surrogate biomarkers 
to effectively evaluate therapeutic response in GBM.  
1H MRS provides a method of measuring changes in choline-containing tumor 
metabolites to serve as a pharmacodynamic biomarker of ChoKα inhibition and 
therapeutic response. Al-Saffar et al. have reported the efficacy of MN58b on 
subcutaneously implanted colon and breast cancer models (Al-Saffar et al., 2006), 
however, there are no reports of MRS studies of ChoKα inhibitor-treated brain tumor 
tissue. In this work, the sensitivity of a brain cancer cell panel to ChoKα inhibition was 
measured by radiotracing and viability studies. We next carried out an exploration of 
ChoKα activity in a model of EGFRviii-mutated rat GBM cells, and studied the effect of 
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epidermal growth factor (EGF) on ChoKα activation and inhibition. Following this, rats 
bearing intracranial GBM tumors were treated with i.p injection of MN58b for 5 
consecutive days and the resected tumors were assessed using 1H MRS. The feasibility of 
JAS239-assisted NIRF detection of ChoKα was tested in pilot studies. The goal of the 
present study was to monitor changes in choline-containing metabolites in an intracranial 
model of rat glioma in response to ChoKα inhibition.  
 
 
 
Figure 6.1. MTT assay demonstrating inhibition of cellular viability of F98, 9L and 9L-
EGFRviii cell lines with MN58b. 24 hr MN58b exposure significantly reduces the viability of the 
F98, 9L and 9L-EGFRviii cells in a dose dependent manner. The data was normalized to 
untreated control cells and represents the average ± SEM of 3 separate experiments performed 
in quadruplicate. Assay run by Sona Saksena of the Delikatny Lab under my guidance. 
 
 
6.2 Results 
MN58b was screened for its ability to inhibit the viability of a panel of rat brain 
tumor cell lines using the MTT assay. MN58b treatment significantly reduced the 
viability of the F98, 9L and 9L-EGFRviii cells in a dose dependent manner, with GI50s of 
20 ± 3 µM, 9 ± 3 µM and 47 ± 2 µM, respectively (Fig. 6.1). The phosphorylation of 14C-
labeled Cho (Rf = 0.07) was measured using TLC and autoradiography in cell extracts. 
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14C-PC (Rf = 0.14) production in the F98, 9L, and 9L-EGFRviii cells was quantified, 
plotted, and fitted to determine IC50s of 2.6 ± 0.7 µM, 1.8 ± 0.5 µM, and 1.8 ± 0.3 µM, 
respectively (Fig. 6.2A,B). No statistical difference in ChoKα inhibition was found 
between these groups.  
 
 
Figure 6.2. Effect of MN58b on ChoK activity in tumor cells. Autoradiography of TLC-
separated 14C-choline containing metabolites (A) allows for the quantification of 14C-PC and 
demonstrates a dose-dependent reduction of choline phosphorylation in response to MN58b 
treatment. The graph (B) shows a dose dependent reduction of ChoK activity in the F98, 9L and 
9L-EGFRviii cell lines. Error bars represent + SEM of 3 separate experiments. 
"  
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The addition of EGF to serum-starved 9L and 9L-EGFRviii cells had no impact on 
cell growth (Fig. 6.3A) or ChoKα activity (Fig. 6.3B). Addition of 20 µM MN58b 
dramatically reduced viability and 14C-PC production, both in serum-starved and EGF-
stimulated conditions (Figure 6.3A,B). Constitutive EGFR downstream signaling due to 
EGFRviii overexpression did not result in any perceivable change in ChoKα activity, and 
these cells were less viable than wild-type 9L cells suggesting they are more serum-
sensitive. 
 
 
Figure 6.3. 9L gliosarcoma cell response to EGF stimulation and MN58b inhibition. (A) MTT 
assays show no effect of EGF in 9L or 9L-EGFRviii cells following serum starvation. MN58b at 10 
µM significantly reduces viability in each condition. (B) MN58b effectively inhibits ChoK activity in 
both cell lines in the presence or absence of EGF, which has no effect on ChoK activity. Error 
bars represent + SEM of 3 separate experiments. 
B 
A 
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Since 14C-radiotracing demonstrated similar treatment response from all three cell 
lines, we chose F98 cells for further study because they most closely resemble human 
GBM (Bryant et al., 2008). Tumors derived from the 9L cell line are a gliosarcoma and 
do not exhibit the necrotic areas seen in GBM (Huszthy et al., 2012). 9L-EGFRviii is 
similar to a GBM but is not as well characterized compared to the F98 tumor model 
(Kapoor et al., 2007). Cellular extracts were prepared from F98 cells treated with 0, 10 or 
20 µM MN58b and analyzed by NMR to determine changes in PC and GPC levels (Fig. 
6.4A). Analysis of the choline-containing peaks showed lower PC levels in response to 
MN58b compared to saline-treated cells (Fig. 6.4B). We observed significantly reduced 
PC concentrations in cells treated with either 10 µM MN58b (5.9 ± 0.7 nmol/107 cells) or 
20 µM MN58b (7 ± 4 nmol/107 cells, P = 0.049) compared to saline-treated cells (19 ± 2 
nmol/107 cells, P = 0.004). We also observed higher GPC concentration in cells after 10 
µM MN58b treatment (6.6 ± 2.0 nmol/107 cells, P = 0.911) and a further increase after 20 
µM MN58b treatment (12 ± 8 nmol/107 cells, P = 0.532) compared to saline-treated cells 
(6 ± 2!nmol/107 cells) but this difference was not statistically significant (Fig. 6.4B). 
Inhibition of the anabolic pathway of choline metabolism has been reported to increase 
GPC at the expense of PC (Aboagye and Bhujwalla, 1999). The PC/GPC ratio was thus 
calculated for each treatment group, and both 10 µM (0.9 ± 0.4, P = 0.012), and 20 µM 
MN58b-treated cells (0.57 ± 0.08, P = 0.007) demonstrated significantly lower PC/GPC 
ratios as compared to saline-treated cells (3.0 ± 0.6) (Fig. 6.4C). 
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Figure 6.4. In vitro NMR of F98 cell extracts. (A) Untreated cells display high levels of PC (3.22 
ppm) and low levels of GPC (3.23 ppm) (top spectrum); 10 µM MN58b reduces the PC 
resonance relative to GPC (middle spectrum) and 20 µM MN58b further reduces this ratio 
(bottom spectrum). (B) A bar graph showing the quantitation of PC and GPC from untreated, 10 
and 20 µM MN58b-treated cells (C). The PC/GPC ratio demonstrates differences between 
untreated, 10 and 20 µM MN58b-treated cells. Error bars represent + SEM of 3 separate 
experiments. * indicates P < 0.05. Cells were treated and harvested by Ranjit Ittyerah in the 
Poptani Lab and spectra were analyzed with assistance from Manoj Kumar. 
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High-resolution 1H NMR of F98 tumor extracts also demonstrated changes in PC and 
GPC values in MN58b-treated tumors (Fig. 6.5A), following the trends observed in 
cultured cells. Significantly lower PC levels were observed in MN58b-treated tumors 
(0.33 ± 0.06 nmol/mg, P = 0.019) compared to saline-treated tumors (0.59 ± 0.06 
nmol/mg). The saline-treated tumors demonstrated significantly higher PC (P = 0.030) 
than normal brain (0.30 ± 0.09 nmol/mg). Significantly higher GPC was also observed in 
MN58b-treated tumors (0.44 ± 0.05 nmol/mg, P = 0.009) compared to normal brain (0.23 
± 0.05 nmol/mg). The GPC in saline-treated tumors (0.40 ± 0.03 nmol/mg, P = 0.015) 
was significantly higher than contralateral normal brain. However, the GPC concentration 
between saline-treated and MN58b-treated tumor was not significantly different (P = 
0.593). When the PC/GPC ratios were computed, a significantly lower PC/GPC ratio was 
observed in MN58b-treated (0.76 ± 0.09, P = 0.05) than saline-treated tumors (1.5 ± 0.3) 
(Fig. 6.5B). However, there was no significant difference in the PC/GPC ratio between 
MN58b-treated (P = 0.124) and normal brain (1.4 ± 0.4) (Fig. 6.5C). 
In a pilot study, injection of 20 nmoles JAS239 i.v. into a mouse bearing a 9L-derived 
xenograft led to levels detectable by NIRF optical imaging (Figure 6.6A). Because a 
subcutaneous, rather than orthotopic, xenograft was used, this model does not accurately 
account for the major obstacle of the blood-brain barrier. A different mouse bearing an 
MDA-MB-231 breast tumor was injected with 4 mg/kg JAS239 in 1% ethanol for 5 
consecutive days as part of a separate study. The biodistribution data from this bulk 
dosage of JAS239 shows no evidence of JAS239 in brain tissue (Fig. 6.6B).  
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Figure 6.5. Ex vivo NMR of glioma extracts. (A) Representative in vitro 1H NMR spectra from 
perchloric acid extracts of saline-treated (bottom) and MN58b-treated F98 tumors (top). The 
zoomed region (inset) is the spectral region from the choline-containing metabolites. Bar graph 
(B) demonstrates changes in PC and GPC levels from contralateral normal tissue, saline-treated 
tumors and MN58b-treated tumors. Bar graph (C) demonstrates the PC/GPC ratio in the 3 
groups. Asterisk (*) represents significant differences with a P-value of < 0.05. Error bars 
represent + SEM. The Poptani group handled all animal work for this experiment.  
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Figure 6.6. JAS239 in glioma models. (A) An athymic nude mouse with a 9L glioma xenograft 
was injected with 20 nmol JAS239 by Julie Czupryna of the Small Animal Imaging Core. NIR 
optical images were acquired by Sona Saksena of the Delikatny Lab using a LiCOR Pearl 4 hr 
after injection (Ex 710 nm, Em 800 nm). (B) A separate mouse with an MDA-MB-231 tumor was 
injected for 5 consecutive days with 4 mg/kg JAS239 and the organs were separated for NIRF 
imaging in an IVIS Spectrum. (C) No JAS239 accumulation can be detected in the brain. 
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6.3 Discussion 
In this section, the effect of the choline kinase inhibitor MN58b on choline 
metabolism was examined in a glioma model. High ChoKα activity was found in cultured 
tumor cells and this corresponded with elevated PC levels found in cells and in tumor 
tissue extracts, confirming that PC is a viable biomarker for ChoKα-driven oncogenic 
transformation. The significant decrease in cellular ChoKα activity after treatment with 
MN58b indicates that inhibition of ChoKα may be an effective adjuvant in the treatment 
of gliomas.  
Three different glioma cell lines were studied in vitro and their sensitivity to MN58b 
was observed via MTT and ChoKα assays. We observed the phosphorylation of 14C-
labeled choline using a TLC-based ChoKα assay and found inhibition of ChoKα activity 
in a dose dependent manner. While MN58b inhibited 14C-PC production with similar 
potency in each of the three cell lines, the EGFRviii mutation imparted some resistance in 
terms of increased viability compared to wild-type 9L cells, which express very little 
EGFR. Because ChoKα has been reported to interact with EGFR in breast cancer cells 
(Miyake and Parsons, 2012), it was intriguing to explore the effect of the constitutively-
active EGFRviii mutation found in a considerable proportion of GBM patients (Gan et 
al., 2013). The 9L gliosarcoma line are known to be relatively insensitive to EGF 
stimulation!(Tichauer, Samkoe, Sexton, et al., 2012), but high levels of EGF (200 ng/mL) 
has been reported to induce a 29% increase in cell growth (Guo et al., 2006). Our studies 
were unable to replicate the claim that EGF can stimulate 9L glioma cells, and further 
found no link between EGFR activity and ChoKα activation.  
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Higher choline levels may be suggestive of increased malignant potential, increased 
membrane turnover or activation of oncogenic signaling (Podo et al., 2011). In F98 cell 
extracts high PC levels and PC/GPC ratios were seen using high resolution 1H NMR. We 
observed a decrease in PC and non-significant increase in GPC in response to MN58b 
treatment, showing the effectiveness of ChoKα inhibition on choline metabolite levels. 
MN58b treatment resulted in significant reduction of the PC/GPC ratio in both cellular 
and tumor tissue extracts, which is consistent with previously reported results (Al-Saffar 
et al., 2006). These results were paralleled in the in vivo model. A decrease in PC and in 
PC/GPC ratio was found in tumor extracts. Both PC and GPC were elevated in the extract 
spectra of tumors relative to contralateral tissue, although the contralateral PC/GPC ratio 
was also not significantly different from saline-treated tumor extracts even though their 
absolute levels were much lower. This variability was higher in tissue than in cells 
because gliomas are often histopathologically heterogeneous and have components of 
varying grades of malignancy and necrosis within the tumor.  
Although the promising pilot study with JAS239 suggests that it can be detected in 
subcutaneous glioma xenografts, the lack of evidence that it passes the blood-brain 
barrier makes this only speculative at this point. Because brain cancers can often lead to 
permeabilization of the blood brain barrier, orthotopic GBM tumors would be an 
interesting JAS239 application to explore further. The ability of MN58b to inhibit the 
growth and metabolism of orthotopically implanted F98 tumors indicate that ChoK 
inhibitors can traverse the blood brain barrier, although whether this is due to a 
compromised barrier is yet to be determined. The advantage of an inherently fluorescent 
drug is the ease with which biodistribution studies can be performed, allowing follow-up 
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studies to be planned or modified based upon simple measurements in pilot tracer studies. 
These studies could be useful in detecting compromised blood brain barriers, or in aiding 
the delineation of tumor margins during surgical resection. At this preliminary level, 
inclusion of JAS239 in these expensive and time-consuming rat GBM models could not 
be justified, although further pursuit of this strategy is warranted. 
ChoKα is particularly interesting as a therapeutic target in GBM because of its link to 
hypoxia. Glunde et al. reported increased total choline and ChoKα activity in a prostate 
cancer model and established a correlation between hypoxia, choline metabolites, and 
Chokα activity (Glunde et al., 2008). These authors also suggested that hypoxia-inducible 
factor-1 alpha (HIF-1α) activation of hypoxia response elements (HREs) within the 
putative ChoKα promoter region can increase ChoKα expression within hypoxic 
environments, consequently increasing cellular PC and tCho levels within these 
environments. Hypoxic tumor microenvironments pose a problem for adjuvant 
treatments; cancer cells located in hypoxic environments undergo adaptive responses, 
which render them resistant to radiation and chemotherapy, resulting in recurrence 
(Moeller et al., 2004). Such resistance to treatment contributes to the incidence of cancer 
recurrence. Variations in the extent and degree of hypoxia/necrosis in combination with 
variable angiogenic patterns represent a considerable problem in radiotherapeutics and 
antiangiogenic management of GBM. Thus, it is plausible to hypothesize that inhibition 
of ChoKα activity by a specific ChoKα inhibitor may help in reducing the survival 
pathways which allow GBM tumors to thrive in hypoxic microenvironments, making 
them more sensitive for chemo and radiation therapy. Conflicting evidence shows a 
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decrease in choline phosphorylation in hypoxic prostate cancer cells, although this 
appears to arise from other isoforms of HREs affecting ChoKα activity in human brain 
tumors (Bansal et al., 2011). Thus, there are a number of avenues to explore regarding 
the link between radiation-resistance and ChoKα expression.  
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Chapter 7 
Conclusion 
7.1 Potential applications 
The studies outlined in this work have led to several insights into the advantages and 
shortcomings of our approach to target ChoKα with small molecule theranostics. 
Theranostics is an emerging field that developed out of the molecular imaging and 
pharmaceutical industries based upon their shared need for target specificity. 
Applications of this technology for cancer imaging and therapy have previously been 
described, but these approaches have focused primarily on nanoparticle drug delivery 
agents tagged to molecular imaging contrast agents (Kelkar and Reineke, 2011). The 
nanoparticle revolution is promising, but has failed thus far to make a large impact in 
clinical applications, with the exception of liposomal formulations of some relatively 
insoluble anticancer drugs, such as doxorubicin (Chen et al., 2011). For molecular probes 
and therapeutic agents, small molecules continue to be preferred, due to a precedent in 
industry, the well-defined pharmacokinetics of small molecules, and a relatively straight-
forward FDA approval process. Our approach has identified a prototype small molecule 
that can provide diagnostic information at low doses, and therapeutic benefit at higher 
doses (Fig. 7.1). 
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Figure 7.1. Model of Theranostic Mechanism of ChoKα Inhibitors. Diagnostic: Breast cancer 
cells are known to express higher levels of ChoKα (blue), which subsequently leads to increased 
accumulation of fluorescent inhibitor (red). Non-invasive optical imaging of these molecular 
beacons could therefore be used to detect ChoKα status. Therapeutic: ChoKα inhibitors cause 
apoptosis selectively in cancer cells, while eliciting reversible cell cycle arrest in normal cells. This 
is a self-reporting therapy because the level of accumulated fluorescence would diminish in 
response to treatment. 
 
While the idea of fluorescent kinase inhibitors is not unprecedented (Kim et al., 
2010), this project represents a conceptual leap in clinical applicability because it 
describes the first example of a kinase-targeted small molecule whose fluorescence fits 
within the near infrared wavelength range required for in vivo detection. The original 
conception for this project was to design a probe capable of non-invasively reporting 
tumor stage based upon measurement of the fluorescence emitted from a ChoKα-
retentive agent. As we became more familiar with the target and the breast tumor model, 
the expectations for clinical translation were augmented to better fit the capabilities of 
this technology. As an example, the anabolic nature of ChoKα is a disadvantage 
compared to catabolic targets for which a conjugated quencher-fluorophore system can 
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be “cleaved” by the mechanistic action of the molecular target (Mahmood and 
Weissleder, 2003). Designed as an “always-on” fluorophore, the expectations for JAS239 
and similar probes have been tempered to account for interfering signal emitted from 
non-diseased tissues responsible for metabolism and excretion. In the case of the 
carbocyanines, the high background signal from the kidneys may have been predicted 
due to the cationic nature of these small molecules. By adapting our models and either 
cloaking the intraperitoneal organs or isolating the tumor-bearing tissue, we were still 
capable of making true measurements of disease status, but also introduced a new 
application for this technology centered around fluorescence-guided surgical aid. 
For its tumor-associated fluorescence, JAS239 is being developed in our lab as an 
intraoperative NIRF contrast agent for delineation of tumor margin. In addition to this 
application, however, specific measurements of ChoKα status were also found to be 
feasible in these studies. Heightened NIRF was observed in tumors that genetically-
overexpress ChoKα, although the difference in JAS239 accumulation may not be 
sufficiently robust to use this technology for determination of breast cancer tumor grade. 
An in vivo xenograft model with minimal ChoKα expression would be preferred to the 
MCF7-EV cell line, however such tumors have yet to be identified in the literature. 
Where JAS239 may be most useful is in the in vivo validation of new ChoKα inhibitors. 
Current methods rely on in vivo MRS to measure the composite tCho peak at 3.2 ppm, 
despite the complexity of pathways which contribute to choline metabolism. Alternative 
strategies using radiolabeled choline tracers are also being developed to mitigate these 
concerns, but tracer retention can be influenced by choline transport inhibition and may 
falsely identify agents with neurotoxic side effects. JAS239 itself has been well-tolerated 
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in animals and appears to be a true pre-clinical candidate capable of reducing tCho levels, 
inducing tumor apoptosis, and slowing tumor growth. 
7.2 Next generation inhibitors 
The proof-of-concept goals for this project were achieved using JAS239, however, 
for translation into more sophisticated breast cancer models this technology would 
benefit from improved potency against ChoKα. A new collaboration with Dr. Arnon 
Lavie at the University of Illinois at Chicago will make pure human ChoKα available for 
exploring new inhibitors. Additionally, this group will attempt co-crystallization of 
ChoKα with JAS239 to provide a better understanding of the interaction between protein 
and inhibitor. During this planning process, a set of next generation carbocyanines and 
MN58b-derivatives were designed by our group. After successful synthesis of prototype 
derivatives, the remaining compounds were outsourced to PepTech Corporation for 
synthesis. Although not all of the originally-designed structures could be produced, we 
are still in possession of a small compound library to screen against ChoKα. 
Pilot studies are already underway to characterize the activity of these compounds. It 
was disappointing to not detect NIR fluorescence in solutions of the two resonant 
derivatives of MN58b (E,E-conjMN58b and E,E,E-conjMN58b), however, detection of 
fluorescence in the solid state means that we cannot rule out potential imaging utility in 
whole cell applications. Additionally, a number of strongly fluorescent JAS239 
derivatives were synthesized with rational modifications to several parameters involved 
in pharmacokinetic behavior (e.g. hydrophobicity, structural rigidity, functional group 
replacement). While awaiting pure human ChoKα, a modified ChoKα activity assay was 
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developed to measure 14C-choline phosphorylation in cytosolic preparations from MDA-
MB-231 cells. Using this assay, remarkable activity was found for the MN58b derivative 
compounds, comparable to previously established inhibitors such as HC-3, MN58b, and 
TCD-717 (Fig. 7.2). Surprisingly little activity was found for any of the NIR fluorescent 
compounds. Most notably, 10 µM JAS239 induced only a 14% reduction in PC 
formation, despite our findings outlined in Chapter 4 using whole-cell radiotracing and 
cytosolic NMR assays.  
 
 
 
Figure 7.2. Screen of ChoK inhibition in cytosolic preparations. 14C-PC production in 
cytosolic preparations was used as an indicator of ChoK activity in MDA-MB-231 cells. Dicationic 
compounds are the most effective ChoK inhibitors in the absence of cell membrane components. 
Fluorophore-derived compounds elicit minimal ChoK inhibition in the cytosol. Error bars represent 
+ SEM of 3 separate experiments. Experiments were run with assistance from Michael Chiorazzo 
and Alejandro Arroyo of the Delikatny Lab. 
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Figure 7.3. Comparison of JAS239 and MN58b in MCF7 cytosolic preparations. (A) ChoK 
inhibition in cytosolic preparations of MCF7-EV and MCF7-CK+ cells is only observed in the 
presence of MN58b. (B) In the absence of the reducing agent DTT, JAS239 more effectively 
inhibits ChoK, but high variability is found due to protease activity. MN58b is equally as effective 
in the absence of DTT. Error bars represent + SEM of 3 separate experiments. 
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To further explore JAS239 activity in the context of this membrane-free environment, 
we screened JAS239 and MN58b at 5 and 50 µM concentrations in MCF7-EV and 
MCF7-CK+ cytosolic preparations (Fig. 7.3A). JAS239 was again found to be ineffective 
in this assay, and the presence of dithiothreitol (DTT) became a concern. DTT is a 
reducing agent included in the lysis buffer to inactivate enzymes that have disulfide 
bonds critical to maintaining a catalytically-active structural conformation. As a reducing 
agent, however, it was not clear if JAS239 would remain pharmacologically active in this 
reducing environment, considering its conversion to a non-polar hydrocyanine state under 
strong reducing conditions (see Chapter 3, Section 6 on hydro-JAS239 synthesis). The 
same reaction conditions were followed as in Figure 7.3A, but without addition of the 
DTT and EDTA stock to the lysis buffer. These experiments demonstrated 44% reduction 
in ChoKα activity in the presence of 50 µM JAS239, but there was high experimental 
variability presumably due to the fact that denaturing proteases and counteracting 
phospholipases were no longer inactive in the absence of these crucial lysis buffer 
components (Fig. 7.3B). A logical step would be to add a protease inhibitor in an effort to 
minimize degradation of ChoKα during the reaction period. While DTT removal helped 
to restore JAS239 activity against ChoKα, it did not restore potency to levels observed in 
intact cells. Mass spectrometry analysis will be performed on JAS239 before and after 
DTT treatment to assess possible structural changes caused by this reducing agent. 
7.3 Unexplored mechanisms of choline kinase inhibition 
The data above indicate that JAS239 is more potent against ChoKα in intact cells, an 
unexpected result that may be due to several possibilities. The first possibility is that the 
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rapid uptake of JAS239 in intact cells observed using live-cell fluorescence microscopy 
(Fig. 4.13) caused higher local JAS239 concentrations within the cytosolic space and led 
to greater potency. Consistent with this hypothesis, MN58b is remarkably potent in 
cytosolic preparations, but the dicationic nature of this molecule causes the cell 
membrane to act as a greater barrier to MN58b entry, lowering its potency in vitro. The 
actual potency of MN58b against ChoKα in intact cells may be even less, considering our 
preliminary evidence which attributes some of MN58b’s effect on14C- PC production to 
its inhibition of choline transport (Fig. 4.11). Choline phosphorylation by ChoKα is a 
mechanism cells use to trap this essential nutrient, in a manner similar to glucose 
phosphorylation by hexokinase. Its potential off-target effect on choline transporters has 
never previously been reported, although Rodríguez-González et al. observed reduced 
choline uptake in MN58b-treated cells; this effect was explained by citing a reduction in 
choline phosphorylation and, thus, cellular trapping (Rodríguez-González et al., 2003). 
Interaction with choline transporters does help to explain the respiratory paralysis 
observed in mice treated with 4 mg/kg MN58b (Chapter 5) and in previous generation 
ChoK inhibitors.  
The possibility for off-target effects of JAS239 cannot be ruled out, although the 
binding specificity demonstrated using immunohistochemistry techniques in fixed cells 
provides strong evidence against this. Off-target inhibition of choline transport would 
explain why JAS239 is most effective at reducing PC production in intact cells. Confocal 
microscopy and fluorimetry have detected no identifiable interaction with the plasma 
membrane or the choline transporters. An antagonistic effect on upstream regulators of 
ChoKα (such as Ras or RhoA) could also explain the inactivity in cell lysates, although 
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upstream growth signals are only known to cause changes in ChoKα expression, not 
activity. It is not likely that significant transcriptional changes could occur within the 1-
hour treatment period used in radiotracing studies. For this same reason, JAS239’s effect 
on PC accumulation cannot be due to an indirect action on the phospholipase enzymes 
due to the duration of time that would be required for the choline tracer to be 
incorporated into PtdCho. The quaternary ammonium group of JAS239 led to concerns 
that DNA intercalation or mitochondrial uncoupling may contribute to the molecule’s 
antiproliferative effects. DNA intercalation was ruled out as a mode of antiproliferative 
activity when JAS239 was found to be excluded from the nucleus. Measurements of 
JAS239 viability (EC50) were substantially lower in Trypan exclusion assays, which 
measure plasma membrane integrity, than in MTT assays, which measure mitochondrial 
integrity. This difference in potency between the two assays suggests that mitochondrial 
toxicity is not the driving factor in JAS239’s antiproliferative effect.  
It has recently been suggested that ChoKα’s contribution to tumorigenesis is through 
a non-catalytic mechanism, most likely related to its newly reported scaffolding function 
(Falcon et al., 2013). For ChoKα to not be the direct target of JAS239, the probe would 
likely bind to a protein currently unknown to form a scaffolding complex with ChoKα. 
This possibility could explain the colocalization between JAS239 and ChoKα, but would 
not explain why exogenous choline addition rescues the inhibitory effect of JAS239, nor 
could it explain the reversal of JAS239 binding by a ChoKα antibody. We observed no 
evidence of ChoKα recruitment to the plasma membrane in our immunohistochemistry 
studies, but JAS239 may be a useful tool in the effort to characterize ChoKα’s binding 
partners. 
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7.4 Future studies 
Screening for ChoKα inhibition and antiproliferative effects is currently under way 
for the JAS239 and MN58b derivatives. Identification of interesting candidates will then 
be co-crystallized with ChoKα and structure-activity relationships will then be assessed. 
Many molecular biology tools that were not available at the start of this project, such as 
ChoKα-specific antibodies, siRNA, and ELISA kits, are now commercially available. 
These offer new and specific strategies to explore ChoKα inhibitors at a level of detail 
that was not previously possible. We believe the most promising application for JAS239 
derivatives is in NIRF-guided tumor resection. Use of an inducible orthotopic tumor 
model would allow small tumors to be resected from mice. Disease-free margins from 
animals with tumors resected by naked eye could be compared to those resected by 
NIRF-guidance; the result of such studies could provide further evidence to support the 
utility of these probes. For therapeutic assessment, studies of new dose formulations and 
treatment regimens may identify a strategy that stops or reverses tumor growth. Finally, 
testing synergistic effects with existing drugs that target compensatory pathways could 
validate ChoKα inhibition as a clinically viable treatment option.  
In summary, JAS239 remains the most effective small molecule ChoKα-targeted 
theranostic. Its interaction with ChoKα is most likely at the choline binding site, although 
further studies with the pure enzyme are needed to understand this mechanism. The 
single cationic charge on JAS239 may be the reason it is only half as potent as the 
dicationic inhibitors such as MN58b. By removing one quaternary ammonium group, 
however, JAS239 shares less structural features with HC-3 and is better tolerated than 
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MN58b in mice. The single charge also appears critical for fluorescence in less rigid 
structures. With fluorescence in the NIR wavelength range, attenuation of the Kennedy 
pathway, and a low toxicity profile, JAS239 is a promising multi-functional small 
molecule for identification and treatment of cancer. The use of a dye as a signal 
transduction inhibitor represents a return to the paradigm of the therapeutic “magic 
bullet”, although our modernization of Ehrlich’s postulation more closely resembles a 
diagnostic beacon fired from a NIRF gun. 
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APPENDIX 1 
 
Synthesis and characterization of E,E-conjMN58b (PTC1452-01) 
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APPENDIX 2 
 
Synthesis and characterization of E,E,E-conjMN58b (PTC1452-02) 
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APPENDIX 3 
 
Synthesis and characterization of TCD-717 (PTC1452-07) 
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APPENDIX 4 
 
Synthesis and characterization of cycloJAS239 (PTC1452-08) 
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APPENDIX 5 
 
Synthesis and characterization of cycloJAS239.5 (PTC1452-09) 
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APPENDIX 6 
 
Synthesis and characterization of cycloHITC (PTC1452-10) 
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Synthesis and characterization of cycloHITC.5 (PTC1452-11) 
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